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ABSTRACT 
 
Vaccine development has had a profound impact on healthcare across the 
world. However, there are still multiple challenges that current strategies need to 
overcome to be able to deliver highly targeted and easily administered 
efficacious vaccines. Specifically, viral infections with high mutation rates have 
become a difficult target for such therapies. Among these, Human 
Immunodeficiency Virus (HIV) is one of the major concerns for researchers due 
to ability of the virus to mutate and the rate of new infections in remote locations. 
Since traditional approaches have not had great success against these 
infections, development of novel platforms using single-dose actively targeted 
vaccinations is a promising alternative. This work focused on the design and 
evaluation of a targeted polymeric nanovaccine against this virus, with 
polyanhydride nanoparticles playing dual roles as delivery vehicle and adjuvant. 
The work presented in this dissertation describes the development of a rationally 
designed targeted polyanhydride nanovaccine against HIV.  
Initial research was focused on the screening of different polyanhydride 
nanoparticle formulations and understanding cell-particle interactions using 
antigen presenting cells (APCs), which are key components in the initiation of an 
immune response. These experiments were aimed at understanding the role that 
chemistry and surface functionalization had in the preservation of the structure 
and biological activity of an HIV antigen, and particle internalization and release 
kinetics, to rationally select lead candidates, and to evaluate their ability to 
stimulate dendritic cells. The results showed that all nanovaccine formulations 
xviii 
 
 
used were able to stabilize and sustain antigen release; however, amphiphilic 
chemistries were specifically identified as lead candidates due to their smaller 
initial burst release and ability to preserve antigenicity of fragile proteins. In 
addition, carbohydrate functionalization was not detrimental to the ability of these 
nanovaccines to release antigen and stimulate dendritic cells. In order to further 
understand the interactions of polyanhydride nanoparticles with APCs after 
administration to the body, experiments were carried to analyze the role of 
complement receptor 3, serum proteins and polymer chemistry in the uptake of 
these nanoformulations. The results of this investigation showed the complex 
relationship between the aforementioned factors, which affected the ability of the 
polyanhydride nanoparticles to be taken up by and stimulate macrophages. The 
overall observations from these studies were then used to identify the desired 
characteristics of these polymeric formulations to proceed with in vivo evaluation 
of these nanovaccines.   
The latter chapters of this dissertation were focused on the evaluation of 
the ability of the lead nanovaccine formulations to elicit immune responses using 
in vivo models. Before performing efficacy studies with carbohydrate-
functionalized polyanhydride nanoparticles, it was necessary to assess the safety 
of these novel biomaterials; therefore, safety and biodistribution experiments 
were performed with carbohydrate-functionalized polyanhydride nanoparticles. 
Histopathology evaluation of tissue samples, quantification of urine and serum 
biomarkers, cellular distribution and cytokine secretion confirmed that the 
functionalization of the nanoparticles did not dramatically affected the behavior of 
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the nanoformulations and did not cause any detrimental effects when compared 
to saline treatments. Finally, evaluation of immune responses generated after the 
administration of polyanhydride nanovaccines using an HIV antigen in in vivo 
models was carried out. These formulations were able to induce germinal center 
B cell formation in draining lymph nodes and generate serum antibodies, eliciting 
more robust responses than traditional adjuvants (such as Alum). The results of 
this investigation confirm the ability of polyanhydride nanovaccines to generate 
potent immune responses and to induce both humoral and cellular immunity. In 
summary, the studies described herein demonstrate the promising capabilities of 
polyanhydride nanovaccine formulations to design an efficacious vaccine against 
viral pathogens. 
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CHAPTER 1 
 
Introduction 
 
1.1. Introduction 
 
Vaccine development has played a major role in the improvement of the 
quality of life across the world.[1-3] However, emerging and chronic diseases 
(e.g., HIV, influenza A, cancer) have caused researchers to explore novel 
vaccine delivery technologies, since traditional approaches have not been very 
effective against them. Design of alternative mechanisms for prevention or 
prophylactic treatments towards pathogens like HIV includes the rational design 
of antigens, delivery vehicles, and use of potent adjuvants to create efficacious 
platforms for antigen delivery.[4-6] 
Human Immunodeficiency Virus (HIV) has become one of the greatest 
challenges for researchers around the world.[7, 8] More than 35 million human 
deaths have occurred from the resulting disease, Acquired Immunodeficiency 
Deficiency Syndrome[7], since its outbreak in 1981.[8] The highest number of 
new infections is in remote locations in Africa where continuous treatment to 
avoid the progression of the disease is required.[7] Therefore, a prophylactic or a 
therapeutic intervention strategy that can be easily distributed and administered 
needs to be developed. An ideal vaccine against HIV-1 must elicit a robust and 
balanced (includes cellular and humoral immunity) immune response in order to 
avoid the infection of the host. But the high mutation rate of the virus, its ability to 
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stay dormant for several years, and the different mechanisms to avoid the 
immune system response, have made HIV a difficult challenge for scientists.[9-
12] 
In the quest for safe and efficacious next generation vaccines against 
pathogens like HIV, the use of subunit proteins specific to the pathogen as 
vaccine antigens has gained prominence. These molecules have desirable 
properties as antigens, such as safety and specificity; on the other hand, they 
may have fragile structures and/or poor immunogenicity when used as soluble 
protein.[6, 13] To overcome these limitations, use of adjuvants in vaccine 
formulations has been pursued as a viable strategy, because adjuvants not only 
improve the immunogenicity of these antigens, but may also stabilize these 
molecules and provide sustained delivery of antigens to antigen presenting 
cells.[14-20] 
In order to incorporate these properties into adjuvants and/or delivery 
vehicles, non-traditional molecules have been explored as potential adjuvants, 
including polymer-based, protein-based, and antibody-based platforms.[3, 6, 21-
24] Before studying the mechanisms of adjuvanticity induced by these platforms, 
analysis of the preservation of antigenic structure (primary, secondary, and 
tertiary), which is susceptible to environmental changes (e.g., pH, temperature), 
and its interaction with the chemicals involved in the fabrication process of these 
vehicles (i.e., solvents, detergents) is of paramount interest. 
Another challenge in the rational design of vaccines is the short half-life of 
protein antigens in vivo.[25] Depending on the disease of interest, either localized 
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or dispersed behavior of the vaccine is desirable, which also involves their ability 
to get to the site of action.[26, 27] Typically, these molecules may also require 
passing through biological barriers (e.g., mucosa), depending on the route of 
immunization.[28-31] Therefore, to increase their effectiveness, multiple 
administrations may be required to be able to deliver sufficient amount of the 
antigen to elicit efficacious immune responses. A prime-boost immunization 
regimen may reduce the effectiveness of the treatment, because of the time-
stringent regimen of vaccines and/or their long-term storage, especially in remote 
locations. To improve these approaches, a single dose strategy would provide a 
good solution and also enhance patient compliance. 
In order to direct the antigen to specific locations or cellular populations to 
enhance their immune response and also for dose sparing capabilities, targeting 
mechanisms have been used recently.[27, 28, 30] Typically, these approaches 
are oriented to direct the delivery vehicles to specific cellular receptors (e.g., 
macrophage mannose receptor), organs (e.g., brain), or cell population subsets 
(e.g., tumor cells) by modifying the properties of the delivery vehicle.[28, 32-34] 
For particle-based vaccine technologies, functionalization of their surfaces with 
molecules such as carbohydrates, peptides, or antibodies has become a viable 
methodology.[21, 22, 32-36] 
Among these novel platforms for antigen delivery, biodegradable polymers 
have gained a lot of attention.[6, 24] These systems have flexibility with respect 
to their properties based upon the control of chemical characteristics of the 
material(s). These properties include the ability to tune release kinetics of 
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payload, development of responsiveness to the local environment (e.g., pH), and 
the capacity to be directed towards specific targets.[18, 19, 37-40] These 
materials have been used to design films, micro- and nanoparticles, stents, gels, 
scaffolds depending on the target disease and administration route.[24, 41-44] 
Specifically, polyanhydrides represent a family of biodegradable polymers 
that present a set of desirable properties for the design of novel platforms for 
drug and antigen delivery vehicles.[24, 44, 45] Polyanhydrides are hydrophobic 
materials with surface-eroding mechanisms that have shown in previous studies 
to stabilize a variety of antigens (i.e., proteins, peptides), display sustained 
antigen release kinetics, degrade into safe and non-mutagenic degradation 
products, show excellent biocompatibility, and adjuvant properties.[24, 44, 45] 
The anhydride monomers that have been most commonly studied are sebacic 
acid (SA), 1,6-bis(p-carboxyphenoxy) hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) (Figure 1.1). 
 
Figure 1.1. Chemical structures of A) sebacic acid, B) 1,6-bis(p-carboxyphenoxy) 
hexane, and C) 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane. 
 
Polyanhydride nanoparticle-based vaccines (or nanovaccines) have been 
shown to preserve the antigenicity of proteins (e.g., F1-V, ovalbumin, PspA, rPA, 
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hemagglutinin) upon release, stimulate both humoral and cellular immune 
responses, and elicit protection in live challenge experiments.[19, 46-51] These 
properties make them promising candidates as drug and vaccine delivery 
vehicles. Based on these characteristics of polyanhydrides, the main goal of this 
research was the design of novel targeted polyanhydride nanoparticle-based 
vaccine delivery vehicles, specifically for HIV-1 antigens, that can help elicit 
strong and balanced immune responses that result in efficacious treatments 
against this virus. 
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CHAPTER 2 
 
Literature Review 
 
2.1 Summary 
 
Polymeric particles have been widely used as vaccine delivery vehicles. 
Particle systems based on a variety of natural and synthetic polymers have been 
studied for the delivery of multiple payloads. This chapter reviews the properties 
of these polymeric systems, particle characteristics that are important for 
induction of immune responses, and targeting approaches to enhance the 
function of these systems. Section 2.2 explores the structure-performance 
relationships of different polymer-based systems for drug and vaccine delivery. In 
Section 2.3, an analysis of specific particle characteristics, such as size, shape, 
hydrophobicity and surface chemistry that have been previously reported as 
important for the immune response, is presented. Section 2.4 reviews targeting 
strategies that have been used for cancer therapy and specific activation of 
antigen presenting cells. Finally in Section 2.5, a brief overview of HIV 
pathogenesis, vaccine challenges, and future directions is discussed. 
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2.2 Biodegradable polymers for drug and vaccine delivery 
 
2.2.1 Natural polymers 
Polymers have always existed in nature (e.g., DNA, polysaccharides, 
proteins)  and have played important roles in plant, animal and human life.[1] 
These compounds can be classified into three types: proteins (e.g., albumin, 
gelatin, collagen), lipid-based compounds (e.g., liposomes), and polysaccharides 
(e.g., chitosan, cellulose). Degradation of these polymers usually involves 
hydrolytic or enzymatic reactions that break the bonds of the main chain.[2-4] 
Albumin is a macromolecular carrier that is attractive for the design of drug 
and vaccine delivery carriers. It has been shown to be non-toxic, biodegradable, 
biocompatible, and easy to purify and solubilize in water.[5, 6] In addition, its 
degradation products are metabolizable and non-toxic after in vivo administration 
[5, 6], allowing it to be a viable candidate as a delivery vehicle. 
There are three albumin proteins that have been widely used in 
biomedical applications: ovalbumin, bovine serum albumin and human serum 
albumin. Ovalbumin (OVA) is a phosphoglycoprotein that consists of 385 amino 
acid residues with a molecular mass of 47 kDa and an isoelectric point (pI) of 4.8. 
OVA has been used extensively as a carrier for drug delivery and as a model 
antigen, due to the low cost and stability of its properties under different pH and 
temperatures.[5, 7, 8] Another albumin protein that has been used in biomedical 
applications is BSA (bovine serum albumin), which is a 69 kDa protein with a pI 
of 4.7 due to its physical properties, abundance and cost-effectiveness. Finally, 
to minimize immune responses after administration, human serum albumin [9] 
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has been used instead of BSA or OVA. This protein is the most abundant protein 
in the human serum, with a concentration of 35-50 g/L and a half-life of 19 
days.[8, 10] Having a Mw of 66.5 kDa, high solubility, robust pH (4.7) and 
temperature stability, and resistant to organic solvents, it has become an 
attractive alternative for gene and drug delivery.  
Studies with these naturally occurring proteins as carriers have advanced 
to different clinical trials in different disease applications.[6, 11, 12] Paclitaxel-
albumin nanoparticles called Abraxane® have been developed for metastatic 
breast cancer treatment.[6, 13, 14] Another platform using albumin nanoparticles 
currently in clinical trials use lipophilic drugs against cancer progression, such as 
mTOR rapamycin, heat shock protein inhibitor Hsp90, docetaxel, etc.[6, 12] 
Levermir® (insulin detemir) and Victoza® (liraglutide) are two products from Novo 
Nordisk that treat diabetes and have shown good results regulating blood sugar 
levels for long term use.[6] These products were recently approved by the U.S. 
FDA in 2005 and 2009, respectively. Treatments that require crossing the blood 
brain barrier for drug delivery have also been developed, using adsorption of 
oximes to HSA nanoparticles.[15, 16] In addition, the ability to modify the surface 
of these nanoparticles with folate for specific targeting has also been studied.[8] 
Collagen is the most abundant protein in human body (20-30% of total 
amount of proteins) and the primary structural material of vertebrates, present in 
multiple tissues such as bone, cartilage, and ligaments, and is also one of the 
main components of blood vessels.[11, 17-19] It is composed of polypeptide 
strands, mainly based upon proline and hydroxyproline. This material has been 
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used in biomedical applications because of its biodegradability, biocompatibility, 
and weak antigenicity, to create different architectures with different mechanical 
properties.[11, 19, 20]  
 
Figure 2.1. Cumulative release of pDNA from pDNA–collagen and pDNA–LIP–
collagen (liposome) and physical structure of collagen after release of pDNA. [19] 
 
Collagen nanoparticles have been used to provide sustained release of 
anti-cancer drugs, antibiotics, growth factors, and retinol and facilitate 
transportation of the encapsulated agent to specific tissues.[17, 18] In addition, 
this platform has been used to deliver DNA, siRNA, antibiotics, and proteins as 
shown in Figure 2.1, where pDNA release from collagen gels is demonstrated. 
However, a disadvantage of collagen-based delivery vehicles is their lack of 
mechanical strength and their bulk erosion mechanism that hinder their ability to 
provide controlled release. 
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Gelatin is denatured collagen isolated from animal skin or bone and 
extracted using acid and alkaline hydrolysis, giving it low antigenicity. It is a 
polyampholyte due to the presence of both cationic and anionic groups together 
with hydrophobic residues.[11, 21] It has a triple helical structure with multiple 
sequences from glycine, proline and alanine. It has largely been used in 
pharmaceutical and medical applications because of its properties, such as its 
biocompatibility in physiological environments and non-toxic degradation 
residues.[22] It has also been approved by the U.S. FDA for food and cosmetic 
products and GRAS materials.[23] Gelatin-based particles have been used as a 
carrier of proteins such as lysozyme, albumin, a variety of anticancer drugs, 
antivirals, antimicrobials, antimalarial drugs, anti-inflammatory compounds, and 
anti-diabetic therapy, and for gene delivery.[11, 21, 24-28] Its properties have 
been tailored by crosslinking with different materials (e.g., formaldehyde, 
glutaraldehyde, and other bifunctional reactives) as shown in Figure 2.2.  
 
Figure 2.2. Crosslinking reaction mechanism of gelatin with glutaraldehyde.[28] 
 
Another category of natural polymeric materials that has been commonly 
used as a drug delivery platform is liposomes and several liposome-based 
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formulations are currently in clinical use.[29] Liposomes are vesicles that have 
one or many phospholipid bilayers that allow polar drug molecules to be 
entrapped in them. There have been two “generations” of liposomes based on 
size and charge.[30, 31] Delivery of multiple drugs, glycolipids and molecules, 
such as sialic acid, DNA or monoclonal antibodies, has been investigated.[29-31] 
However, some of the limitations of this platform are the poor capability to retain 
encapsulated agents within, the effects of serum protein adsorption on drug 
release profiles, and their rapid clearance from circulation by uptake of 
mononuclear phagocytic cells. In attempts to improve their efficacy, poly(ethylene 
glycol) (PEG)-based coatings have been grafted to their surface to regulate 
release kinetics and to increase their in vivo half-life.[29, 31] 
Although chitosan has been used in multiple applications since 1859, its 
potential use in pharmaceutical and biomedical applications has only 
beendeveloped in the last 20 years.[32] Chitosan is derived from the 
deacetylation of chitin, creating a polysaccharide with random units of D-
glucosamine and N-acetylglucosamine as shown in Figure 2.3.[33] Chemical 
modifications of this material have been used to modulate their degradation rate 
for drug delivery. This includes combining or crosslinking it with other polymers to 
create hydrogels, fibers, micelles or particles that can be used to encapsulate a 
variety of agents such as immunosuppressants, antibiotics, vaccines, anti-
inflammatory drugs, DNA, siRNA, and different proteins.[3, 32, 34, 35] A concern 
with this platform is that its functional properties depend on the chain length, 
charge density and distribution, molecular weight, degree of deacetylation and 
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pH, which all influence the toxicological profile of drug delivery systems based on 
chitosan.[3, 33, 35] 
 
Figure 2.3. Chemical structure of chitosan with X = degree of acetylation and n = 
number of sugar units per polymer.[32] 
 
2.2.2. Polyesters 
Poly(glycolic acid) (PGA), poly(lactic acid) , poly(ε-caprolactone) (PCL) 
and their copolymers (e.g., PLGA) have been extensively studied as biomaterials 
for drug delivery. These polyesters are biodegradable materials and were 
originally designed for sutures, due to their degradation into natural compounds 
such as L-lactic acid and glycolic acid. These materials have been characterized 
extensively and their synthesis and fabrication conditions have been tailored to 
obtain physical and chemical properties desirable for different applications in 
drug and vaccine delivery. A wide variety of delivery vehicles based on PLGA, 
PLA or PGA have been developed, such as particles, films, scaffolds and fibers 
for various agents (e.g., antibiotics, anti-cancer drugs, proteins, DNA).[35-46] 
Their commercial availability and ease of processing has enhanced their use by 
researchers.  
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The physicochemical properties of these biomaterials are highly 
dependent on the copolymer composition. The bulk erosion mechanism is 
controlled by the ratio of glycolic acid to lactic acid in PLGA copolymers. The 
higher the glycolic acid content, the faster is the erosion rate. [44, 47] However, 
the bulk eroding nature of PLGA also results in microenvironments that are 
dominated by the presence of GA, which lowers its solubility in non-toxic 
solvents, causing a threshold of 50 mol% of glycolic acid, limiting the control over 
release kinetics.  
Poly (ε-caprolactione) (PCL) is a synthetic α-polyester that has a low 
Tg.[35] PCL is FDA approved for drug delivery and sutures because of its 
biodegradable characteristics and slower degradation profiles when compared 
with other polymers of the same family (i.e., lactic and glycolic acids). PCLA has 
been commonly used in blends to modulate the release rate of rapid degradation 
materials.[35, 43] Even though this polymer exhibits bulk erosion, its crystalline 
structure extends its in vivo half life to over two years by slowing down fluid 
entrance to the polymer matrix.[48, 49] PCL has been studied as a drug carrier 
for its mechanical properties by combining it with lactic acid to improve its 
processability and decrease its degradation rate.[48],[50] 
The degradation process of polyesters occurs in four steps. First, water 
enters the polymer matrix and cleavage of ester bonds occurs (Panel B, Fig. 2.4). 
Second, a differentiation begins between the surface and inner sections and a 
highly acidic environment causes the rapid degradation of the polymer structure 
(Panel C, Fig. 2.4). Third, low-molecular weight oligomers are transported 
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towards the outer layer, and when the molecular weight decreases to a certain 
threshold allowing its solubilization in the liquid environment, allowing more water 
to penetrate, thus enhancing the degradation of the polymer (Panel D, Fig. 2.4). 
Finally, as depicted in Panel E of Fig. 2.4, the shell remains after the inner core 
has been solubilized, completing the process (Panel F, Fig. 2.4).[51]  
 
Figure 2.4. Scanning electron photomicrographs of (75:25 L/G) PLGA 
microspheres at different degradation states. A) Immediately after preparation, B) 
1, C) 4, D) 7, E) 14, and F) 76 days after degradation at 37°C. Release studies 
were performed at 37°C in phosphate buffer saline ( 7.5 mg/mL). [51] 
 
A limitation of polyester-based devices is their bulk erosion, which does 
not offer control of the release rate of the payload. In addition, the highly acidic 
microenvironments and degradation products of these copolymers affects the 
stability of the payload.[47, 52] Finally, a bolus-type burst release occurs when 
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these materials are subject to aqueous conditions, and the hydration of the 
polymer matrix can destabilize the pH-sensitive payloads.[44, 53, 54] 
2.2.3. Polyurethanes 
Polyurethanes are synthetic thermosetting polymers with urethane or 
carbamate bonds (-NH-COO-) in their backbone structures that are formed by 
the reaction of isocyanates and diols. Devices made of these materials have 
been widely used in the biomedical and pharmaceutical fields that include heart 
valves, intra-aortic balloons, aortic grafts, catheters, vascular grafts, implants, 
and drug delivery systems.[55, 56] These materials have been tailored to have 
biodegradable properties for use in ligament reconstruction, temporary scaffolds, 
and controlled release devices.[55, 57, 58] This was achieved by the addition of 
labile or hydrolyzable moieties in the polymeric structure backbone such as 
polyols.  
Regarding the use of these materials as drug delivery vehicles, local 
delivery of clorhexidine diacetate (CDA) was demonstrated using non-degradable 
medical grade polyurethane for antiseptic use in dentistry and other topical 
uses.[57] In addition, biodegradable polyurethanes with polyols were reported to 
deliver gliclazide, which is a hydrophobic drug for diabetes.[59] Furthermore, 
polyurethane implants have been used to release dexamethasone.[60] Even 
though polyurethanes have been widely used in biomedical applications, their 
long-term safety and efficacy still needs to be further analyzed. Due to the 
necessity to incorporate chemical moieties that allow degradation, polyurethanes 
have seen limited use for controlled drug delivery. 
20 
 
 
 
2.2.4. Vinyl polymers  
Polymethacrylates are synthetic anionic and cationic polymers that are 
FDA-approved with a safe and non-toxic profile. They are synthesized using 
dimethylaminoethylmetacrylates, methacrylic acid, and methacrylic acid esters in 
different ratios. Their usage has been primarily in transdermal delivery systems. 
Commercialized as Eudragit©, polymethacrylates have been studied as delivery 
vehicles for drugs such as felodipine (widely used in the treatment of 
hypertension) and model proteins as albumin.[61-64]  
Poly(vinyl alcohol) (PVA) is a synthetic water-soluble polymer (Figure 2.5) 
that is non-toxic, biocompatible, and biodegradable. This material is hydrophilic 
and swells up when subjected to hydration; previous studies report volume 
expansion up to 500%.[65] This material and copolymers thereof have been used 
in controlled drug delivery systems.[66-69] The release kinetics profile of drugs 
from these materials can be controlled by the content of vinyl alcohol, by 
incorporating electrolytes into the polymer matrix and by application of film 
coatings onto the PVA-based materials.[65, 70] These materials have been 
synthesized via cryopolymerization of a highly concentrated PVA solution by 
several freeze-thaw cycles.[66, 71] This process helps avoid exposure of the 
payload to potentially harmful reagents and high temperatures. Release of drugs 
such as theophylline (for respiratory diseases treatment), oxytetracycline 
hydrochloride and tylosin tartrate (antibiotics for veterinary use) from PVA-
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hydrogel systems and proteins (i.e. albumin, insulin and IgG) has been 
previously reported.[64, 72] 
Poly(acrylic acid) (PAA) is an anionic biocompatible polyelectrolyte (Figure 
2.5) that has been previously used for pH-sensitive drug delivery.[67, 68, 73] 
PAA has the unique property of being in the liquid phase at pH 5 and becoming a 
gel at pH 7.[68] Permeation of cations into the gelled polymer collapses the gel 
back to a liquid. In addition, this polymer possesses highly mucoadhesive 
properties. These characteristics are desirable for drug delivery due to the 
previously mentioned swelling properties in aqueous conditions, allowing the 
release of molecules or proteins at neutral pH. Systems based on PAA generally 
have rapid release kinetics and the high water solubility of the polymer limits its 
use.[68, 74] These drawbacks can be overcome by crosslinking PAA with other 
polymers, but their interactions determine the mesh size, degradation rate, and 
diffusion of the encapsulated agent.[70] Lightly crosslinked PAA-based systems 
have been commercialized such as Polycarbophil® and Carbopol® and exhibit 
favorable mucoadhesive properties for drug delivery in the gastrointestinal 
tract.[74] 
 
Figure 2.5. Chemical structures of common vinyl polymers (PVA and PAA).[73] 
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2.2.5. Poly(alkyl cyanoacrylates) 
Poly(alkyl cyanoacrylates) (PACA) are biodegradable polymers that have 
been extensively used to prepare nanoparticles for drug delivery.[75, 76] The 
degradation of PACA is carried out by esterases as shown in Figure 2.6 and is 
highly dependent upon the length of the alkyl chain.[75, 76] Cyanoacrylates are 
acrylic monomers that are rapidly polymerized in the presence of water via 
anionic or zwitterionic polymerization. Therefore, low amounts of water can 
trigger the polymerization reaction, forming long chains of PACA. Since 1960, 
cyanoacrylates have been studied for use in biomedical application, as 
adhesives or degradable sutures.[75]  
Ethyl, n-butyl and octyl cyanoacrylate have been approved by the FDA, 
encouraging the development of novel applications with these materials.[75, 76] 
Recently, PACA nanoparticles were used for antileishmanial, loperamide, 
dalargin, tuborcurarine, methotrexate and doxorubicine delivery since it has been 
shown to cross the blood brain barrier and been up taken by tumor cells.[77-85] 
The ability of PACA nanoparticles to overcome multi-drug resistance allows them 
to target tumors more effectively than regular chemotherapy since the PACA 
nanoparticles adsorb to the tumor cell surface, and the formation of an ion pair 
between the drug and the polymeric particles, thus enhancing their drug 
delivery.[85] However, the development of delivery platforms based on these 
polymers has been restricted to applications where rapid degradation of the 
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polymer matrix is desirable, thus reducing its value as a vehicle that can provide 
sustained release kinetics. 
  
Figure 2.6. Degradation mechanism of PACA by esterases.[85] 
 
2.2.6. Polyethers 
Polyethers have been used in biomedical and pharmaceutical fields due to 
their high biocompatibility and high chemical stability.[86, 87] The most 
commonly used polyether is polyethylene glycol (PEG). PEG is a non-toxic, 
highly water soluble, non-immunogenic material that is FDA approved.[86, 87] 
The use of PEG has increased due to its ability to enhance uptake and 
increase solubility of various drugs and antigens.[86, 88] Polyether-based 
platforms have been developed for multiple applications, because they have a 
long half-life in the body, reduce immunogenic activity of attached proteins, and 
are not affected by the enzymatic activity of the metabolism of the body which 
mechanism can be seen in Figure 2.7.[86, 89, 90] In order to confer these 
properties on other materials, processes have been developed to link PEG 
chains to molecules such as proteins and peptides.[86, 89, 90] 
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Figure 2.7. Depiction of PEGylation of a protein.[86] 
 
PEG-based systems have been commercialized for multiple applications, 
including cancer therapy, diagnostics and drug/antigen delivery.[88] 
Commercialized PEgylated molecules such as Pegasys® and Pegintron® (α-
Interferon), Neulastra® (granulocyte colony stimulated factor (GCSF)), and 
Adagen® (adenosine deaminase) have been approved by the FDA.[88, 90] 
Clinical studies of PEG-conjugates have included IL-2, hemoglobin (for patients 
under radiation treatment for solid tumors), growth hormone antagonist, and 
staphylokinase mutein (for treatment of acute myocardial infarction).[88, 90] 
One potential limitation to the use of PEG is that it is non-degradable, and 
so if high molecular weight PEG is used, it could accumulate in the kidney and 
liver.[86] In addition, these materials have loading restrictions that can be 
overcome by attaching dendrimeric structures onto the surface of the polymer 
groups, but these modifications increase the cost of the product.[88] 
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2.2.7. Polyanhydrides 
Polyanhydrides were first synthesized in 1909 and used for textile 
applications by DuPont in the 1930s. These polymers are hydrolytically unstable 
and degradable, which has made them viable candidates for its use in medical 
and pharmaceutical applications. 
 
Figure 2.8. Basic chemical structure of polyanhydrides.[91] 
 
Polyanhydrides are versatile materials due to the hydrolytic reactivity of 
the anhydride linkage (Figure 2.8), which is the most reactive among carbon or 
carbonyl bonds. This characteristic allows them to form different backbone 
structures, but maintain the biodegradability of the polymer. By modifying the 
length of the main chain and/or copolymerization of anhydride monomers in 
multiple ratios can help tailor the degradation of the polymer.[92-100] For 
example, ethylene glycol groups have been inserted into a 1,6-bis(p-
carboxyphenoxy)hexane (CPH) backbone, replacing the hexane, and creating a 
more amphiphilic anhydride called 1,8 bis(p-carboxyphenoxy)-3,6 dioxaoctane) 
(CPTEG).[97] 
The classical method to prepare polyanhydrides is to use melt 
polycondensation.[93] A dicarboxylic acid is refluxed using excess of acetic 
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anhydride, obtaining a mixed anhydride solution. Then acetic anhydride is 
removed using high temperatures and vacuum to generate high molecular weight 
polyanhydrides. The reaction time and temperature, as well as the presence of 
catalysts, have a direct impact on the polymer chain length, purity, and 
polydispersity index. 
The tailorable degradation kinetics of polyanhydrides is one of the main 
benefits of these materials with respect to drug delivery applications. The 
degradation rates of polyanhydrides have been shown to vary from a week to 
several months by simply changing the molar ratio of the monomers.[97-99] The 
most hydrophobic monomer studied is CPH and increasing its content in the 
copolymer slows the release of payload, while the amphiphilic (i.e., CPTEG-
containing) copolymers exhibit a higher burst effect and accelerates the polymer 
degradation, leading to faster release profiles for payload.[97, 101] 
Because of their hydrophobicity, these materials possess a surface 
erosion mechanism that can be controlled by copolymer composition.[97, 98, 
100, 102-105] Due to the ability of polyanhydrides to control their degradation 
kinetics, multiple drugs have been encapsulated within these materials, including 
drugs for eye and neuroactive disorders, antibiotics, anticoagulants, anticancer, 
and chemotherapeutic agents.[106-110] A polyanhydride-based device that has 
been approved by the FDA for human use is the Gliadel® wafer, composed of a 
20:80 ratio of 1,3 bis(p-carboxyphenoxy) propane (CPP) and sebacic acid (SA), 
which is loaded with carmustine (1,3-bis(2-chloroethyl)-1-nitro-sourea (BCNU)) 
and used as a post-surgical brain tumor implant.[111] Other drug delivery 
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applications include a polyanhydride cylinder for the delivery of anesthetic 
drugs,[35] oral delivery of insulin,[93] and plasmid DNA and delivery systems to 
treat brain tumors.[35] The commercially available Septacin® devices for 
antibiotic delivery are based on copolymers consisting of sebacic acid and 
dimers of erucic acid.[105, 106] 
Poly(sebacic acid), which is the most well-studied polyanhydride, 
degrades in a period of weeks when subjected to water conditions.[93] SA also 
can be polymerized with other monomers such as fumaric acid, which increases 
its circulation in the body and enhances its properties for oral bioadhesive 
administration of dicumarol (anticoagulant).[107] It has also been used in 
combination with fatty acid dimer to analyze the release of multiple proteins such 
as lysozyme, trypsin, heparinase, ovalbumin, albumin and immunoglobulin.[97, 
98, 101, 102] 
Polyanhydrides have been recently used as vaccine delivery carriers 
using copolymers based on CPH, SA, and CPTEG, (Figure 2.9). These materials 
have been fabricated into microparticles and nanoparticles and administered via 
different routes (i.e., intranasal, subcutaneous) for the delivery antigens to the 
immune system.[103, 104] Previous studies have analyzed the biocompatibility, 
antigen stabilization, release kinetics, efficaciousness, and immunomodulatory 
effects of this system using both in vitro and in vivo models.[103, 104, 108-110, 
112-122] 
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Figure 2.9. Chemical structures of SA, CPH (middle) and CPTEG (bottom). 
[110,123] 
 
In vitro and in vivo studies have been used to analyzed the interactions of 
polyanhydride particles in order to rationally design “pathogen mimicking” 
nanoparticle-based platforms to effectively stimulate the immune system.[117, 
118, 120-122] Delivery of different molecules to antigen presenting cells has 
been studied to analyze activation patterns and determine appropriate 
formulations of polyanhydride nanoparticles to induce immune activation.[114, 
117, 120-122] Antigenically stable proteins have been released after 
encapsulation into polyanhydride nanoparticles: including tetanus toxoid, 
ovalbumin, PA (protective antigen towards Bacillus anthracis), PspA 
(Pneumococcal surface protein A, a virulence factor of Streptococcus 
Pneumoniae), and viral hemagglutinin (Influenza surface protein).[98, 101, 114-
117, 124] In addition, surface functionalization of polyanhydrides nanoparticles 
with targeting molecules (e.g., carbohydrates) has been performed to enable 
specific interactions with receptors on immune cells.[117, 120, 122] Finally, in 
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vivo studies using a murine model have demonstrated induction of both humoral 
and cellular responses, as well as efficacy against live challenge.[125, 126]  
 
2.3. Nanoparticle characteristics as adjuvants and/or delivery vehicles 
The main characteristics of nanoparticles that affect their performance as 
adjuvants and/or delivery vehicles include particle size, shape, hydrophobicity 
and surface charge. 
 
2.3.1. Particle size 
Particle size and size distribution determine the biodistribution after 
administration, loading of antigens and their release kinetics, and interactions 
with immune cells. For some immunization routes, particle size is even more 
important because of the deposition, uptake, and distribution in the organs 
exposed to the administration site. Generally, small sized particles are 
considered more ideal for biological barrier permeation, cellular uptake, and for 
crossing capillaries after administration.  
Particle size is typically characterized using different methods, especially 
for submicron particles. These methods include light scattering, microscopy 
(scanning electron microscopy, transmission electron microscopy, and atomic 
force microscopy), laser light diffraction, analytical ultra-centrifugation, field flow 
fractionation, chromatography, and capillary electrophoresis.[127]  
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Payload amount and release kinetics from particle delivery systems are 
affected by particle size.[128, 129] Due to the larger surface area, smaller 
particles have the encapsulated agent closer to the surface, and therefore, when 
degradation occurs they result in a larger burst of payload and a faster release 
profile compared to larger particles. Microparticles generally have cores that 
allow higher amounts of payload to be encapsulated. Release rates of different 
payloads have been analyzed and found to be dependent upon particle size, in 
addition to the inherent physicochemical interactions between the payload and 
the biomaterial.[129, 130]  
Another aspect that is affected by particle size is the in vivo biodistribution 
of nanoparticles. When used in intravenous formulations, small particles (<20-30 
nm) are eliminated by renal excretion, while larger particles are taken up by 
phagocytic monocytes and transported to the liver, spleen, and bone marrow (in 
smaller amounts).[131] It is known that 30-150 nm nanoparticles locate in the 
bone marrow, heart, kidney, and stomach, while 150-300 nm particles are 
localized in the liver and the spleen.[132-134] There are also fenestrations in the 
aforementioned organs that allow particles to escape the endothelial barrier and 
enter the parenchyma of the liver and spleen. Generally, these fenestrations 
allow 20-400 nm particles to travel across the previously mentioned organs. 
However, when inflammation or tumors affect the area, this size is increased to 
780 nm.[127]  
Multiple studies have shown advantages of nanoparticle delivery platforms 
for drug and vaccine delivery over micron-size vehicles.[130, 135-137] 
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Nanoparticles are more readily internalized by cells compared to microparticles, 
specifically for intracellular targets because of their smaller size.[136, 137] 
Additionally, the use of smaller size therapeutic delivery systems has shown to 
be more effective to cross the blood brain barrier and sustain release of 
treatment agents for brain tumors.[138, 139] Regarding particle internalization, 
submicron particles are more efficiently internalized by a wider diversity of cells 
than are particles larger than one micron.[129, 140] 
Nonetheless, studies of nanoparticle systems used as vaccine delivery 
vehicles have reported that immune responses depend on size for different 
formulations.[130, 137] Particles ranging in size from 20 nm to 70 µm have been 
used in vaccine formulations and have resulted in different cellular activation and 
immunological responses.[137, 140] A key step in the induction of robust immune 
responses is to enable antigen to reach the lymphatic system. One way to 
accomplish this is through antigen presenting cells (APCs) that can control, 
enhance, and mediate the immunological consequences elicited by vaccination. 
Previous studies have reported that particles with a size of 500 nm or less are 
optimal for APC uptake.[141-143] Within this range, using a model for respiratory 
syncytial virus, 20-200 nm particles are taken up via endocytosis, eliciting Th1-
type cellular immunity. In contrast, following this same model, it was reported that 
particles >500 nm are internalized by phagocytosis or micropinocytosis, and 
generated a more humoral response.[142] In a related study using 430 nm, 1 µm, 
10 µm, and 32 µm polystyrene particles, it was shown that the 430 nm and 1 µm 
particles were effectively internalized by dendritic cells, but the internalization 
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decreased as particle size increased, based on observations using confocal 
microscopy.[144]  
The route of delivery also has an important effect on the induction of 
immune response, more so than particle size. For example, oral and intranasal 
(i.n.) immunization of tetanus toxoid (TT) using 100 and 450 nm and 1 µm 
sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) particles was 
performed and anti-TT IgG titers were measured.[145] Using the i.n. route, the 
450 nm formulation elicited higher titers than oral administration; however, when 
the 100 nm particles were administered, the latter route generated a higher 
response. The microparticles performed similarly, regardless of route. Similar 
results have been reported in other studies using different antigens.[137] For 
intranasal administration, it is known that the particle size has significant impact 
on particle biodistribution, toxicity, deposition, and immune response.[146, 147] 
Such effects have been studied using localized regions or whole lung deposition 
models.[146-148] Particle size determines the pattern of pulmonary deposition 
after inhalation and different sized particles are known to deposit in different 
regions of the lung as depicted in Figure 2.10.[149] These behaviors have also 
been modeled as shown in Figure 2.11. 
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Figure 2.10. Representation of the respiratory system and its sections.[149] 
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Figure 2.11. Average predicted total and regional lung deposition based on 
International Commission on Radiological Protection (ICRP) deposition model for 
nose breathing males and females engaged in light exercise. Alv: alveolar region; 
TB: tracheobronchial region.[150] 
 
2.3.2. Shape 
Among particle characteristics, size and surface charge have been studied 
extensively to assess their influence on the immune response.[129, 151] 
However, very few in vivo studies have compared the effect of differently shaped 
nanoparticles on the resultant immune response.[151] Studies have shown that 
particle shape influenced different aspects of particle-based delivery systems, 
such as their biodistribution, cellular internalization and toxicity.[151] 
Methods to create particles of different shapes include using pre-
fabricated spherical particles and modifying their shape as shown in Figure 2.12 
or using lithographic methods such as the PRINTTM technology that has been 
developed recently.[151-155] The first approach has limitations because 
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materials properties can render the creation of particles with different aspect 
ratios difficult.  
  
Figure 2.12. False-colored scanning electron photomicrographs of alveolar 
macrophages interacting with polystyrene particles with different shapes. A) 
Elliptical disk (attached at the end side), B) Elliptical disk (attached at the flat 
side), and C) spherical nanoparticle. Scale bar=5 µm.[151] 
 
Initial studies focused on the impact of shape on the release kinetics of 
payload.[156] Previous studies have shown that drug or antigen release is highly 
dependent on surface area, therefore, degradation of spherical particles when 
using surface erodible polymers resulted in zero-order kinetics after an initial 
burst.[93, 97, 156] Creation of non-spherical particles provides an opportunity to 
vary the release kinetics of drugs or antigens. 
There have been limited efforts to analyze the effect shape following in 
vivo administration. Since it has been shown that non-spherical shapes and sizes 
can be located in different vesicles, organs, and tissues, initial studies have been 
focused on their biodistribution after administration to the body.[131, 132] The 
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non-spherical shape affects their alignment and permeation into organs, affecting 
how they drain to the lymphatic system, kidney, liver, or spleen. Some 
experiments have shown that spherical particles need to be less than 200 nm in 
diameter to be able to enter the spleen after intravenous administration, while 
flexible disk-shaped red blood cells of even ~10 µm can be transported through 
the spleen consistently.[131] This information, combined with the spleen 
morphology, which includes that the filter channels have slit forms, suggests that 
for certain applications, specific shapes might be more beneficial than traditional 
spherical structures.  
It is known that particle uptake by APCs is affected by the shape.[151-154] 
Previous studies have focused on preparing particles with the same surface 
area, but different shapes, comparing traditional spherical structures with non-
spherical particles (i.e., cubes, rods) to analyze the differences in surface marker 
expression and cytokine secretion after particle internalization.[152, 153, 157] It 
is not clear if particle shape affects the activation mechanisms of APCs. An in-
depth understanding of the effect of particle shape on APC activation and on 
tailoring the immune response may be desirable to design efficacious particle-
based vaccines. 
 
2.3.3. Hydrophobicity and surface charge 
Previous studies have analyzed the electrostatic characteristics of particle 
systems and their involvement in the induction of immune responses.[157, 158] 
For specific applications, a negative surface charge is desirable to enhance 
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particle uptake into certain vesicles or phagocytic cells (e.g., macrophages), 
while for others (e.g., targeting to non-phagocytic cells) positive charge has 
shown to enhance their functionality.  
For vaccine delivery applications in which getting antigen inside cells is 
highly desirable, the adsorption of serum proteins onto the surface of the 
particles (e.g., opsonization) is beneficial.[159] Therefore, the use of hydrophobic 
materials that enhance serum protein adsorption may enhance particle uptake. 
Hydrophobicity is an important factor in particle internalization due to the lipid-rich 
domains that are present in the cell membrane, where interactions with cell-
surface receptors, and complement proteins can be carried out.[159] Generally, 
as the hydrophobicity of the particle increases, the probability of particle 
internalization by phagocytic and macropinocytotic pathways also increases. In 
addition, receptor-mediated uptake may be enhanced by more specific particle-
cell interactions.[160] This may be achieved by incorporating targeting strategies 
into hydrophobic particle-based systems. 
However, when extended circulation of particles (e.g., for systemic gene 
delivery) is required, hydrophilic surfaces are required to reduce the interaction 
between the immune cells and the particle formulation. In order to achieve this, 
surface coating using methods such as PEGylation, as mentioned previously, 
have been used.[80, 86, 88] Other strategies include use of surfactants or 
copolymers such as polyethylene oxide, polyoxamer, and Tween 80 that 
enhance the hydrophilic characteristics of the particles.  
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2.4. Targeting mechanisms for drug and vaccine delivery 
2.4.1 Introduction 
Many drugs and vaccines exhibit decreased efficacy upon in vivo 
administration because they are unable to reach their desired target cells or 
tissue. In recent years, numerous combination systems have been developed as 
represented in Figure 2.13 to enhance the potency of drugs and vaccines by 
designing delivery vehicles that can be targeted to specific organs, tissues, or 
cells.  
 
Figure 2.13. Design of adjuvants/delivery vehicles for targeted delivery.[161] 
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2.4.2. Desired immune system components 
Among the desired targets for antigen delivery platforms, two types of 
cellular populations have generated great interest, which are cancer cells and 
APCs.[162-164] Understanding and optimization of platform characteristics that 
play important roles in the efficient delivery of therapeutics to cancer cells and 
APCs has been widely studied. 
 
2.4.2.1. Tumor cells 
One of the main applications of targeted delivery systems is tumor 
treatment. Work in this area has focused on designing diagnostic systems and 
drug delivery vehicles that can locate cancer cells and help treat or aid in the 
surgical removal of tumors. To enable successful treatment of tumors, the most 
important characteristic is the specificity of the targeting molecule.  
Previous studies in cancer therapy have shown that there are tumor-
specific targets that can be utilized in order to deliver treatments to tumor sites. 
Rational design of delivery approaches highly depend upon the knowledge of 
these targets and an appropriate administration route. For example, the folate 
receptor is over-expressed on the surface of many types of cancer cells, and is 
therefore, a popular target when drug delivery to cancer cells is desired.[165] 
Previous studies have analyzed this strategy with tumor cell lines (e.g., HeLa, 
HEK 293) and efficient cellular uptake was observed by attaching folic acid on 
the surface of poly(ethylene imine) coated mesoporous silica  nanoparticles.[166] 
Recent studies have identified other molecules that have great selectivity for 
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tumor cells, such as an adriamycin-conjugated PEG linker that has cleavable 
peptide sequences (alanyl-valine, alanyl-proline, and glycyl-proline) that is 
cleavaged at tumor cells.[165] Use of these molecules in active targeting 
approaches for cancer treatment is currently underway. 
Another strategy that has been widely studied is the use of antibodies that 
are specific for cancer types. Several of these therapies have been approved by 
the FDA and they will become a commercial alternative for cancer treatment 
using less invasive methods than surgery; these products include Rituxan®, 
Herceptin®, Mylotarg®, Campath®, Zevalin®, Iressa® as treatments for a variety of 
diseases including non-Hodgkins lymphoma, chronic lymphocytic leukemia, 
breast cancer and non-small cell lung cancer, among others.[161, 165, 167, 168] 
Other methodologies for cancer therapy include targeting of molecules 
that stimulate angiogenesis, such as vascular endothelial growth factor (VEGF), 
basic fibroblast growth factor, platelet-derived growth factor, transferrin, or 
epidermal growth factor (EGF).[165, 169] This strategy uses angiogenesis 
inhibitors such as interferons (α, β, and γ), thrombospondin-1 and -2, angiostatin, 
and endostatin. Drug therapies that have been widely studied for cancer therapy 
include the use of doxorubicin, paclitaxel and camptothecin-based 
molecules.[165, 169] Appropriate and specific design of these systems to target 
molecules present in cancer cells can help improve the delivery of treatments to 
tumor sites and also help in cancer diagnosis. 
Targeting mechanisms can be active or passive; active targeting involves 
the attachment of molecules that are specifically recognized by receptors (e.g., 
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proteins, carbohydrates), while passive targeting depends on particle 
characteristics, such as size, shape, and chemistry. The benefits of using 
targeted strategies are enhanced cellular uptake, dose sparing, specificity of 
therapy, and improved efficacy.   
 
2.4.2.2. Antigen presenting cells 
Among the components of the innate immune system, the first line of 
defense depends on the correlated action of APCs, neutrophils, natural killer 
(NK) cells, complement, mucosa, physical barriers (e.g., skin), cytokines and 
chemokines that act together to uptake foreign entities and if necessary initiate 
immune responses towards them. The innate immune cells are generally 
available at tissue or organ surfaces, besides the lymphatic system which is the 
main link between the innate and adaptive immune responses. After the initial 
response, T and B lymphocytes join the immune repertoire, thus, eliciting 
complete immune system activation. 
Dendritic cells (DCs) are leukocytes that are specialized in antigen uptake, 
processing, and presentation, and are important in the integration of innate and 
adaptive immune responses. These cells are generally located at the interface 
between the body and environment; therefore, they have the ability to screen for 
a wide variety of foreign entities. These cells possess properties that make them 
central to the initiation of an immune response, such as antigen internalization, 
processing, and presentation, migration to lymph nodes, and activation of other 
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cells by cytokine secretion. Based on the context of APC activation, and by 
establishing specific combinations of the above properties, these cells are able to 
influence the type of immune responses. 
There are two stages in DC activation that can decide the type of immune 
response that is mounted towards an antigen. The first step is the recognition of 
a danger signal, which triggers DC differentiation and activation, thus attracting 
other cells, due to cytokine and chemokine secretion, and expression of co-
stimulatory molecules, guiding the activated DCs to the lymph nodes. The 
second step starts when DCs enter the lymphatic system and drives generation 
of antigen-specific T cells that then interact with B cells for the secretion of 
antibodies.  
Macrophages are also sentinel cells that phagocytose foreign bodies and 
are involved in innate immunity. These cells internalize and digest viruses, 
bacteria, and parasites, and then present antigen moieties to trigger an immune 
response. However, they are located in specific organs and their interaction with 
the lymphatic system is limited, unless they interact with DCs for their activation. 
Despite this limitation, macrophages are very important in the immune responses 
generated in certain organs, such as the lungs.[170] 
In order to recognize the aforementioned danger signals, APCs have 
pattern recognition receptors (PRRs) that recognize microbial-associated 
molecular patterns (MAMPs), which are small moieties that are present in a 
variety of pathogens. Recognition of these PAMPs (Figure 2.14) leads to APC 
activation and triggers the immune cascade. PRRs can be membrane bound or 
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cytosolic. Included in the first group are Toll-like receptors (TLRs) and C-type 
lectin receptors (CLRs), while retinoic acid-inducible gene I-like (RIG-I) receptors 
and nucleotide-binding oligomerization domain (NOD-like) receptors belong to 
the second group.  
 
Figure 2.14. Methods of pathogen recognition by pattern-recognition receptors 
(PRRs) in APCs.[164] 
 
One of the main APC targeting strategies is the use of TLR ligands to 
specifically interact with TLRs. These receptors are single-pass type I 
transmembrane-spanning proteins characterized by multiple leucine-rich 
repeats.[171] A total of 13 TLRs have been identified in mice and humans, but 
not all of them are present in all mammalian species. TLRs have been identified, 
  
each with a different origin or possible 
collection of pathogen-
2.15. 
Figure 2.15. Identified members from the Toll
respective agonist, origin, and examples.
 
Another commonly targeted group of PRRs is the CLR family. C
lectin receptors bind carbohydrates (e.g., mannose, 
dependent manner using highly conserved glycan
173] CLRs can recognize a wide variety of microbes, leading to their 
internalization and presentation, which initiates an immune respon
a variety of CLRs that are present in DCs and macrophages, including the 
CD206 macrophage mannose receptor (MMR), CD209 (DC
DEC-205, and the macrophage galactose lectin (MGL).
importance of these receptors in the pathogenesis of multiple diseases, it has 
been suggested that targeting this signaling pathway can be very important for 
vaccine design.[173, 174]
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2.4.2.3. Targeting approaches
The concept of targeting was initiated by Paul Ehrlich making the 
hypothesis that a magic bullet could efficaciously enhance the properties of drugs 
by directing them to their target.
components: one that would recognize and specifically bind the target and 
another that would provide therapeutic action to the targeted location. Since the 
development of subunit vaccines and new drugs, this concept has expa
three components as depicted in Figure 2.16: the first is the antigen or the drug, 
the second is the carrier or the adjuvant, and the third is the targeting mechanism 
or molecule. Carrier vehicles currently include polymer vehicles, particles, cell
proteins, liposomes, and micelles. All of these delivery vehicles have been 
functionalized for targeting using a wide variety of strategies, including antigen or 
drug specificity, targeting molecules, and environmentally responsive platforms.
Figure 2.16. “Magic bullet” development is based on three components: antigen 
or drug, adjuvant or delivery vehicle, and targeting molecule.
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2.4.2.4. Antigen specificity 
Some of the strategies explored in this area include the use of antibodies, 
which have been used in monoclonal forms to target the desired location for drug 
and antigen delivery.[165, 174, 175] For specific diseases (i.e., cancer), the 
properties of these antibodies have been exploited to increase the effectiveness 
of antitumor treatment delivery to the desired site.[174] One of these strategies 
involves the engineering of these molecules to create bispecific antibodies that 
have dual affinities, one to the tumor therapeutic molecule and the second to a 
molecular target in the tumor environment.[165, 174] 
As mentioned previously, the use of monoclonal antibodies to enhance 
target treatment for cancer therapy has led to several FDA-approved products, 
such as Rituxan® or Zevalin®, which are based on anti-CD20 antibodies for non-
Hodgkin’s lymphoma, Mylotarg®, which is an anti-CD33 antibody for acute 
myelogenous leukemia, and Campath®, which is an anti-CD52 antibody for B cell 
chronic lyphocytic leukemia.[165, 174] These therapies are designed to target 
and specifically kill cancer cells, either by direct action of the antibody (i.e., 
receptor blockade, delivery of a drug or cytotoxic agent), immune-mediated cell 
killing mechanisms (i.e., complement-dependent cellular cytotoxicity), or specific 
effects on tumor vasculature, and most importantly, by avoiding damage to 
healthy cells surrounding them.[176] The use of these platforms also elicits an 
immune response towards the tumor in order to prevent its proliferation by 
activation of multiple components of the immune system.[176-178] 
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2.4.2.5. Environmentally responsive delivery vehicles 
In recent years, there have been numerous advances in the design of 
delivery platforms that respond to their environmental conditions (i.e., pH, 
temperature). These delivery vehicles can be rationally engineered to change 
their physical or chemical characteristics when entering into a specific 
environment. In addition to pH and temperature, other stimuli-responsive 
platforms involve mechanisms such as ultrasonic radiation, electric field, glucose 
levels, urea, morphine, antibody concentration, and temperature.[179, 180] 
There are different pH responsive therapies that have been developed. 
Generally, these therapies have been designed to release their therapeutic 
payload in endosomal compartments, or within the stomach or intestines, that 
have different pH than the rest of the gastrointestinal tract.[179, 180] Hydrogels 
exhibit controlled swelling properties that are stimuli-responsive.[69, 70, 180] By 
changing their structural conformation, they release cargo at the location where 
the pH is different.[69, 179] This technology has been applied to deliver drugs, 
such as amoxicillin, salicylamide, prednisolone, riboflavin, and salicylic acid, 
among others.[69, 70, 179-181] 
Another methodology that has been well studied is temperature-
responsive platforms. One of the applications of these platforms is in the design 
of micelles and nanogels that modify their structure at physiological 
temperatures. The aforementioned platforms have been used for drug and 
vaccine delivery, DNA or dsRNA delivery, and gene therapy.[179, 182] Release 
and delivery of curcumin, paclitaxel, and other drugs or compounds from such 
materials have also been investigated.[179, 182, 183] 
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2.4.2.6. Channeling molecules 
Conjugation of specific ligands onto delivery vehicles shares a conceptual 
framework with the previously referred, for the purpose of enhancing the delivery 
of therapeutic drugs or vaccine delivery. These molecules typically target cellular 
receptors on APCs or tumor cells. In addition, peptide and drug attachment on 
the surface of various delivery vehicles has also been explored.[160, 173, 184, 
185] Molecule-based targeting approaches are highly dependent on the 
specificity of the targeting mechanism. These mechanisms will be discussed in 
more detail in Section 2.4.3, where active targeting approaches for nanoparticles 
will be discussed. Similar studies have been carried out with polymeric micelles, 
nanogels, nanotubes, microparticles, and liposomes, among others.[29, 69, 171, 
186-188] 
 
2.4.3. Nanoparticle targeting strategies 
In the design of novel vehicles for drug and vaccine delivery, nanoparticles 
have taken center stage. Due to the ability to fabricate nanoparticles with a wide 
variety of materials, and to control their size, shape and surface chemical 
characteristics, numerous nanoparticle-based platforms have been developed for 
drug and vaccine delivery.[35] 
Targeted nanoparticles have been widely studied to enhance antigen or 
drug delivery. There are two ways of designing targeted nanoparticles: passive 
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and active. The first is based on the control of particle characteristics such as 
size, shape, charge, or chemistry. The second is based on attachment of 
targeting molecules such as antibodies, carbohydrates, TLR agonists or 
peptides, among others. 
 
2.4.3.1. Passive targeting 
A significant advantage of nanoparticles over other approaches is their 
ability to effectively deliver their payload to specific regions of the body, their 
internalization by cells, and the ability to fabricate them using a wide variety of 
materials. This is enabled by control of particle characteristics such as size, 
shape, charge, or chemistry. These properties allow tailoring nanoparticle 
characteristics to release antigen or drug in a controlled manner as discussed in 
Section 2.3.  
 
2.4.3.2. Active targeting 
In recent years, active targeting of nanoparticle platforms has received 
enhanced interest in order to design highly specific delivery vehicles that can 
target different cellular populations, environments, or receptors. Among these 
strategies, linkage of molecules that can be recognized by a selected number of 
receptors in restricted cell populations has been widely used.[129, 131, 160] 
These molecules can have a wide variety of functionalities, such as antibodies, 
carbohydrates, and peptides, among others.[129, 131, 160, 173] This strategy 
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has been previously studied with tumor cells as described previously in Section 
2.4.2.1. 
TLR targeting strategies have also been incorporated into multiple 
platforms. Poly I:C, CpG oligonucleotides, and lipid-related molecules are some 
of them, that have been used  to target Toll-like receptors in dendritic cells and 
macrophages, to deliver therapeutic drugs or molecules such as imiquimod, 
single stranded RNA, 852A molecule (TLR-7 agonist) and IMO-2055.[184, 189] 
By incorporating TLR agonists, previous studies have shown an enhancement in 
particle internalization and response by the desired target cells (i.e., cancer 
cells).[184, 189] 
Carbohydrate targeting has been explored more recently thanks to a more 
detailed understanding of viral and bacterial mechanisms of cellular entry and 
infection.[162, 172, 190, 191] Specific receptors such as DC-SIGN and MMR 
have been targeted by using functionalized nanoparticles with glycan 
moieties.[173, 192, 193] These nanoparticles mimic the natural process 
recognition by APCs as shown in Figure 2.17. CLRs, as previously described, 
recognize sugar residues and internalize them (some CLRs, like Dectin-2, 
require cross-linking before uptake mechanisms are initiated), making them a 
viable target to enhance antigen delivery and presentation.  
Several studies have analyzed the role of targeting CLRs in the 
development of vaccines. Because conventional strategies have encountered 
multiple challenges in the prevention and treatment of severe infectious 
diseases, including Acquired Immunodeficiency Syndrome, tuberculosis, 
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autoimmune diseases, or cancer; use of active targeting strategies involving 
carbohydrates to mimic their pathogenic behavior and elicit immune responses 
are being explored.[162, 194-196] Some of these initial studies include ex vivo 
stimulation of DCs by sugar-functionalized particles to deliver therapeutic drugs 
and activate immune cells.[117, 120, 122, 194] In addition, targeting of CLRs 
such as DEC 205, DC-SIGN, and MMR by antibodies have elicited antigen-
specific CD4+ T cells and C8+ T cell responses.[172, 197, 198] In vivo 
immunization of mice with the Dectin-1 ligand curdlan, induces antigen-specific T 
cell immunity through the SYK-CARD9 pathway, generating CD4+ TH1 and 
TH17 cells, as well as CD8 T cell responses.[172] These receptors can also be 
targeted by antibodies to induce tolerance to prevent autoimmune diseases, such 
as type 1 diabetes. As reported in previous studies, mannosylation of 
polyanhydride nanoparticles enhanced particle internalization, and induced DC 
and alveolar macrophage activation.[117, 120, 122] Also, mannosylated chitosan 
microparticles have been shown to effectively target the mannose receptor in 
alveolar macrophages.[163] These studies suggest potential strategies for 
immunization. 
This platform has also used oligomannoses to modulate the immune 
response, based on the up-regulation of secreted IL-10.[190, 199] In addition, 
targeting DEC205 by antibodies resulted in the induction of tolerance in absence 
of TLR agonists included in the formulation.[200, 201] These results offer insights 
into the development of new strategies for the treatment of allergies and 
autoimmune diseases.  
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Figure 2.17. Antigen presentation using CLRs.[202] 
 
 
For viral infections (e.g., human immunodeficiency virus (HIV)), the use of 
carbohydrate-targeting based strategies has been studied extensively due to the 
important role of the glycoproteins present on the surface of the HIV virion (i.e. 
gp41, gp120) and their involvement in the pathogenesis of the viral spread.[195, 
196, 203] Targeting DC-SIGN using mannosylated structures has emerged as an 
important strategy in the development of HIV vaccines or treatments.[195, 196] 
2.5. HIV: Overview and current challenges 
The Human Immunodeficiency Virus (HIV) pandemic has become one of 
the major global health problems. An estimated 34 million people were infected 
as of 2011, and more than 25 million deaths have been attributed to the 
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subsequent disease, Acquired Immunodeficiency Syndrome, since it emerged in 
the early 1980s.[204] Sub-Saharan Africa and other remote locations still bear 
over 75 percent of new infections each year.[204] One of the main approaches in 
the development of an HIV vaccine is the mimicking of the viral envelope 
glycoproteins to elicit immune responses towards the virus by using subunit 
vaccines. 
2.5.1. Overview of HIV infection 
HIV is a 120 nm spherical lentivirus of the Retroviridae family. The virion 
has two lipid membranes, called the viral envelope, formed by two trimers as 
shown in Figure 2.18. One of them is a group of external surface glycoproteins 
(gp120) bounded to a stem of transmembrane glycoproteins (gp41). Envelope 
glycoproteins allow the fusion of the virus to the host cell membrane. Inside is a 
cone-shaped core that envelopes a capsid with more than two thousand copies 
of the virion and three enzymes (protease, reverse transcriptase and integrase), 
which are responsible for the proliferation of the virus inside the host. The capsid 
contains two strands of viral genomic RNA, which are precursors of the viral 
proteins that start cell transfection. 
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Figure 2.18. Depiction of an HIV virion.[205] 
 
There are only a few monoclonal antibodies that have these 
characteristics, b12, 2G12, 447-52D, 2F5, 4E10 and Z13e1.[206, 207] The first 
three are specific to the HIV glycoprotein gp120 and the latter to gp41. 
Nonetheless, antibodies that target gp41 have shown more breadth than the 
others.[206, 207] The 4E10 antibody neutralizes all the virus isolates from 
different clades, and even though 2F5 or Z13e1 do not neutralize every isolate, 
they have been shown to exhibit cross-clade activity.[206, 207] 
HIV infection is characterized by sustained activation of the immune 
system. Upon entrance at the mucosal surface, HIV-1 infects submucosal CD4+ 
T cells and initiates the spread of the viral infection. This virus does not rely 
completely on the host cell machinery, but also on its proteins that act during the 
cell cycle to modulate cellular signaling. Even though the entrance of this virus is 
through T cells, other types of cells are also permissive to HIV-1 infection, 
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including macrophages. Macrophages with or without infection become activated 
by the presence and the signaling cascade of the gp120 protein from the HIV 
virion. The activation of these two critical types of cells (CD4+ T cells and 
macrophages) helps to mount an immune response against the virus.  
This virus is able to escape from adaptive antibody and T cell responses 
by eliciting persistent viral replication in macrophages and other immune cells 
and also by the consistent destruction of CD4+ T cells, which leads to the 
development of AIDS.[203, 207, 208] Infection with HIV-1 generates antibody 
responses towards viral proteins, but only antibodies against the surface-
exposed envelope glycoprotein possess neutralization capabilities.[207-209] 
 
2.5.2. Vaccine strategies 
Most successful vaccines involve the production of functional antibodies. 
Licensed vaccines that have been developed towards viral infections generally 
elicit neutralizing antibodies (NAbs) towards the pathogen. Therefore, in the 
development of an HIV-1 vaccine, elicitation of Nabs is a primary goal. Even 
though neutralizing antibodies are generated as the infection progresses, by the 
time the immune response is mounted, the adaptive immune response is not 
able to fight the virus.  
The main approach in the development of an HIV vaccine involves the 
elicitation of neutralizing antibodies by the construction of subunit proteins, based 
on the surface protein region, which involves gp41, gp120, and gp160. Among 
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these strategies, most efforts have been focused on the regions of gp120 and 
gp41, due to the availability and importance of these molecules in the viral 
entrance.[206, 208] Typically, peptides, mini proteins and other molecules have 
been constructed as vaccine antigens.[207, 210] 
Since most of HIV infections are initiated via vaginal or rectal 
transmission, several researchers have investigated immune responses elicited 
in the mucosa-associated lymphoid tissue (MALT).[211, 212] The elicitation of 
antibodies using mucosal routes is shown in Figure 2.19. Therefore, many 
studies carried have been through immunizations at mucosal surfaces. 
Regarding genital administration of vaccine antigens, specifically using 
intravaginal immunizations in animal models or humans, results have shown that 
this route generated antibodies predominantly in local secretions, but not 
systemically, which is necessary to fight an HIV infection.[211] In rectal 
immunizations, there have been studies where human volunteers in phase 1 
clinical trials were injected intramuscularly with virus-like particle vaccines with 
HIV p17/p24 proteins.[211, 212] The studies were carried out for six months with 
three immunizations and no strong immune responses were elicited by the 
individuals.[211]  
Finally, it has been shown that intranasal immunizations have been the 
most successful in the generation of systemic responses and in the elicitation of 
neutralizing antibodies.[211] These immunizations include peptide antigens, DNA 
vaccines, and live bacterial and viral vectors.[212, 213] Polymeric nanoparticles 
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that were used intranasally with HIV-1 capturing nanoparticles generated 
antigen-specific immunoglobulin A in vaginal washes in mice.[211] 
 
Figure 2.19. Mucosal immunization elicits antibodies against HIV.[211] 
 
2.5.3 Current therapies and challenges  
Since there is no HIV vaccine currently available to prevent viral infection, 
the only available option is to treat patients already exposed to the virus. The 
treatment consists of the use of antiretroviral drugs (ARVs).[204] Antiretroviral 
therapy (ART) involves the combination of at least three ARVs to help suppress 
the effects of HIV and thus stop the progression of the disease. These 
therapeutics have effectively reduced the mortality rate of seropositives (HIV 
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infected subjects), particularly when used in controlled regimens and at early 
stages of the progression of AIDS.[204, 214] 
Of the 34 million living people infected with HIV in 2011, the World Health 
Organization (WHO) and the United Nations Programme on HIV/AIDS  
calculated that at least 15 million individuals need ART, of which 9.7 million 
individuals had access to it.[204] WHO has been highly involved in the 
prevention of HIV infection by offering education, support, and other tools and in 
efforts to increase production of ARTs so they can be delivered to developing 
countries. 
These therapies do not prevent infection, or transmission of the virus, but 
they help control it and avoid disease progression. However, they are very 
expensive and require strict administration regimens, making it difficult to supply 
across the world. Thus, there is an urgent need to design a prophylactic tool that 
is easy to administer, that elicits strong immune responses against HIV, and that 
prevents viral infection. 
 
2.6. Summary 
Biodegradable polymers have been used for multiple applications, 
including as adjuvants/delivery vehicles for antigens. For HIV vaccines, the 
importance of the choice of adjuvant/delivery vehicle is particularly enhanced, 
since the potency of the immunogen and its delivery to specific locations or 
tissue is critical for the generation of a robust immune response.  Polyanhydride 
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nanoparticles have exhibited desirable characteristics for antigen delivery as 
adjuvants and/or delivery vehicles. Therefore, exploiting their properties to design 
an HIV vaccine is a promising approach. This literature review suggests that to 
design an effective HIV vaccine, a combination of a potent antigen, an adjuvant 
that enhances the immunogenicity of the antigen and delivers it to the right 
cellular population(s), and a route of immunization that results in systemic 
responses to prevent HIV infection are necessary. 
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CHAPTER 3 
 
Research Goals and Thesis Organization 
 
The overall goal of this research is to design novel polyanhydride 
nanoparticle-based systems as targeted vaccine delivery vehicles, specifically for 
HIV antigens. It is hypothesized that these subunit nanovaccines can help elicit 
strong and balanced immune responses that will result in efficacious treatments 
against this virus. To achieve this objective, a combination of concepts and 
techniques from polymer chemistry, immunology, carbohydrate chemistry, 
nanotechnology, and molecular biology has been woven together for the rational 
design of these delivery vehicles. The specific goals of this research are: 
• Specific goal 1: Identification of carbohydrate-functionalized polyanhydride 
nanovaccine formulations that stabilize HIV-1 antigens 
• Specific goal 2: Analysis of the role of polymer chemistry on serum protein 
adsorption patterns onto polyanhydride nanoparticles and macrophage 
activation 
• Specific goal 3: Evaluation of the in vivo biodistribution and safety of 
carbohydrate-functionalized polyanhydride nanoparticles 
• Specific goal 4: In vivo evaluation of carbohydrate-functionalized 
polyanhydride nanoparticles with respect to inducing anti-HIV antigen 
antibodies 
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The information obtained from these studies will help us understand the role 
of polymer chemistry, serum protein adsorption, route of administration, and 
active targeting mechanisms in the induction of efficacious immune responses.  
The studies presented herein describe the experiments carried out to 
accomplish specific goals listed previously. Chapter 4 focuses on specific goal 1 
and deals with the identification of carbohydrate-functionalized polyanhydride 
nanoparticles that stabilize HIV-1 antigen and that activate dendritic cells. 
Chapter 5 describes the studies performed to evaluate the effects of serum 
protein adsorption and polymer chemistry on antigen presenting cell activation 
(specific goal 2). Chapter 6 includes studies on the safety and biodistribution of 
targeted polyanhydride nanoparticles after administration into mice (specific goal 
3). Chapter 7 presents the results obtained during in vivo studies that have been 
carried out with different polyanhydride particle formulations (specific goal 4). 
Finally, ongoing and future studies that will continue this work are discussed in 
chapter 8.  
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4.1. Abstract 
The functionalization of polymeric nanoparticles with ligands that target 
specific receptors on immune cells offers the opportunity to tailor adjuvant 
properties by conferring pathogen mimicking attributes to the particles. 
Polyanhydride nanoparticles are promising vaccine adjuvants with desirable 
characteristics such as immunomodulation, sustained antigen release, activation 
of antigen presenting cells, and stabilization of protein antigens. These 
capabilities can be exploited to design nanovaccines against viral pathogens, 
such as HIV-1, due to the important role of dendritic cells and macrophages in 
viral spread. In this work, an optimized process was developed for carbohydrate 
functionalization of HIV-1 antigen-loaded polyanhydride nanoparticles. The 
carbohydrate-functionalized nanoparticles preserved antigenic properties upon 
release and also enabled sustained antigen release kinetics. Particle 
internalization was observed to be chemistry-dependent with positively charged 
nanoparticles being taken up more efficiently by dendritic cells. Up-regulation of 
the activation makers CD40 and CD206 was demonstrated with carboxymethyl-
α-D-mannopyranosyl-(1,2)-D-mannopyranoside functionalized nanoparticles. The 
secretion of the cytokines IL-6 and TNF-α was shown to be chemistry-dependent 
upon stimulation with carbohydrate-functionalized nanoparticles. These results 
offer important new insights upon the interactions between carbohydrate-
functionalized nanoparticles and antigen presenting cells and provide 
foundational information for the rational design of targeted nanovaccines against 
HIV-1.  
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4.2. Introduction 
Functionalization of antigen delivery platforms to enable active targeting of 
cells is a well-studied approach for the design of novel adjuvants/delivery 
formulations for vaccines.[1-4] Activation of cellular receptors on antigen 
presenting cells (APCs) can enable tailored immune responses against 
pathogens.[5-7] One such approach is the use of carbohydrate moieties to 
activate pattern recognition receptors like C-type lectin receptors (CLRs), which 
play an important role in both innate and adaptive immune responses.[2,5,8-11] 
This strategy could be important for viral infections, particularly human 
immunodeficiency virus (HIV), due to the key role of dendritic cells (DCs) and 
macrophages in the spread of the virus.[12-15]  
In recent years the HIV epidemic has become one of the greatest 
challenges for researchers around the world.[16-17] Since its outbreak in 1981, 
more than 25 million people have died of Acquired Immunodeficiency Syndrome 
(AIDS), and over 33 million people are currently infected.[18] HIV-1 infection is 
characterized by the inhibition of the immune response from CD4+ T cells that 
allows constant replication of the virus and depletion of T helper cells, which 
ultimately causes disease progression.[12,16,19-21] One of the mechanisms that 
HIV-1 uses to block the immune response due to CD4+ T cells is infection of 
plasmacytoid DCs to prevent the maturation and proliferation of these cells, 
resulting in the induction of a T regulatory lineage.[12,14,15,22-24] Given the 
multiple roles that DCs play in the innate and adaptive immune responses, other 
functions are also affected due to the interaction of the virus with these cells. 
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These include suppression of TLR7 and TLR9 activation, which are known 
antiviral Toll-like receptors, and blockage of the release of Type I and II 
interferons.[15, 22] Therefore, it has been hypothesized that activation of DCs is 
required to prevent HIV-1 infection.[7,15,22] 
One of the main strategies to prevent the continuous spread of HIV-1 
worldwide is the development of an efficacious vaccine.[16,19,25] Presently, one 
of the main foci in the development of efficacious HIV-1 vaccines is the use of 
recombinant proteins as antigens.[16,17,26] Even though these antigens are 
safe, they are poorly immunogenic, and therefore need an adjuvant to elicit a 
robust immune response.[26] In this regard, biodegradable polyanhydride 
nanoparticles have shown promise as adjuvants and/or delivery vehicles with 
beneficial properties, including antigen stabilization, sustained antigen release, 
APC activation, and immune modulation, that can be exploited to formulate a 
successful HIV-1 vaccine.[27-34] This study focuses on the use of gp41-54Q-
GHC as the immunogen (to be described in more detail elsewhere), which 
contains the Heptad Repeat Region 2 (HR2) and the membrane proximal 
external region (MPER) of the HIV-1 glycoprotein gp41.[26] Polyanhydride 
nanoparticles based on sebacic acid (SA) 1,6-bis(p-carboxyphenoxy) hexane 
(CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and CPH were 
used to encapsulate and release stable gp41-54Q-GHC immunogen. The 
nanoparticles were functionalized with carboxymethyl-α-D-mannopyranosyl-(1,2)-
D-mannopyranoside (di-mannose) to specifically target the macrophage 
mannose receptor (MMR). Bone marrow derived DCs were stimulated with these 
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nanoparticles and their activation patterns were analyzed. The current studies 
demonstrate the dual capabilities of functionalized polyanhydride nanoparticles to 
stabilize an HIV-1 antigen and to target and activate DCs. 
 
4.3. Materials and Methods 
4.3.1. Materials 
Chemicals needed for monomer synthesis, polymerization, and 
nanoparticle synthesis included 1-methyl-2-pyrrolidinone, anhydrous (99+%), 
terephthalic acid (99+%) and sebacic acid (99%) and all were purchased from 
Aldrich (Milwaukee, WI); 1,6-dibromohexane, 4-p-hydroxybenzoic acid, and 
triethylene glycol were purchased from Sigma Aldrich (St. Louis, MO); 4-p-
fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); acetic acid, 
acetic anhydride, acetonitrile, dimethyl formamide (DMF), ethyl ether, hexane, 
methylene chloride, pentane, petroleum ether, potassium carbonate, sulfuric 
acid, and toluene were purchased from Fisher Scientific (Fairlawn, NJ). For NMR 
characterization, deuterated chemicals, including chloroform and dimethyl 
sulfoxide (DMSO), were purchased from Cambridge Isotope Laboratories 
(Andover, MA). For nanoparticle functionalization, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride, N-hydroxysuccinimide, and 
ethylenediamine were purchased from Thermo Scientific (Waltham, MA). Glycolic 
acid was purchased from Acros Organics (Pittsburgh, PA). β-Mercaptoethanol, 
Escherichia coli lipopolysaccharide (LPS) O26:B6, and rat immunoglobulin (rat 
IgG) were purchased from Sigma Aldrich (St. Louis, MO). Materials required for 
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the DC culture medium included: granulocyte-macrophage colony-stimulating 
factor (GM-CSF), purchased from PeproTech (Rocky Hill, NJ); HEPES buffer, 
RPMI 1640, penicillin-streptomycin, and L-glutamine, purchased from Mediatech 
(Herndon, VA); and heat inactivated fetal bovine serum, purchased from Atlanta 
Biologicals (Atlanta, GA). Materials used for flow cytometry included: BD 
stabilizing fixative solution purchased from BD Bioscience (San Jose, CA); 
unlabeled anti-CD16/32 FcγR, purchased from Southern Biotech (Birmingham, 
AL); allophycocyanin (APC) anti-mouse CD40 (clone 1C10), Alexa Fluor® 700 
conjugated anti-mouse MHC Class II (I-A/I-E) (clone M5/114.15.2) and their 
corresponding isotypes APC-conjugated rat IgG2aκ (clone eBR2a), PE-
conjugated rat IgG2aκ (clone eBR2a), Alexa Fluor 700®-conjugated rat IgG2bκ 
were purchased from eBiosciences (San Diego, CA). APC/Cy7 conjugated anti-
mouse CD11c (clone N418), PE/Cy7 conjugated anti-mouse CD86 (clone GL-1), 
FITC conjugated anti-mouse CD206 (clone C068C2) and their corresponding 
isotypes APC/Cy7 conjugated Armenian Hamster IgG (clone HTK888), PE/Cy7 
conjugated rat IgG2aκ (clone RTK2758), FITC conjugated rat IgG2aκ (clone 
RTK2758) were purchased from BioLegend (San Diego, CA). Cadmium selenide 
quantum dots (QDs) (emission at 630 nm) were a kind gift from Dr. Aaron Clapp 
at Iowa State University. 
 
4.3.2. Construction of pET-gp41-54Q-GHC 
The plasmid encoding gp41-54Q-GHC was constructed based on pET-
gp41-54Q (to be described elsewhere), which encodes 54 amino acids of the C-
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terminal ectodomain of HIV-1 gp41 (based on M group consensus sequence, 
MCON6). The terminal lysine residue was mutated to glutamine. A short linker 
(GSGSG), followed by a 6xHis tag and a cysteine residue (C) was attached right 
after the Gln (Q) by PCR using a forward primer 5’-
CGCGGATCCGAGTGGGAGCGCGAGATC-3’ and a reverse primer 5’-
CCATGAATTCTTAGCAATGGTGATGATGGTGATGTCCCGATCCCGATCCC 
TGGATGTACCACAGCCAGTT-3’. The PCR product was digested by BamHI 
and EcoRI and then ligated into corresponding sites in pET-21a to yield pET-
gp41-54Q-GHC. Construct was confirmed by sequencing. 
 
4.3.3. Expression and purification of gp41-54Q-GHC 
Protein expression and purification were performed according to the 
method of Penn-Nicholson et al. [35] with a few modifications. For gp41-54Q-
GHC expression, E. coli T7 Express IysY/Iq (New England Biolabs) was 
transformed with pET-gp41-54Q-GHC and cultured overnight at 37 °C in 
superbroth containing ampicillin (50 µg/mL). Cells were diluted 1:100 in fresh 
superbroth and cultured to 1.0 OD600 at 37°C. Protein expression was then 
induced with 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) and continued 
to grow until OD600 reached 5.0. Cells were harvested by centrifugation at 4,600 
rcf for 30 min in a Sorvall Legend XFR centrifuge (Thermo Scientific). The cell 
pellet was washed in phosphate-buffered saline (PBS, pH 7.4) and lysed by 
sonication using a Branson Digital Sonifier. The sample was sonicated until the 
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suspension became translucent, followed by centrifugation at 15,000 rcf for 20 
min in Avanti® J-26 XPI centrifuge (Beckman Coulter). After an additional three 
repetitions of PBS resuspension, sonication, and centrifugation, the pellet 
containing inclusion bodies was solubilized in PBS containing 8 M urea and 
sonicated. Insoluble debris was removed by centrifugation at 15,000 rcf for 20 
min, and soluble proteins were bound to Ni-NTA resin (QIAGEN) by mixing on an 
end to end shaker overnight at 4 °C. The mixture wa s loaded onto a column, and 
the protein was renatured through serial incubations with 20 bed volumes of PBS 
containing a decreasing step gradient of urea at 8 M, 6 M, 4 M, 3 M, 2 M, 1 M, 
and 0 M. The column was washed with PBS containing 20 mM imidazole, and 
the protein was eluted with PBS containing 250 mM of imidazole. Purified protein 
was finally dialyzed in PBS (pH 8). The endotoxin content in gp41-54Q-GHC was 
quantified using a commercially available QCL-1000 Limulus Amebocyte Lysate 
(LAL) kit (Lonza, Switzerland) and found to be < 0.1pg/µg of protein, which is 
acceptable for use in cell-based assays [36-38] for subunit proteins. 
 
4.3.4. Monomer and polymer synthesis 
Monomers of 1,6-bis(p-carboxyphenoxy) hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were synthesized as described 
previously.[27,29,39] CPTEG:CPH and CPH: SA copolymers of various ratios 
were synthesized by melt polycondensation as previously described.[39-41] The 
chemical structure was characterized with 1H NMR using a Varian VXR 300 MHz 
spectrometer (Varian Inc., Palo Alto, CA) and the molecular mass was 
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determined using gel permeation chromatography (GPC) on a Waters GPC 
chromatograph (Milford, MA) containing PL gel columns (Polymer Laboratories, 
Amherst, MA). The synthesized 50:50 CPTEG:CPH copolymer had a Mw of 5,400 
Da, the 20:80 CPH:SA copolymer had a Mw  of 14,400 Da and the 20:80 
CPTEG:CPH copolymer had a Mw of 7,700 Da. The polydispersity indexes (PDI) 
of these copolymers were 1.5, 1.4 and 1.3, respectively. These values are 
consistent with previous work.[29-33,39] 
 
4.3.5. Nanoparticle synthesis 
Polyanhydride nanoparticles were synthesized using anti-solvent 
nanoencapsulation as described previously.[42] Briefly, gp41-54Q-GHC (1% w/w) 
and 20 mg/mL polymer were dissolved in methylene chloride (at 4°C for 50:50 
CPTEG:CPH and at room temperature (RT) for 20:80 CPH:SA). The polymer 
solution was sonicated at 40 Hz for 30 s using a probe sonicator (Ultra Sonic 
Processor VC 130PB, Sonics Vibra Cell, Newtown, CT) to create a 
homogeneous protein/polymer mixture and rapidly poured into a pentane bath (at 
-40°C for CPTEG:CPH and at RT for CPH:SA) at a solv ent to non-solvent ratio of 
1:250. Particles were then collected by filtration and dried under vacuum for 1 h.  
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4.3.6. Nanoparticle functionalization 
4.3.6.1. Synthesis of carboxylated di-mannose 
carboxymethyl-α-D-mannopyranosyl-(1,2)-D-mannopyranoside was 
synthesized using an alkenyl fluorous tag as previously reported.[43] Fluorous 
solid phase extraction (FSPE) was used to purify all the intermediates.[44-46] 
The double bond was cleaved by ozonolysis to produce an aldehyde at the 
reducing end, which was further oxidized to carboxylic acid by Jones oxidation. 
The global deprotection of the protecting groups was carried out by Birch 
reduction to generate the target dimannoside.[47-50] 
4.3.6.2. Surface functionalization 
carboxymethyl-α-D-mannopyranosyl-(1,2)-D-mannopyranoside was 
conjugated onto the surface of polyanhydride nanoparticles using an amine-
carboxylic acid coupling reaction.[47-50] Particles with glycolic acid groups on 
the surface (linker) and non-functionalized (NF) particles were used as controls. 
The conjugation reaction was performed in two reaction steps. Briefly, a 
nanoparticle suspension was made in nanopure water (10 mg/mL), and 10 
equivalents of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDC) and 12 equivalents of N-hydroxysuccinimide (NHS), and 10 equivalents of 
ethylenediamine were added. This reaction was carried out at 4°C temperature 
for 1 h at a constant agitation of 17 rcf. Following the reaction, the particles were 
centrifuged at 10,000 rcf for 10 min and the supernatant was removed. The 
particles were washed with the same volume of nanopure water, centrifuged at 
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10,000 rcf for 10 min and the supernatant was removed. A second reaction was 
performed with 10 eq. of EDC, 12 eq. of NHS and 10 eq. of the corresponding 
functionalizing agent (i.e., di-mannose or glycolic acid) in nanopure water, using 
constant agitation at 17 rcf for 1 h at 4°C. Partic les were sonicated before and 
after each reaction to break aggregates. After the reaction was completed, 
nanoparticles were collected by centrifugation (10,000 rcf, 10 min) and dried 
under vacuum for 1 h.  
 
4.3.7. Nanoparticle characterization 
Characterization of morphology and size of both the functionalized and the 
NF nanoparticles was performed using scanning electron microscopy (SEM, FEI 
Quanta 250, Kyoto, Japan) and quasi-elastic light scattering (QELS, Zetasizer 
Nano, Malvern Instruments Ltd., Worchester, UK). In order to confirm the 
successful attachment of the glycans onto the nanoparticles, QELS was used to 
measure the ζ-potential of the nanoparticles. To quantify the amounts of the 
carbohydrates conjugated to the nanoparticles, a high throughput version of a 
phenol-sulfuric acid assay was used.[47,51] A microplate reader (SpectraMax 
M3, Molecular Devices, Sunnyvale, CA) was used to obtain the absorbance of 
standards and unknown samples using a wavelength of 490 nm. The total 
amount of sugar per unit weight of nanoparticles (µg/mg) was calculated. 
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4.3.8. Antigen release kinetics  
In vitro antigen release kinetics studies were performed using a micro 
bicinchoninic acid (BCA) assay. Samples of protein-loaded nanoparticles were 
suspended in 750 µL of phosphate buffered saline (0.1 M, pH 7.4) with 0.01% 
w/v sodium azide and incubated at 37°C and 106 rcf.  For each time point, 
samples were centrifuged at 10,000 rcf for 10 min, the supernatant was removed 
and aliquoted at 4°C, and fresh buffer was added to  each sample to maintain 
perfect sink conditions. Aliquots were analyzed using micro BCA at an 
absorbance of 562 nm. Ethylenediamine-functionalized nanoparticles were used 
as a control for carbohydrate-modified nanoparticle quantification because the 
ethylene glycol linker interfered with the micro BCA assay. The experiment was 
carried out for 30 days, and the amount of released protein was normalized with 
total amount of protein encapsulated, as described previously.[52,53] After 30 
days, the remaining protein was extracted by adding 750 µL of 17 mM NaOH 
solution. Protein encapsulation efficiency and antigen loss because of 
functionalization conditions were estimated using the micro-BCA assay. 
 
4.3.9. Gel electrophoresis  
For electrophoretic analysis of released gp41-54Q-GHC, nanoparticles 
were suspended in 250 µL of PBS (pH 7.4) for 1 h. After incubation, samples 
were centrifuged at 10,000 rcf for 10 min and supernatants were removed and 
stored for further analysis. Protein concentrations were measured using a micro-
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BCA assay and 500 ng of gp41-54Q-GHC released from each polymer chemistry 
was loaded in 4-20% polyacrylamide gels and run for 2 h at 120 V. Protein 
standards (10-250 kDa) were used to measure molecular weight. The gels were 
incubated in fixative solution (40% methanol, 10% acetic acid) for 3 h at 4°C. 
Staining with Flamingo fluorescent gel stain (BioRad Laboratories, Richmond, 
CA) was performed at 4°C overnight. Gels were scann ed using a Typhoon 9410 
Variable Mode Imager (GE Healthcare). [54] 
 
4.3.10. Antigenic analysis of released immunogen 
Antigenic analysis of gp41-54Q-GHC immunogen one hour after release 
from NF and functionalized 50:50 CPTEG:CPH nanoparticles was performed 
using an enzyme-linked immunosorbent assay (ELISA). Briefly, gp41-54Q-GHC 
(30 ng/well) was coated onto 96 well CostarTM High Binding plates (Costar 
#3590) using antigen coating buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM 
NaN3, pH 9.6) overnight at 4°C. Non-specific antibody b inding was prevented by 
blocking wells with 290 µL of PBS (pH 7.4) containing 2.5% skim milk and 10% 
fetal bovine serum (FBS) (1 h at 37°C). Plates were  washed six times with 0.1% 
Tween 20 in PBS. Primary antibodies (2F5 [55-57], 4E10 [58] and Z13e1 [59-60]) 
were diluted at 1:1,000 in blocking buffer, and 100 µl were added to each well 
and incubated for 2 h at 37°C. The plates were wash ed six times and secondary 
antibody (goat anti-human) (Thermo-Scientific; Cat# 31430) at 1:3,000 dilution 
was added to each well and incubated (100 µL, 1 h at 37°C). The plate washing 
process was repeated six times and wells were developed using 100 µL of TMB-
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HRP substrate for 10 min. The reaction was stopped with 50 µL of 2 N H2SO4. 
The developed plates were analyzed using a microplate reader (SpectraMax 
M3).  
 
4.3.11. In vitro DC uptake and activation 
4.3.11.1 Mice 
C57BL/6 (B6) mice were purchased from Harlan Laboratories 
(Indianapolis, IN). Mice were housed in specific pathogen-free conditions where 
all bedding, caging, and feed were sterilized prior to use. All animal procedures 
were conducted with the approval of the Iowa State University Institutional 
Animal Care and Use Committee.   
 
4.3.11.2. DC culture and stimulation 
Dendritic cells were derived from bone marrow, harvested from tibias and 
femurs of C57/BL6 mice as described previously in published protocols.[40, 47, 
50,61] DCs were >90% positive for CD11c (data not shown). Briefly, mice were 
euthanized using carbon dioxide inhalation and cardiac puncture was performed 
to ensure death. Bone marrow cells were harvested from tibias and femurs, and 
cultured in 10 mL of DC media containing RPMI-1640 with 10% FBS, 5% 
penicillin/streptomycin, 5% 2mM L-glutamine, 0.5% gentamycin, 2.5% HEPES 
buffer, 0.1% β-mercaptoethanol, and 0.1% granulocyte macrophage colony-
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stimulating factor (GMCSF) in T-75 cell culture grade flasks. At day 2, 10 mL of 
fresh DC media was added. At day 6, 10 mL of DC media were removed, 
centrifuged at 250 rcf for 10 min, and cells were resuspended in fresh media and 
added to corresponding flasks. At day 8, DCs were removed from the flasks, 
centrifuged at 250 rcf for 10 min and counted for plating. Cells were plated in 24 
well plates using a concentration of 1 x 106 cells per well. GMCSF was added at 
0.1 vol.% to DC media on days 0, 2, and 6. The DCs were stimulated with 200 
ng/mL of Escherichia coli lipopolysaccharide (LPS, positive control) or 
polyanhydride nanoparticles at 125 µg/mL.[40,42,45-50] Non-stimulated (NS) 
cells were used as a negative control.[40,42] 
 
4.3.11.3 Particle internalization 
Analysis of particle internalization was performed by co-encapsulating 
quantum dots (QDs, 630 nm emission) and gp41-54Q-GHC. 1% (w/w) QD-
loaded and 1% (w/w) gp41-54Q-GHC-loaded polyanhydride nanoparticles were 
prepared. Nanoparticles were suspended in PBS for 48 h and supernatants were 
collected and used to stimulate DCs as a control to account for released 
QDs.[61,62] Bone marrow-derived DCs were stimulated with nanoparticle 
formulations for 48 h and using flow cytometry, particle positive cells were 
quantified. Non-stimulated cells were used as control.[61,62] 
4.3.11.4 Flow cytometric analysis of cell surface markers and CLRs 
Cultured cells were analyzed using flow cytometry as described 
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previously.[40-42] Antibodies for CD40, CD86, MHC II and CD206 and their 
corresponding isotypes were used in these studies. Samples were analyzed 
using a Becton-Dickinson FACSCantoTM  flow cytometer (San Jose, CA) and the 
data was processed using the FlowJo vX software (TreeStar Inc., Ashland, OR).  
4.3.12. Cytokine secretion 
Supernatants of cultured cells were recovered 48 h post-stimulation and 
were analyzed for presence of IL-6, IL1-β, TNF-α, IL-12p40, and IFN-γ using a 
multiplex cytokine assay processed in a Bio-Plex 200 TM system (Bio-Rad, 
Hercules, CA) as described in previous protocols.[40,52] 
 
4.3.13. Statistical analysis 
The cell surface marker expression and cytokine secretion data were 
subjected to statistical analysis using Prism6 (GraphPad, La Jolla, CA). One-way 
ANOVA and Tukey’s HSD were used to determine statistical significance among 
treatments and p-values ≤ 0.05 were considered significant. 
 
4.4. Results 
4.4.1 Chemistry-dependent gp41-54Q-GHC kinetics and stabilization 
upon release from polyanhydride nanoparticles 
The sizes of the 20:80 CPH:SA, 20:80 CPTEG:CPH and 50:50 
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CPTEG:CPH nanoparticles were 445 ± 230 nm, 179 ± 48 nm, and 231 ± 77 nm, 
respectively. The release profiles of gp41-54Q-GHC from these particles are 
shown in Figure 4.1. These data show that over 80% of the amount of gp41-54Q-
GHC encapsulated within the particles was released within 30 days for all three 
formulations studied. Based upon the release profiles in Figure 4.1, there was a 
more pronounced “burst” release of the immunogen from the 20:80 CPH:SA 
nanoparticles within the first 72 h in comparison to the release from the 
CPTEG:CPH formulations. The amphiphilic 50:50 CPTEG:CPH formulation 
provided sustained release of the immunogen with a small burst. The 
encapsulation efficiency of gp41-54Q-GHC into the nanoparticles was chemistry-
dependent with 79%, 70%, and 92% for 20:80 CPH:SA, 20:80 CPTEG:CPH, and 
50:50 CPTEG:CPH, respectively. Analysis of released gp41-54Q-GHC via gel 
electrophoresis showed that bands consistent with the molecular weight of the 
non-encapsulated antigen (~14 kDa) were present in the polyacrylamide gels. As 
shown in Figure 4.1 the ~14 kDa protein band was present for the antigen 
released from all the nanoparticle formulations. However, the band 
corresponding to protein released from 50:50 CPTEG:CPH nanoparticles was 
more intense than that corresponding to protein released from 20:80 
CPTEG:CPH or 20:80 CPH:SA nanoparticles. A small amount of degraded 
protein was visible in the lane corresponding to the 20:80 CPTEG:CPH 
nanoparticles. No low molecular weight bands were observed in the lanes 
corresponding to the other two chemistries. Based upon these results and upon 
our previous work, which suggested that amphiphilic formulations were more 
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suitable for release of stable proteins [31, 41, 42, 50, 52], the 50:50 CPTEG:CPH 
nanoparticle formulation was chosen to perform the carbohydrate 
functionalization and DC activation studies.  
Figure 4.1. gp41-54Q-GHC antigen release kinetics from polyanhydride 
nanoparticles and structural stability upon release. A) Cumulative fraction of 
gp41-54Q-GHC released from (●) 50:50 CPTEG:CPH , (×) 20:80 CPTEG:CPH 
and (□) 20:80 CPH:SA nanoparticles. Error bars represent standard error of the 
mean; results are representative of two independent experiments with duplicate 
samples used in each experiment. B) Primary structure analysis of released 
gp41-54Q-GHC by gel electrophoresis. Samples were analyzed after one hour of 
release from 50:50 CPTEG:CPH, 20:80 CPTEG:CPH and 20:80 CPH:SA 
nanoparticles. 
 
4.4.2. Functionalization and characterization of carbohydrate-modified 
nanoparticles 
The functionalization of gp41-54Q-GHC-loaded 50:50 CPTEG:CPH 
nanoparticles was carried out using the two-step amine-carboxylic acid coupling 
reaction. This reaction was carried out under aqueous conditions, which leads to 
partial degradation of the biodegradable nanoparticles, and loss of payload in the 
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process. In order to minimize this loss, the total reaction time was varied from 
two to 18 hours and the resultant functionalized nanoparticles were characterized 
using QELS to measure zeta potential and the phenol sulfuric acid assay to 
quantify the amount of sugar attached to the surface of the nanoparticles. The ζ-
potential and the surface concentration of the sugars for each formulation are 
shown in Table 4.1. The NF particles are negatively charged, consistent with the 
presence of carboxylic acid moieties with a ζ-potential of -20 ± 2.6 mV, while the 
addition of the linker resulted in a positively charged surface with a ζ-potential of 
23 ± 3.7 mV. The reaction time did not significantly affect the ζ-potential of the di-
mannose-functionalized nanoparticles, suggesting that one hour for each 
coupling reaction was sufficient. Based upon these results, and because of the 
importance of minimizing the time that the nanoparticles were subject to aqueous 
conditions, a total reaction time of two hours for carbohydrate functionalization 
was used in subsequent studies. 
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Table 4.1. Non-functionalized and functionalized nanoparticles were 
characterized by QELS and zeta potential measurements. Particle size data 
represent the mean value± standard deviation (SD) of dynamic light scattering 
data collected in two independent experiments. Zeta potential data represent the 
mean value±SD of three independent readings. Change in zeta potential 
indicates that sugars were efficiently conjugated to the 50:50 CPTEG:CPH 
nanoparticles' surface. Sugar density on nanoparticles' surface was determined 
by a colorimetric phenol-sulfuric acid assay. Amount of sugar was determined 
using standard curves; data is presented as mean ± SD of two independent 
experiments.  
 
4.4.3. gp41-54Q-GHC release kinetics from functionalized 
nanoparticles  
Figure 4.2 shows the sustained release of gp41-54Q-GHC immunogen 
from NF, linker-, and di-mannose functionalized 50:50 CPTEG:CPH 
nanoparticles for 30 days. The data in Figure 4.2 shows that surface 
functionalization did not affect the cumulative release kinetics from the 
functionalized nanoparticles in comparison with the NF nanoparticles. The 
protein loss because of the exposure to aqueous conditions was observed to be 
24-30% for the functionalized nanoparticles. All the formulations showed a small 
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burst and >80% of the total amount of protein encapsulated in the nanoparticles 
was released from all the formulations. 
 
Figure 4.2. Cumulative fraction of gp41-54Q-GHC released from (●) NF, (×) 
linker- and (□) di-mannose-functionalized 50:50 CPTEG:CPH  nanoparticles. 
Error bars represent standard error of the mean; results are representative of two 
independent experiments with duplicate samples used in each experiment. 
 
4.4.4. gp41-54Q-GHC antigenicity was preserved upon release from 
functionalized nanoparticles 
The antigenicity of the released gp41-54Q-GHC from the NF and 
functionalized 50:50 CPTEG:CPH nanoparticles was evaluated with an ELISA by 
using three broadly neutralizing monoclonal HIV-1 antibodies (2F5, Z13e1 and 
4E10) and the results are shown in Figure 4.3. Samples of released protein after 
1 h in PBS (pH 7.4) at 37°C were compared to non-en capsulated gp41-54Q-
GHC. The relative antigenicity is defined as the ratio between the antigenicity of 
the released immunogen compared to that of the non-encapsulated immunogen. 
The data in Figure 4.3 demonstrate that the antigenicity of the immunogen 
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released from all the formulations was preserved based on its recognition by all 
three monoclonal antibodies.  
 
Figure 4.3. Antigenic analysis of released gp41-54Q-GHC at 37°C from NF, 
linker-, and di-mannose-functionalized 50:50 CPTEG:CPH  nanoparticles. 
Antibody binding capability was measured by ELISA using three HIV monoclonal 
antibodies: Z13e1, 2F5, and 4E10. Error bars represent standard error of the 
mean from results obtained from two independent experiments with triplicate 
samples in each experiment. 
 
4.4.5. Internalization by DCs was enhanced by functionalization 
The internalization of gp41-54Q-GHC-loaded polyanhydride nanoparticles 
by DCs was investigated using QDs to identify cells that were positive for 
nanoparticles. The internalization data in Figure 4.4 is expressed as the 
percentage of cells that were positive for the QDs. These results indicate that the 
internalization of the nanoparticles was enhanced by functionalization. In 
particular, DCs internalized both linker- and di-mannose-functionalized 
nanoparticles more than two-fold in comparison with the NF nanoparticles. About 
3% of DCs internalized the NF 50:50 CPTEG:CPH nanoparticles, while ~6% of 
DCs internalized the linker- and di-mannose-functionalized nanoparticles. These 
results are consistent with previous studies in which CPTEG:CPH particles were 
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internalized by bone marrow-derived DCs.[54] 
 
Figure 4.4. Cellular internalization was enhanced by positively charged 
polyanhydride nanoparticles. The internalization by DCs of QD-loaded NF, linker-
, and di-mannose-functionalized nanoparticles was analyzed using flow 
cytometry. Error bars represent standard error of the mean; results are 
representative of three independent experiments with triplicate samples used in 
each experiment. 
 
4.4.6. Functionalized nanoparticles enhanced DC expression of CD40 
and CD206 
DC activation was evaluated by stimulating bone marrow-derived DCs 
with gp41-54Q-GHC-containing nanoparticle formulations. Non-stimulated cells 
were used as a negative control and cells stimulated with LPS were used as a 
positive control. The up-regulation of MHC II, the co-stimulatory surface markers 
CD40 and CD86, and the CLR, CD206, was analyzed using flow cytometry. The 
data in Figure 4.5 is presented as the mean fluorescence intensity (MFI) from 
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positive cells compared to isotypes for the marker of interest for each of the 
treatment groups. All the markers studied showed significant up-regulation 
compared to the negative control, as anticipated. Moreover, the data showed up-
regulation of the co-stimulatory molecule CD40 and the CLR CD206 for cells 
stimulated with linker- and di-mannose-functionalized nanoparticles in 
comparison with NF nanoparticles as shown in Figure 4.5. The results also 
indicated that functionalization did not enhance the up-regulation of MHC II and 
the co-stimulatory molecule CD86 compared to the NF nanoparticles.  
Figure 4.5. Di-mannose-functionalized nanoparticles enhanced DC expression of 
co-stimulatory molecules and CLRs. After stimulation with either 125 µg/mL of 
NF or functionalized nanoparticles for 48 h, DCs were harvested and analyzed by 
flow cytometry for surface expression of MHC II, CD86, CD40, and CD206. LPS-
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stimulated and non-stimulated cells (NS) were used as positive and negative 
controls, respectively. Data are expressed as the mean ± SEM of three 
independent experiments performed in triplicate. * and # represent groups that 
are statistically significant (p ≤ 0.05) compared to the NS or NF groups, 
respectively. MFI = mean fluorescence intensity. 
 
4.4.7. Functionalized nanoparticles modulated DC secretion of pro-
inflammatory cytokines 
The gp41-54Q-GHC-loaded nanoparticles were used to stimulate DCs 
and the supernatants were analyzed using a Bioplex assay to measure 
concentrations of the following cytokines: IL-6, IL-1β, TNF-α, IL-12p40, and IFN-
γ. Figure 4.6 shows that cells stimulated with the functionalized nanoparticles 
secreted less IL-6 and TNF-α, compared to that of the NF treatment, specifically 
when gp41-54Q-GHC is loaded into the nanoparticles. There were no significant 
differences for IL-1β, IL-12p40, and IFN-γ secretion between cells stimulated with 
antigen-loaded NF and functionalized particles (data not shown). The cytokine 
secretion from DCs stimulated with all the nanoparticle treatments was enhanced 
significantly compared to the negative control.  
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Figure 4.6. Enhancement of cytokine secretion after stimulation with NF 
nanoparticles is consistent with the amount of gp41-54Q-GHC released from 
polyanhydride nanoparticles. After stimulation with 125 µg/mL of NF or 
functionalized nanoparticles for 48 h, supernatants were collected and assayed 
for IL-6 and TNF-α. Data is represented as mean concentration of cytokines ± the 
SEM of three independent experiments performed in triplicate for antigen-loaded 
nanoparticles and two independent experiments in triplicate for blank 
nanoparticles. LPS was used as a positive control stimulant, and non-stimulated 
cells (NS) were used as a negative control. LPS control had the following MFI 
values: 50,000 for IL-6 and 25,000 for TNF-α. * and # represent statistical 
significance (p ≤ 0.05) compared to the NS or NF groups, respectively.  
Cumulative mass of released gp41-54Q-GHC from NF and functionalized 
nanoparticles over 72 h. Results are expressed as the average of two 
independent experiments with duplicate samples in each.  
 
4.5. Discussion 
Surface functionalization of polymeric nanoparticles to achieve targeted 
delivery of antigen has been used to enhance vaccine efficacy by directing 
antigens to specific cells of the immune system.[2,3,8,41-42,47,53] Previous 
studies have shown that particle size, charge, shape, chemistry and surface 
functionality affect the immune response.[28,31-32,40,47] Therefore, rational 
design of particle-based adjuvants must involve optimization of these attributes to 
enhance the efficacy of the immune response. This strategy has also been 
utilized to mimic pathogenic signals in order to generate potent and protective 
immune responses.[39-42] In the current studies, the HIV-1 immunogen gp41-
54Q-GHC was encapsulated into different polyanhydride formulations 
functionalized with carbohydrates and the stability of the released gp41-54Q-
GHC and the effect of the functionalization on DC activation were investigated.  
The HIV-1 antigen gp41-54Q-GHC was first encapsulated in three 
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different polyanhydride nanoparticle formulations, i.e., 50:50 CPTEG:CPH, 20:80 
CPTEG:CPH and 20:80 CPH:SA. These nanoparticles enabled sustained 
antigen release kinetics and provided an appropriate environment to preserve the 
primary structure of gp41-54Q-GHC. Released protein from 50:50 CPTEG:CPH 
nanoparticles displayed a more intense band after gel electrophoretic analysis 
when compared to the other formulations. This result combined with the high 
encapsulation efficiency of the protein and the amphiphilic properties of this 
copolymer suggested that this chemistry was the most appropriate to stabilize 
gp41-54Q-GHC [30,31,53]; accordingly, this chemistry was chosen for further 
studies with carbohydrate functionalization and DC activation. 
The functionalization of antigen-loaded polyanhydride nanoparticles was 
optimized and the total reaction time was reduced to two hours with 24-30% loss 
of immunogen during the process. As shown in Figure 4.2, the release kinetics of 
gp41-54Q-GHC from the different polyanhydride nanoparticle formulations 
displayed similar behavior, independent of the type of functionalization (i.e., linker 
and di-mannose) and was consistent with the release of the immunogen from the 
NF nanoparticles.[29] All these formulations provided sustained release of gp41-
54Q-GHC, which is a desirable attribute for vaccine formulations. This is because 
it has been demonstrated previously that prolonging the presence of antigen in 
the host can improve the generation of antigen-specific memory cells that can 
trigger potent immune responses towards future infections.[19,32] 
The gp41-54Q-GHC immunogen released from the functionalized 
polyanhydride nanoparticles maintained its antigenic activity upon release, which 
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was tested by its ability to bind to three monoclonal HIV-1 antibodies: 2F5, 4E10 
and Z13e1 (Figure 4.3). The slight increase in the relative antigenicity of the 
protein released from the NF nanoparticles with the 2F5 antibody and that 
released from all the nanoparticle formulations with the 4E10 antibody may be 
attributed to minor conformational changes of the antigen after encapsulation and 
release, as observed previously.[31,52-53,62-63] These results indicated that the 
functionalization process did not significantly affect the antigenicity of gp41-54Q-
GHC upon release. The small changes in antigenicity, if any, may be attributable 
to the encapsulation and release processes, as shown previously.[31,52-53,63-
64] 
It is known that cells internalize positively charged nanoparticles more 
effectively than neutral or negatively charged nanoparticles.[2-3,8] Previous 
studies have demonstrated the effect of surface charge on particle internalization 
and the results from the current studies are consistent with these studies.[39-41] 
Functionalization with linker results in positively charged nanoparticles, which 
were internalized more efficiently by DCs, as shown in Figure 4.4. There were 
significant differences in cells positive for nanoparticles between the 
functionalized and the NF nanoparticles, indicating the importance of surface 
charge and/or specific internalization pathways (i.e., mannose receptor-mediated 
endocytosis) with respect to particle uptake. The enhanced internalization was 
observed for both the di-mannose- and the linker-functionalized nanoparticles, 
suggesting that surface charge may be more important than receptor-mediated 
uptake. On the other hand, previous work has shown that targeting specific 
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receptors such as the macrophage mannose receptor by functionalizing 
nanoparticles with carbohydrates such as di-mannose resulted in enhanced APC 
activation.[39-41,48] Based on these observations and the current work, it is 
hypothesized that combinatorial use of both surface charge and functionalization 
with ligands that target specific CLRs may be important for enhanced 
internalization of the functionalized nanoparticles. This enhanced internalization 
can lead to the efficient delivery of antigen to the APCs, which is important for the 
induction of robust T cell-mediated immune responses.[2-3,40,65] It is important 
to note even though only a small percentage of cells were positive for CPTEG-
containing particles in vitro, antigen-encapsulated 50:50 CPTEG:CPH 
formulations have been shown in previous studies to induce protective immunity. 
The appropriate activation of APCs is an important component of an 
immune response a subsequent live challenge.[32,34]  In addition, it has been 
hypothesized that HIV-1 infection of DCs via dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN) may cause DC-DC viral 
transmission, or DC-T cell infection amplification.[66,67] In addition, it is known 
that DC-SIGN+ immature DCs, which are located in vaginal, cervical and rectal 
mucosa, are the first type of cells to encounter the HIV-1 virion.[68] It is also 
known that DC-SIGN captures HIV-1 in the periphery and facilitates its transport 
to secondary lymphoid organs rich in T cells.[66] While these functions are 
performed by DC-SIGN in DCs, they are performed by the MMR in macrophages 
and epithelial DCs, which are present at mucosal surfaces.[68, 69] In this regard, 
surface functionalization of nanoparticle-based vaccines or anti-viral delivery 
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vehicles with carbohydrates offers the possibility to target CLRs such as the 
MMR or DC-SIGN in macrophages or dendritic cells.towards pathogens.[1,16,47-
48,50] Specifically, during HIV-1 infection, DCs and macrophages play critical 
roles in the induction of robust and balanced immune responses.[1-2,14-
16,19,22-23] Even though DC-SIGN has been identified as a key player in HIV-1 
infection, the presence of the MMR on epithelial DCs and macrophages offers 
the possibility to specifically target nanovaccines and/or anti-viral delivery 
vehicles towards these cellular populations, since mucosal vaccination has been 
shown to elicit antibodies across these surfaces, specifically in vaginal and 
genital tissues.[70] 
Therefore, up-regulation of APC activation markers, including CD206, is a 
desirable characteristic of adjuvants used in conjunction with an HIV-1 
vaccine.[25,52-53]  All the nanoparticle formulations studied herein enhanced the 
DC surface expression of MHC II, the co-stimulatory molecules CD40 and CD86, 
and the CLR CD206 compared to non-stimulated cells (Figure 4.5). While cells 
stimulated with the carbohydrate-functionalized nanoparticles showed enhanced 
expression of CD40 and CD206 compared to cells stimulated with NF 
nanoparticles, the surface expression of CD86 and MHC II were similar in cells 
stimulated by both NF and functionalized nanoparticles. The MFI of cells 
stimulated with the gp41-54Q-GH-encapsulated nanoparticles was higher than 
that of the cells stimulated by the NF nanoparticles, regardless of 
functionalization (data not shown). The enhanced expression of CD40 and 
CD206 is consistent with the internalization data of Figure 4.4 because it has 
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been shown previously that particle uptake is required for the up-regulation of 
these molecules.[41-42] It is known that CD40 is important for DC maturation that 
drives T cell activation, while CD206-mediated antigen delivery has been shown 
to enhance humoral immune responses.[1,2,10,65,71] These characteristics are 
desirable when designing an HIV-1 vaccine due to the important role of a 
balanced immune response involving both cellular and humoral 
components.[19,72] The results in Figure 4.5 also indicated that functionalization 
did not enhance the up-regulation of MHC II and the co-stimulatory molecule 
CD86 compared to the NF nanoparticles. This observation suggests the 
presence of a bystander effect, which enables cells that are in close proximity 
with nanoparticles to enhance their surface expression of MHC II and CD86, 
rendering nanoparticle internalization unnecessary.[48,54] These data are 
consistent with previous studies that also postulated a bystander effect for up-
regulation of MHC II and CD86.[48,54] 
Nanoparticle functionalization modulated cytokine secretion by DCs, as 
shown in Figure 4.6. The secretion of IL-1β, IL-12p40 and IFN-γ was similar in 
cells stimulated by NF or functionalized nanoparticles. In contrast, the DC 
secretion of IL-6 and TNF-α was higher when stimulated with the NF 
nanoparticles in contrast to the functionalized nanoparticles. This observation 
may be attributed to the higher amount of antigen present in the NF 
nanoparticles compared to that in the functionalized nanoparticles. These results 
are consistent with the mass of gp41-54Q-GHC released from the nanoparticles 
within the first 72 h as shown in Figure 4.6. In control experiments, it was 
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demonstrated that the antigen-containing nanoparticles (regardless of 
functionalization or lack thereof) resulted in higher cytokine secretion than their 
respective “blank” (i.e., no antigen) counterparts. The antigen-dependent 
response of cytokine secretion suggests that the higher amount of protein 
encapsulated within the NF nanoparticles compared to the carbohydrate-
functionalized nanoparticles may be important and is consistent with previous 
observations.[5] The presence of antigen within the particles appears to be more 
important for IL-6 and TNF-α secretion than for the secretion of IL-1β, IL-12p40 
and IFN-γ. These results are consistent with previous work, in which it has been 
shown that when targeting specific CLRs such as SIGNR1, there is a decrease in 
the secretion of cytokines such as IL-6 or TNF-α.[73,74] It has also been shown 
using a colitis model that deficiency of this receptor results in a decrease in the 
secretion of these cytokines.[75] These results suggest that creating 
combinations of NF and functionalized nanoparticle formulations may provide the 
benefits of enhanced internalization, up-regulation of cell surface markers, and 
enhanced secretion of the appropriate cytokines, all of which will lead to potent 
immune responses. 
The current experiments demonstrate that polyanhydride nanoparticles 
can serve as a promising adjuvant and/or delivery system for an HIV-1 
nanovaccine. The studies provide important insights upon the behavior of APCs 
when stimulated with nanoparticles of different chemistries, surface charge, 
functionalization, and antigen encapsulation. Such insights are valuable for the 
rational design of adjuvants/delivery vehicles for vaccine development. The 
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desirable characteristics of the polyanhydride nanoparticle platform include the 
provision of antigen stability, sustained release, enhanced particle uptake, and 
DC activation. Carbohydrate functionalization of the nanoparticles enhanced their 
adjuvant capabilities by enabling charge and receptor-mediated uptake 
mechanisms. The current studies demonstrate the potential of using 
functionalized polyanhydride nanoparticles as an adjuvant/delivery vehicle for 
HIV-1 antigens and provide the opportunity to tailor specific properties to lead to 
efficacious immune responses downstream. 
4.6. Conclusions 
In these studies, carbohydrate-functionalized polyanhydride nanoparticles 
were investigated as targeted antigen delivery vehicles and adjuvants for gp41-
54Q-GHC, an HIV-1 antigen. Polymer chemistry, surface functionalization, and 
antigen encapsulation were analyzed and their effect on DC activation was 
evaluated. The results demonstrated that amphiphilic polyanhydride 
nanoparticles released antigenic gp41-54Q-GHC and that functionalization 
enhanced particle internalization. Functionalization also enhanced the up-
regulation of DC activation markers, while regulating cytokine secretion. These 
data offer important insights into the performance of functionalized nanoparticles 
with respect to releasing stable HIV-1 immunogens and activating DCs. Active 
targeting of these nanoparticles by functionalization with carbohydrates offers a 
promising opportunity to design efficacious vaccine delivery systems for HIV-1. 
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5.1. Abstract 
An in-depth understanding of the interactions of antigen delivery vehicles 
with antigen presenting cells and the complement system is important for 
tailoring adjuvant properties and eliciting efficacious immune responses. 
Polymeric nanoparticles have been widely used as adjuvants and delivery 
vehicles, and upon parenteral administration, serum proteins adsorb onto these 
particles, modifying their interactions with the components of the immune system. 
The current studies present a systematic analysis of the role of the presence of 
complement receptor 3 (CR3), serum protein adsorption, and polymer chemistry 
on the uptake and activation of bone marrow-derived macrophages. The results 
suggest that all of these factors affected macrophage activation. Serum protein 
adsorption was dependent on polymer chemistry and hydrophobicity, with a wide 
variety of proteins being adsorbed onto the surface of the nanoparticles. 
Secretion of the pro-inflammatory cytokines IL-6 and TNF-α was up-regulated by 
the presence of CR3 and because of serum protein adsorption, resulting in a 
classically activated macrophage phenotype, which is known to be beneficial for 
the induction of immune responses. The complex dependence of the activation of 
macrophages on nanoparticle chemistry, CR3, and protein opsonization provides 
new insights that can aid the rational design of antigen delivery platforms for 
induction of robust immune responses. 
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5.2. Introduction 
A major area of research in vaccine design is focused on the generation of 
robust immune responses towards specific antigens [1, 2]. In order to elicit these 
responses and confer protective immunity, activation of the innate immune 
system is critical [3-5]. A key component of innate immunity is the activation of 
antigen presenting cells (APCs) by recognition of microbial-associated molecular 
patterns (MAMPS) by pattern recognition receptors (PRRs) [6-8]. The 
interactions between APCs and antigen delivery systems can be tailored to 
enhance antigen presentation and processing, thus impacting the downstream 
immune response [9, 10]. Therefore, in order to rationally design vaccine delivery 
vehicles, an understanding of the role of carrier chemistry and surface 
functionality on interactions with APCs is necessary [11-14]. 
Complement system activation is one of the mechanisms of innate 
immunity that is used to induce inflammatory responses to help the body fight 
infections [3-5, 15]. Complement is a series of plasma proteins that interacts with 
pathogens and opsonizes them, causing a cascade of signals [4, 15]. 
Opsonization of pathogens and foreign bodies is part of the mechanism used by 
the immune system to increase uptake and antigen processing by phagocytic 
cells through specific recognition of complement receptors [4, 16-19]. In 
particular, complement receptor 3 (CD11b/CD18) is the most promiscuous of 
these integrins, because of its broad diversity of ligand recognition, which 
includes iC3b, fibrinogen, ICAM-1, haptoglobin, etc. [17-19] Complement 
receptor 3 (CR3) is known to mediate internalization of opsonized and non-
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opsonized pathogens through different pathways and has been implicated in the 
binding of β-glucans and soluble and particulate saccharides by human 
phagocytic cells [17, 20]. Previous studies have shown that this integrin facilitates 
the polysaccharide binding associated with lipopolysaccharide (LPS), Leishmania 
lipophosphoglycan, Klebsiellapneumoniae acylpolyglactoside, and 
Mycobacterium tuberculosis and aids the uptake of Salmonella typhimurium and 
Ross River virus [21-26]. In order to rationally design pathogen mimicking 
vaccine delivery systems, the role of CR3 on the interactions between immune 
cells and antigen delivery vehicles needs to be systematically analyzed.  
Polymeric nanoparticle-based adjuvants/delivery systems have been 
studied for the past several decades as an alternative strategy to develop 
efficacious vaccine formulations [27]. In particular, biodegradable polyanhydride 
particles have demonstrated superior capabilities with respect to antigen 
stabilization, sustained antigen release, and immune stimulation that make them 
promising candidates for vaccine adjuvants and/or delivery vehicles [5, 9, 14, 28-
30]. In addition, polyanhydride particles have shown: i) uptake by and activation 
of APCs [9, 12, 30]; and ii) surface chemistry and polymer chemistry-dependent 
serum protein adsorption patterns [12, 16, 30, 31]. These attributes have 
important implications for adjuvant design and development and for the induction 
of efficacious immune responses [9, 28-32]. 
In this study serum protein adsorption patterns onto two types of 
polyanhydride nanoparticles and their effects on macrophage uptake and 
activation were investigated. These two formulations have been shown to be 
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potent adjuvants, based on their ability to enhance both humoral and cell-
mediated immunity [33-35]. CR3 knockout (CR3-/-) mice were used to understand 
the role of this receptor in nanoparticle internalization. The insights gained from 
these studies can be used to unravel the role of particle/protein and particle/cell 
interactions on the activation of APCs and aid in the rational design of efficacious 
vaccine adjuvants/delivery systems. 
 
5.3. Materials and Methods 
5.3.1. Materials 
Chemicals needed for monomer synthesis, polymerization, and 
nanoparticle synthesis are: 1-methyl-2-pyrrolidinone, anhydrous (99+%) p-
carboxy benzoic acid (99+%), and sebacic acid (99%), purchased from Aldrich 
(Milwaukee, WI); 1,6-dibromohexane, 4-p-hydroxybenzoic acid, and triethylene 
glycol, purchased from Sigma-Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile, 
obtained from Apollo Scientific (Cheshire, UK); and acetic acid, acetic anhydride, 
acetonitrile, dimethyl formamide (DMF), ethyl ether, hexane, methylene chloride, 
pentane, petroleum ether, potassium carbonate, sulfuric acid, and toluene, 
purchased from Fisher Scientific (Fairlawn, NJ). For 1H NMR characterization, 
deuterated chemicals, including chloroform and dimethyl sulfoxide (DMSO), were 
purchased from Cambridge Isotope Laboratories (Andover, MA). β-
mercaptoethanol, E. coli LPS O26:B6 and rat immunoglobulin (rat IgG) were 
purchased from Sigma Aldrich. Materials required for harvest and culture 
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mediums for macrophages included: Dulbecco’s Modified Eagle Medium with 
high glucose, sodium pyruvate, 1M HEPES buffer, penicillin-streptomycin, and L-
glutamine, purchased from Mediatech (Herndon, VA); and heat inactivated fetal 
bovine serum, purchased from Atlanta Biologicals (Atlanta, GA). Materials used 
for flow cytometry included: BD stabilizing fixative solution purchased from BD 
Bioscience (San Jose, CA); unlabeled anti-CD16/32 FcγR, purchased from 
Southern Biotech (Birmingham, AL); allophycocyanin anti-mouse CD40 (clone 
1C10), PE conjugated anti-mouse MHC Class I (H-2Kd/H-2Dd) (clone 34-1-2S), 
FITC conjugated anti-mouse MHC Class II (I-A/I-E) (clone M5/114.15.2) and their 
corresponding isotypes APC-conjugated rat IgG2aκ (clone eBR2a), PE-
conjugated rat IgG2aκ (clone eBR2a), FITC-conjugated rat IgG2bκ (clone 
eB149/10H5) were purchased from eBiosciences (San Diego, CA). APC/Cy7 
conjugated anti-mouse F4/80 (clone BM8), PE/Cy7 conjugated anti-mouse CD86 
(clone GL-1), PerCP/Cy5.5 conjugated anti-mouse CD80 (clone 16-10A1) and 
their corresponding isotypes APC/Cy7 conjugated rat IgG2aκ (clone RTK2758), 
PE/Cy7 conjugated rat IgG2aκ (clone RTK2758), PerCP/Cy5.5 conjugated 
Armenian Hamster IgG (clone HTK888) were purchased from BioLegend (San 
Diego, CA). Cadmium selenide quantum dots (QDs) (emission at 630 nm) were a 
kind gift from Dr. Aaron Clapp at Iowa State University. 
 
5.3.2. Monomer and Polymer Synthesis 
Di-acid monomers based on 1,6-bis(p-carboxyphenoxy) hexane (CPH) 
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were synthesized as 
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described previously [28, 36]. SA and CPH prepolymers were synthesized by the 
methods described by Shen et al. [32] and Conix et al. [36], respectively. 
Subsequently, 20:80 CPH:SA and 20:80 CPTEG:CPH copolymers were 
synthesized by melt polycondensation as described by Kipper et al. [14] and 
Torres et al. [9], respectively. The chemical structure was characterized with 1H 
NMR using a Varian VXR 300 MHz spectrometer (Varian Inc., Palo Alto, CA) and 
the molecular mass was determined using gel permeation chromatography 
(GPC) on a Waters GPC chromatograph (Milford, MA) containing PL gel columns 
(Polymer Laboratories, Amherst, MA). The 20:80 CPH:SA copolymer had a Mw of 
14,000 Da and a polydispersity index (PDI) of 1.4 and the 20:80 CPTEG:CPH 
copolymer had a Mw of 7,800 and a PDI of 1.3. These values are consistent with 
previous work [27, 28, 32, 33, 37, 38]. 
5.3.3. Nanoparticle Synthesis 
Polyanhydride nanoparticles were synthesized using an anti-solvent 
nanoencapsulation method as described previously [39]. Briefly, polymer (20 
mg/mL) was dissolved in methylene chloride (at 4°C for 20:80 CPTEG:CPH and 
at room temperature (RT) for 20:80 CPH:SA). The polymer solution was 
sonicated at 40 Hz for 30 s using a probe sonicator (Ultra Sonic Processor VC 
130PB, Sonics Vibra Cell, Newtown, CT) and rapidly poured into a pentane bath 
(at -40°C for CPTEG:CPH and at RT for CPH:SA) at a solvent to non-solvent 
ratio of 1:250. Particles were collected by filtration and dried under vacuum for 1 
h. Nanoparticles were characterized using scanning electron microscopy (SEM, 
FEI Quanta 250, Kyoto, Japan). 
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5.3.4. Mice 
C57BL/6 mice were purchased from Harlan Laboratories (Indianapolis, IN) 
and CR3-/- mice (C57BL/6 background) were obtained as a generous gift from Dr. 
Mary Ann McDowell of the University of Notre Dame. Mice were housed in 
specific pathogen-free conditions where all bedding, caging, and feed were 
sterilized prior to use. All animal procedures were conducted with the approval of 
the Iowa State University Institutional Animal Care and Use Committee.   
 
5.3.5. Murine serum protein adsorption onto polyanhydride 
nanoparticles 
Blood was obtained via cardiac puncture after euthanasia of the mice, 
samples were centrifuged at 10,000 rcf for 10 min, and serum was removed and 
stored at -20°C. For the adsorption studies, 13.3% w/v suspensions of 
polyanhydride nanoparticles were prepared in phosphate buffer saline (PBS, pH 
7.4). Nanoparticle suspensions were incubated with serum in a 1:4 volume ratio 
(i.e., 25% nanoparticles and 75% serum). The nanoparticle/serum suspension 
was sonicated for 30 s at 40 Hz and incubated for 30 min at 37°C under constant 
agitation. Next, the suspension was centrifuged at 10,000 rcf for 10 min to pellet 
the nanoparticles. Supernatants were removed, nanoparticles were re-
suspended in PBS, and the centrifugation step was repeated. This process was 
repeated three times and the nanoparticles were dried under vacuum for 1 h and 
stored for characterization and further use. 
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5.3.6. Nanoparticle surface analysis 
To assay for the presence of serum protein on the nanoparticle surface, 
energy-dispersive X-ray spectroscopy (EDS) analysis of elemental composition 
was performed. Samples of serum-coated nanoparticles were prepared in carbon 
stubs, and analyzed using an AZtec EDS system incorporated in a scanning 
electron microscope (Oxford Instruments, Concord, MA). The quantified 
elements were presented as percent of total content and the experiments were 
performed in triplicate. 
 
5.3.7. Analysis of adsorbed serum proteins 
 
Analysis of serum proteins adsorbed onto polyanhydride nanoparticles 
was performed using 2D gel electrophoresis [30, 31]. After adsorption, 
nanoparticles were dried and incubated with 250 µL of elution buffer with 5% 
(w/v) sodium dodecyl sulfate (SDS) and 2.3% (w/v) dithioerythritol to elute 
protein. Nanoparticle samples were heated at 95°C f or 10 min and centrifuged for 
10,000 rcf for 10 min, and the supernatants were removed from the particle pellet 
for analysis. To quantify and analyze serum proteins, supernatants were passed 
through SDS removal columns (Pierce, Cat # 87777) to reduce the amount of 
SDS because of its interference with microBCA and gel electrophoresis. To 
analyze eluted proteins, equal amounts of protein in elution buffers were 
processed for the first dimensional separation. For the first dimension, IPGPhor 
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systems (GE Healthcare, Piscataway, NJ) were used with 7-cm IPG strips (pH 3-
10) and a slow voltage ramping protocol: 50 V for 12 h, 500 V for 1 h, 1000 V for 
1 h, and 8000 V for 6 h. For the second dimension of the separation analysis the 
IPG strips were loaded in 4-20% polyacrylamide gels and run for 4 h at 90 V. The 
gels were incubated in fixative solution (40% methanol, 10% acetic acid) for 3 h 
at 4°C. Staining with Flamingo fluorescent gel stai n (BioRad Laboratories, 
Richmond, CA) was performed at 4°C overnight, follo wing which a de-staining 
process with a 0.1% Tween 20 solution was carried out for 30 min to reduce 
background. The gels were scanned using a Typhoon 9410 Variable Mode 
Imager (GE Healthcare). Images were collected using ImageQuant TL and 
qualitative analyses were performed using ImageJ (version 1.47, NIH, Bethesda, 
MD) and Progenesis SameSpots (Nonlinear Dynamics, Durham, NC) to 
determine the location and intensity of the spots on the gels. The intensity of 
each spot was normalized with the total fluorescence and the values are 
presented as percentages of the total fluorescence of the gels. Identification of 
each spot was performed by comparison of experimental gels with murine serum 
protein profiles found in the literature and in protein databases [40-45].  
 
5.3.8. Macrophage culture and stimulation 
Macrophages were derived from bone marrow cells and harvested from 
tibias and femurs of C57BL/6 or CR3-/- mice as described previously in published 
protocols [46-48]. Macrophages were identified using an F4/80 antibody. Briefly, 
mice were euthanized using carbon dioxide inhalation and cardiac puncture was 
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performed. Bone marrow cells were harvested from tibias and femurs and 
maintained in 10 mL of Complete Tissue Culture Media (CTCM) containing 
Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum, 1% 
penicillin/streptomycin, 1% 2mM L-glutamine, 2.5% HEPES buffer, and 0.1% β-
mercaptoethanol. Cell culture was performed using 12 mL of bone-marrow 
macrophage media containing Dulbecco’s Modified Eagle Medium, with 20% 
fetal bovine serum, 30% L-cell conditioning supernatant, 1% 
penicillin/streptomycin, 1% 2 mM L-glutamine, and 1% sodium pyruvate in T-75 
Cell culture grade flasks at a cell density of 12 x 106 in an incubator at 37°C with 
5% CO2 for 6 days. At day 2, 12 mL of fresh bone marrow macrophage media 
were added. After 6 days, flasks were placed on ice for 30 min, macrophages 
were removed from the flasks using cell scrapers, centrifuged at 250 rcf for 10 
min and counted for plating. Cells were plated in 24 well plates using a 
concentration of 5 x 105 cells per well in CTCM. Macrophages were stimulated 
with 0.125 mg/mL of polyanhydride nanoparticles, based on previous studies [9, 
30]. Non-stimulated (NS) cells were used as a negative control and 200 ng/mL of 
Escherichia coli LPS was used as a positive control.  
 
5.3.9. Internalization profiles of serum-coated nanoparticles 
Cadmium selenide quantum dot (QD)-loaded polyanhydride nanoparticles 
were synthesized using an anti-solvent nanoencapsulation method [39]. Briefly, 
1% w/w QDs (630 nm emission) were suspended with respective polymer 
solution and nanoparticles were fabricated as previously described. 
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Nanoparticles were suspended in PBS (pH 7.4, 37°C) for 48 h and supernatants 
were collected and used as controls to account for released QDs [49]. Serum 
adsorption onto these nanoparticles was performed as described previously and 
used for macrophage internalization experiments. Bone-marrow derived 
macrophages were stimulated with nanoparticle formulations for 48 h and 
particle-positive cells were quantified using flow cytometry. Non-stimulated cells 
were used as control [30]. 
 
5.3.10. Identification of Complement Component C3  
To identify and quantify complement component 3 (C3) in the eluted 
protein samples from the nanoparticles, a sandwich ELISA was performed. A 
mouse complement component C3 ELISA kit was purchased from Kamiya 
Biomedical Company (Seattle, WA) and used following manufacturer’s 
instructions to determine amounts of C3 in eluted protein samples from 
polyanhydride nanoparticles based on a calibration curve. Briefly, samples were 
diluted to 1:50,000 using provided sample diluent. 100 µL of samples, calibrators, 
and positive control (provided) were added to the designated wells. Microtiter 
plates covered with aluminum foil were incubated at room temperature (RT, 25 
°C) for 20 ± 2 min. Next, well contents were remove d and filled with wash 
solution (provided and appropriately diluted). This process was repeated four 
times. 100 µL of enzyme-antibody conjugate were added to each well, and 
incubated at RT for 20 ± 2 min covered from light. A washing process was 
performed as previously described, and then 100 µL of TMB substrate solution 
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was added. Plates were incubated in the dark for 10 min and 100 µL of stop 
solution (provided) was added. Absorbance was measured at 450 nm.  
 
5.3.11. Activation of macrophages by serum-coated nanoparticles 
Cultured cells from wild type (WT) and CR3-/- C57BL/6 mice were 
analyzed using flow cytometry and cell surface marker expression was measured 
as described previously [9]. Serum adsorption onto nanoparticles was performed 
as described previously and used for macrophage activation studies. Antibodies 
for CD40, CD80, CD86, and MHC II and their corresponding isotypes were used. 
Samples were analyzed using a Becton-Dickinson FACSCantoTM flow cytometer 
(San Jose, CA) and the data was processed using the FlowJo vX software 
(TreeStar Inc., Ashland, OR).  
 
5.3.12. Cytokine secretion by macrophages 
Supernatants of cultured cells 48 h post-stimulation were analyzed for 
secretion of IL-6, IL-1β, TNF-α, IL-12p40, IFN-γ, and IL-10 using a multiplex 
cytokine assay with a Bio-Plex 200 TM system (Bio-Rad, Hercules, CA) as 
described in previous protocols [48, 50]. 
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5.3.13. Statistical Analysis 
 
Statistical analysis was used to analyze the cell surface marker 
expression and cytokine secretion data. One-way ANOVA and Tukey’s HSD 
were used to determine statistical significance among treatments and p-values < 
0.05 were considered significant. 
 
5.4. Results  
5.4.1. Particle size and characterization 
The size of the 20:80 CPTEG:CPH nanoparticles was 208 ± 60 nm, while 
that of the 20:80 CPH:SA nanoparticles was 306 ± 122 nm (data expressed as 
average ± standard deviation). The zeta potentials of the 20:80 CPH:SA and 
20:80 CPTEG:CPH nanoparticles were -20 ± 3.7 mV and -24 ± 4.1 mV, 
respectively, which are consistent with previous work [51].  
 
5.4.2. Polymer chemistry-dependent serum protein adsorption profiles 
Serum protein adsorption onto polyanhydride nanoparticles was analyzed 
using EDS and the results are shown in Table 5.1. The nitrogen content ranged 
from 1-2% for the serum-coated nanoparticles, while no nitrogen was detectable 
on the surface of the non-serum coated particles. No significant differences were 
observed in the nitrogen content between the CR3-/- and the WT treatments, or 
between the two chemistries tested.  
  
 
Table 5.1. Energy-dispersive X
composition of non-coated and serum
Presence or increase in the nitrogen content of polyanhydride nanoparticles 
represents the serum protein coating effect. Data reported as mean ± standard 
error of the mean (SEM) of three independent 
triplicate. Non-coated nanoparticles were used as controls to assess the absence 
of nitrogen.   
 
Protein separation using 2D gel electrophoresis was used to identify 
serum proteins eluted from the surface of polyanhydride nanopar
5.1 shows representative images of 2D gels of the eluted serum proteins. The 
greatest amounts of protein that were adsorbed onto both nanoparticle 
chemistries were albumin, IgG, and apolipoproteins. However, there were 
differences in the profiles between the two chemistries. 
proteins were adsorbed onto the more hydrophob
nanoparticles. Additionally, more diverse proteins 
CPTEG:CPH nanoparticles than that on
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-ray spectroscopy (EDS) analysis of elemental 
-coated polyanhydride nanoparticles. 
experiments performed in 
ticles. Figure 
Greater amounts of 
ic 20:80 CPTEG:CPH 
were adsorbed on
to the 20:80 CPH:SA nanoparticles. 
 
to the 20:80 
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Figure 5.1. Serum protein adsorption onto polyanhydride nanoparticles is 
chemistry dependent. Representative 2-D gels of proteins of:  (A) Wild-type  
serum proteins onto 20:80 CPTEG:CPH nanoparticles, (B) Wild-type serum 
proteins onto 20:80 CPH:SA nanoparticles. Identified proteins are numbered and 
are listed and quantified as presented in Table 5.2. 
 
Table 5.2 shows how nanoparticle chemistry affected the relative 
composition of the adsorbed protein mixture eluted from the nanoparticles. The 
most abundantly adsorbed proteins on both types of nanoparticles were albumin, 
immunoglobulins and alipoproteins, with these protein spots accounting for 30-
40% of the total fluorescence from the gels. Fibrinogen, complement factor B, 
serotransferrin, lactotransferrin, and IgG2a chain C were more abundantly 
adsorbed on the 20:80 CPTEG:CPH nanoparticles. In contrast, α1-acid 
glycoprotein, ceruloplasmin, apolipoprotein E, hemopexin and CDR1 accounted 
for a higher percentage of fluorescence on the 20:80 CPH:SA nanoparticles. 
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Table 5.2. Quantification of murine serum proteins from 2-D gel electrophoresis.  
Identification of protein nanoparticles was performed using isoelectric point (pI) 
and molecular weight (MW). Normalized volume was quantified using Progenesis  
SameSpots ©. Percentage of normalized volume is presented for each gel. (A) 
Wild-type serum proteins onto 20:80 CPTEG:CPH nanoparticles, (B) Wild-type 
serum proteins onto 20:80 CPH:SA nanoparticles.  
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5.4.3. Polyanhydride nanoparticle internalization is CR3- and serum 
protein adsorption-dependent  
Particle uptake is one of the main benefits of opsonization and one of the 
key functions of CR3 [4, 17-19]. Figure 5.2 (panel A) shows that nanoparticle 
internalization was strongly affected by polymer chemistry, which in turn 
influenced the importance of the CR3 receptor and serum protein adsorption. In 
these experiments, about 5-20% of bone marrow derived macrophages from WT 
mice internalized the 20:80 CPTEG:CPH and 20:80 CPH:SA nanoparticles, 
respectively. Upon adsorption of serum proteins on these nanoparticles, about 
15-30% of cells internalized the particles. However, for the 20:80 CPH:SA 
chemistry, there were no significant differences in internalization before and after 
serum adsorption. In contrast, there was a ~5-fold increase in 20:80 
CPTEG:CPH nanoparticle internalization after adsorption of serum proteins. 
When these experiments were performed with macrophages derived from the 
bone marrow of CR3-/- mice, the internalization patterns changed, with only 5-8% 
of particles being internalized for both chemistries, which was two-fold lower 
compared to the internalization of the 20:80 CPH:SA nanoparticles by the WT 
mice, but similar to the percent of WT macrophages internalizing 20:80 
CPTEG:CPH  particles. Upon adsorption of serum proteins, the percent of CR3-/- 
macrophages that internalized nanoparticles was affected by the polymer 
chemistry. For CPH:SA nanoparticles, there was a significant increase in particle-
positive macrophages, up to ~20%, which is two-fold higher than the percent of 
particle-positive macrophages prior to serum adsorption. In contrast, there were 
no significant differences observed between the uptake levels of non-serum and 
  
serum-protein adsorbed 20:80 CPTEG:CPH nanoparticles. Figure 
also shows the quantification of complement component 3 using ELISA 
C3/mg of nanoparticles. For both nanoparticle formulations, the amounts of C3 
were similar (11-12 ng/mg
gel electrophoresis data in Table 
component 3a and 3b (rows 5 and 6) 
formulations (2.16% and 2.57% for 20:80 CPTEG:CPH and 20
nanoparticles, respectively).
Figure 5.2. Internalization profiles of serum protein coated polyanhydride 
nanoparticles and quantification of c
Particle internalization was analyzed using flow cytometry in 
derived macrophages. Quantum dots (630 emission) were encapsulated in 
polyanhydride nanoparticles and used as tracking agent. Data are expressed as 
the mean ± the SEM of three independent experiments performed in triplicate. * 
represent groups that are statistically significant (p 
/-
. B) Complement component 3 was quantified using ELISA. Three independent 
experiments were performed in triplicate. Wild type
as positive control. Quantification
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5.2. The total amount of complement 
were similar for both nanoparticle 
:80 CPH:SA 
 
omplement component 3 adsorption
bone marrow 
≤ 0.05) compared to the CR3
 serum was diluted and used 
 was obtained using a calibration curve.
5.2 (panel B) 
in ng of 
the 2D 
 
. A) 
-
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5.4.4. Internalization is necessary for the activation of bone marrow-
derived macrophages 
In these studies, bone marrow-derived macrophages from WT and CR3-/- 
mice were cultured and stimulated with polyanhydride nanoparticles prior to and 
after incubation with mouse serum. The effect of particle presence within the 
cells on the surface expression of MHC II and surface markers was studied using 
flow cytometric analysis. Figure 5.3 shows the cell surface expression of MHC II 
and the co-stimulatory molecules, CD40 and CD86, upon incubation of 
macrophages with polyanhydride nanoparticles. Macrophages were separated 
into particle positive and negative populations; the left panel of Figure 5.3 shows 
the percentage of particle-positive cells that were also positive for MHC II, CD40 
and CD86 markers, while the right panel shows the percentages for particle-
negative cells that were positive for the same markers. The results indicate that 
serum protein adsorption significantly affected the activation of macrophages by 
20:80 CPH:SA nanoparticles, but this effect was not evidenced when the cells 
were incubated with the 20:80 CPTEG:CPH nanoparticles. It was also observed 
that this effect was caused by the presence of CR3, which was found to be 
necessary for the enhanced expression of CD40 and CD86 when serum proteins 
were adsorbed to the surface of these nanoparticles. As it has been reported 
previously, CD40 is a cell surface marker that requires particle internalization to 
be up-regulated, confirming the results shown in Figures 5.2 and 5.3 in this work 
[30, 51]. While the CR3 receptor appears to be important for the up-regulation of 
CD40, and CD86, it was not needed for MHC II expression by macrophages after 
stimulation with serum-adsorbed 20:80 CPH:SA nanoparticles. Serum protein 
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adsorption onto 20:80 CPH:SA nanoparticles caused the up-regulation of MHC II 
and CD40 in macrophages from WT mice, but this effect was not observed with 
the 20:80 CPTEG:CPH nanoparticles. However, the most striking factor in the 
activation of either WT or CR3-/- bone marrow-derived macrophages was the 
need for nanoparticle internalization. For both chemistries, with or without serum 
proteins adsorbed, cell activation was dependent on particle internalization. The 
percentage of particle-positive macrophages also positive for MHC II and CD40 
ranged from 80-100%, while for CD86, this percentage was 15-60%. These 
amounts substantively decreased to 10-40% for MHC II and CD40 and 5-10% for 
CD86 for particle-negative cells that were also positive for these respective 
markers. These trends were also observed when the analysis was replaced with 
the mean fluorescence intensity of these markers.  
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Figure 5.3. Activation profiles of bone marrow-derived macrophages by serum 
protein coated polyanhydride nanoparticles. Cell surface marker expression was 
analyzed via flow cytometry. Expression of CD40, CD86, and MHCII was particle, 
CR3 and serum coating dependent. LPS and Non-stimulated groups were used 
as positive and negative controls, respectively. Data are expressed as the mean 
± the SEM of three independent experiments performed in triplicate. *, # and ♦ 
represent groups that are statistically significant (p ≤ 0.05) compared to 
the correspondent CR3-/- , non-serum adsorbed and particle negative group, 
respectively.  
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5.4.5. Cytokine secretion is dependent upon both serum protein 
adsorption and the presence of CR3 
The amounts of IL-6, IL-12p40, and TNF-α secreted by bone marrow-
derived macrophages upon stimulation with polyanhydride nanoparticles are 
shown in Figure 5.4. The results indicated that both serum protein adsorption and 
the presence of CR3 were important for the secretion of cytokines. Serum protein 
adsorption onto the 20:80 CPTEG:CPH nanoparticles resulted in reduced 
secretion of IL-6, IL-12p40, and TNF-α. However, there was no effect of serum 
protein adsorption on the cytokine secretion of cells stimulated with 20:80 
CPH:SA nanoparticles. The secretion of IL-6 and TNF-α was found to be 
dependent upon the presence of CR3 when cells were stimulated with 20:80 
CPTEG:CPH nanoparticles. Similarly, in the absence of CR3, macrophages 
secreted lower amounts of IL-6 and TNF-α when stimulated by 20:80 CPH:SA 
nanoparticles with serum protein adsorbed. For both nanoparticle formulations, 
regardless of serum protein adsorption, the secretion of TNF-α by macrophages 
was significantly reduced in the absence of CR3. 
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Figure 5.4. Cytokine secretion profiles of bone marrow-derived macrophages 
after stimulation with serum protein coated polyanhydride  nanoparticles. 
Cytokine secretion was analyzed using a Bioplex assay. Amounts of IL-6, IL-10, 
TNF-α and IL-12p40 was chemistry and complement dependent. LPS and Non-
stimulated groups were used as positive and negative controls, respectively. 
Data are expressed as the mean ± the SEM of three independent experiments 
performed in triplicate. * represent groups that are statistically significant (p ≤ 
0.05) compared to the correspondent CR3-/- group, respectively.  
 
5.5. Discussion 
In the development of next generation vaccine delivery vehicles, polymeric 
carriers have been extensively used because their material properties can be 
tailored to elicit specific immune responses [1, 2]. In this work, two types of 
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polyanhydride nanoparticles were incubated with mouse serum, allowing serum 
proteins to be adsorbed onto the nanoparticles, mimicking the opsonization 
process that foreign entities (e.g., pathogens, delivery vehicles, implants, etc.) 
need to undergo after entering the body [4-6]. The effect of this adsorption 
process is important for the in vivo performance of parenterally administered 
nanoparticles with respect to immune cell activation.  
Carrier chemistry, surface charge, and surface functionality have all been 
shown to be important for nanoparticle internalization and activation of immune 
cells [10-12, 16, 52]. It is also known that hydrophobic particles adsorb higher 
amounts of protein when exposed to serum [30, 53-55]. Both 20:80 CPH:SA and 
20:80 CPTEG:CPH nanoparticles are hydrophobic, with the latter being more so 
[29]. Previous studies with polyanhydride microparticles showed chemistry-
dependent behavior with respect to their interactions with dendritic cells [30, 31]. 
In the current study, the role of serum protein adsorption and the presence of the 
CR3 receptor on macrophage activation by polyanhydride nanoparticles were 
analyzed. 
The primary contact of the immune system with these particles is through 
innate immunity components, including complement [3-5]. Complement has three 
functions in the induction of immune responses: a) defense against microbial 
infections by recruitment of complement fragments (C3a, C4a, and C5a) that 
interact with complement receptors on APCs to enhance phagocytosis; b) 
recruitment and activation of phagocytes by fragments of complement proteins, 
which act as chemo-attractants; and c) opsonization of pathogens by 
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complement opsonins (C4b, C3b, and C3bi) to recruit phagocytic cells [56]. One 
of the proteins involved in the complement system is complement receptor 3 
(CR3), which is a versatile and promiscuous adhesion and recognition receptor 
[17, 18]. The ability to recognize MAMPs through PRRs is an important feature of 
phagocytic lymphocytes [6, 17]. Therefore, in order to design pathogen 
mimicking nanovaccines, it is necessary to understand the factors that influence 
nanoparticle uptake by and activation of APCs. There are two well-known 
mechanisms of activation of macrophages: classical and alternative [8, 57]. In 
addition, a third activation mechanism has been proposed that elicits an innate 
activation phenotype [8, 57]. Activated macrophages perform a myriad of 
functions, such as phagocytosis, pro-inflammatory signaling, antigen 
presentation, killing of intracellular pathogens and parasites, enhancement of co-
stimulatory antigen expression, promotion of cell growth and tissue repair, and 
enhancement of humoral and allergic immunity [8, 57]. These capabilities make 
macrophages both sentinel and effector cells and they are important for a 
functional immune system. Therefore, analysis of the uptake and activation of 
macrophages by adjuvants and/or delivery vehicles such as polyanhydride 
nanoparticles is of paramount importance.  
The hydrophobicity of the nanoparticles affected protein adsorption and 
activation of the macrophages, as evidenced by expression of cell surface 
markers and cytokine secretion patterns. As shown in Figure 5.1, the more 
hydrophobic 20:80 CPTEG:CPH nanoparticles adsorbed greater amounts and 
with a larger diversity of serum proteins than the 20:80 CPH:SA particles, 
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consistent with previous studies, suggesting that both surface charge and 
hydrophobicity are important for protein adsorption and opsonization by immune 
cells.[11, 12, 30, 53-55] 
Analysis of the protein profiles eluted from the polyanhydride 
nanoparticles shown in Table 5.2 showed that the presence and relative amounts 
of proteins adsorbed were dependent on nanoparticle chemistry. The 20:80 
CPTEG:CPH nanoparticles adsorbed a more diverse set of serum proteins and 
had higher relative values of the dominant components of the eluted mixture 
(e.g., albumin). However, as mentioned previously, there were other proteins that 
were present in the 20:80 CPH:SA elution buffer, that were not as abundant for 
the 20:80 CPTEG:CPH formulation, such as ceruloplasmin or apolipoprotein E. 
Ceruloplasmin and lactotransferrin are important proteins involved in particle 
adhesion to the cell surface, which helps to increase their circulation in the body 
[58]. While apolipoproteins have a variety of roles, apoliprotein E is involved in 
the transportation of lipoproteins to the brain using the low density lipoprotein 
receptor on the blood brain barrier; thus it has been used to target uptake of 
particles to the brain via endocytosis [59]. In addition, apolipoproteins were 
identified when thermally treated poly(L-lactide) microspheres were incubated 
with macrophages, which was attributed to increased crystallinity [60]. This is 
consistent with the current studies, since 20:80 CPH:SA polymer is more 
semicrystalline than 20:80 CPTEG:CPH [32, 61].These differences indicate 
variances in the interactions between complement proteins and polyanhydride 
nanoparticle chemistries.  
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Our previous work indicated that CR3 has a direct role in regulating the 
uptake of polyanhydride microparticles by dendritic cells [30]. The results 
obtained in the current study confirm that depending upon chemistry and type of 
APC, CR3 has a critical function in the internalization of polyanhydride 
nanoparticles. As shown in Figure 5.2 (panel A), the internalization of both 
nanoparticle formulations had different responses to serum protein adsorption, 
depending upon the presence or absence of the CR3 receptor. These results 
suggest that opsonization alone is not enough to enhance uptake, but together 
with receptors such as CR3, effective ways can be developed to target the 
delivery of antigens [13, 15]. Depending on opsonization of the foreign agent, 
CR3 receptor can trigger different intracellular responses [12, 17]. In addition, the 
results shown in Figure 5.2 indicate that serum protein adsorption enhanced the 
internalization of 20:80 CPTEG:CPH nanoparticles. This observation is 
consistent with previous reports, which attribute enhanced internalization to the 
interaction of specific serum proteins with cellular receptors, including 
complement receptors [13, 16, 18]. Nanoparticle uptake is hypothesized to be 
caused by the involvement of the mononuclear phagocyte system (MPS), in 
which macrophages play a very important role, and are involved in the activation 
of cellular and humoral immunity [62, 63]. However, the propensity of these 
particles to be taken up by the MPS provides a good alternative to deliver antigen 
to sites such as mucosal cavities, liver, kidney, or lungs [62]. 
The results shown in Figure 5.3 delineate the effects of nanoparticle 
internalization, chemistry, serum protein adsorption, and the presence of CR3 on 
150 
 
 
the surface expression of cellular markers. Particle hydrophobicity is known to 
affect particle fate after in vivo administration [12, 16]. Adsorptive endocytosis is 
chemistry-dependent, therefore, to extend the half-life of polymeric particles in 
the body, the addition of hydrophilic moieties or coatings is necessary [12, 16]. 
However, for vaccine delivery applications, particle internalization by the desired 
cellular populations highlights the benefits obtained by the use of hydrophobic 
materials [62]. The presence of CR3 is fundamental to the internalization of 
foreign bodies, and so its absence in macrophages results in non-receptor 
mediated endocytosis and/or phagocytosis of foreign bodies. Phagocytic activity 
is one of the primary roles of macrophages, and their activation profile is highly 
dependent on uptake and recognition mechanisms [12, 13, 24, 53, 64]. When 
CR3 is not present, APCs show a diminished capacity to take up and process 
pathogens [18, 24, 25]. The behavior exhibited by the polyanhydride 
nanoparticles mimics pathogenic internalization in the absence of the CR3 
receptor. Indeed, previous work has shown that polyanhydride chemistry and 
molecular structure, size, and surface charge all conferred pathogen mimicking 
capabilities to these particles [49]. Primarily, hydrophobicity, the presence of 
hydroxyl end groups, and the oxygen content of the backbone of the polymer 
were identified as the most important contributors to APC activation, similar to 
pathogenic components like LPS. The data obtained herein provide additional 
evidence that polyanhydride nanoparticles exhibit pathogen mimicking abilities. 
The internalization of the polyanhydride nanoparticles significantly 
impacted the surface expression of CD40, CD86, and MHC II, regardless of the 
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presence of the CR3 receptor or serum protein adsorption. The up-regulation of 
these markers has been described previously as a signature of the classical 
activation mechanism of macrophages [8, 13]. This type of activation enhances 
antigen presentation and killing of intracellular pathogens, which recruits a variety 
of cells and proteins to the site of infection [13]. The display of this activation 
profile in macrophages suggests that polyanhydride nanoparticles effectively 
stimulated macrophages. The enhancement in the ability of these cells to present 
antigen in the context of MHC II molecules has shown to be important for 
cytotoxic CD8+ T cells, facilitated by CD4+ T helper cells [65]. In addition, even 
though the level of up-regulation of these markers was not the same for particle 
positive and negative macrophages, the presence of a bystander effect was 
demonstrated by the data in Figure 5.3. This is caused by the presence of the 
polyanhydride nanoparticles in close proximity to the cells that did not internalize 
the particles, which contributed to macrophage activation. The role of 
macrophages in triggering both humoral and immune responses has been 
described previously, and the capacity of polyanhydride nanoparticles to 
enhance these properties after contact with serum proteins suggests that their in 
vivo performance would result in the induction of robust immune responses. 
In this study, chemistry- and serum protein adsorption-dependent 
secretion of pro-inflammatory cytokines such as IL-6 and TNF-α was observed 
after stimulation with polyanhydride nanoparticles as shown in Figure 5.4. These 
results are also in agreement with the classical activation profile of macrophages. 
This type of activation exhibits enhanced secretion of pro-inflammatory cytokines 
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(e.g., TNF-α, IL-6) and chemokines (e.g., MIP-1α) [13]. There was no significant 
dependence on polymer chemistry for the secretion of IL-12p40, which is known 
to be important for the differentiation of macrophages from a classical M1 lineage 
towards an M2 lineage, which has an immunoregulatory and tissue regeneration 
function [66, 67]. This profile is consistent with the alternative activation 
mechanism of macrophages, which is desirable for therapeutic applications, 
injury, and tissue repair [13]. Since this platform is designed to enhance immune 
responses, activation of macrophages through the classical pathway is more 
beneficial, and the cytokine secretion data confirm this result. 
Altogether, the results described herein provide new insights into the roles 
of particle chemistry, serum protein adsorption and presence of CR3 on the 
internalization of nanoparticles and activation of immune cells. The opsonization 
of foreign entities (such as nanoparticles) is one of the first steps after parenteral 
administration of particle-based vaccines. Therefore, an in-depth understanding 
of the interactions between these particles and serum as well as between the 
particles and immune cells is necessary to rationally design nanovaccines with 
optimal in vivo performance.  
 
5.6. Conclusions 
The studies reported herein systematically analyzed the effects of 
nanoparticle hydrophobicity, the presence of one of the most promiscuous 
phagocytic receptors (i.e., CR3), polymer chemistry, and serum protein 
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opsonization upon the activation of macrophages. The results indicated that each 
of these factors has different levels of impact upon activation of macrophages, 
specifically after particle internalization and together, they contribute to result in a 
classical activation profile of macrophages, which is known to be beneficial for 
the induction of efficacious immune responses. The studies also show that 
controlling the chemistry of polyanhydride nanoparticles will provide more 
opportunities to optimize and tailor the in vivo performance of nanovaccine 
platforms based on these particles. 
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6.1. Abstract 
Carbohydrate functionalization of nanoparticles allows for targeting of C-
type lectin receptors. This family of pattern recognition receptors expressed on 
innate immune cells, such as macrophages and dendritic cells, can be used to 
modulate immune responses. In this work, the in vivo safety profile of 
carbohydrate-functionalized polyanhydride nanoparticles was analyzed following 
parenteral and intranasal administration in mice. Polyanhydride nanoparticles 
based on 1,6-bis-(p-carboxyphenoxy)hexane and 1,8-bis-(p-carboxyphenoxy)-
3,6-dioxaoctane were used. Nanoparticle functionalization with di-mannose 
(specifically carboxymethyl-α-D-mannopyranosyl-(1,2)-D-mannopyranoside), 
galactose (specifically carboxymethyl-β-galactoside), or glycolic acid induced no 
adverse effects after administration based on histopathological evaluation of 
liver, kidneys, and lungs. Regardless of the polymer formulation, there was no 
evidence of hepatic or renal damage or dysfunction observed in serum or urine 
samples. The histological profile of cellular infiltration and the cellular distribution 
and kinetics in the lungs of mice administered nanoparticle treatments followed 
similar behavior as that observed in the lungs of animals administered saline. 
Cytokine and chemokine profiles in bronchoalveolar lavage fluid indicated 
surface-chemistry dependence on modest secretion of IL-6, IP-10, and MCP-1; 
however, there was no evidence of any deleterious histopathological changes. 
Based on these analyses, carbohydrate-functionalized nanoparticles are safe for 
in vivo applications. These results provide foundational information towards the 
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evaluation of the capabilities of these surface-modified nanoparticles as vaccine 
delivery formulations. 
Keywords: safety; biocompatibility; nanoparticles; carbohydrate; polyanhydride 
6.2. Introduction 
The development of novel strategies to improve adjuvant formulations by 
directly targeting innate immune cells is an important area of interest in the 
design of novel vaccines.[1-4] Biodegradable nanoparticles possess promising 
characteristics in this regard by playing dual roles, both as adjuvants and delivery 
vehicles.[5] In particular, polyanhydride particles have been demonstrated to 
induce enhanced expression of MHC I and II on and stimulation of antigen 
presenting cells (APCs), which are fundamental to initiating adaptive immune 
responses.[6-8] After in vivo administration, the nanoparticles interact with a 
variety of cells, including APCs.[9, 10] Before analyzing the effects of surface 
modification upon vaccine efficacy, an assessment of their safety and 
biocompatibility is necessary.[11] 
The use of polymeric nanoparticle systems for drug and vaccine delivery 
offers several advantages, including controlled delivery of encapsulated 
payload(s), and depending on their chemical properties, improved 
biocompatibility, receptor targeting capabilities, sustained antigen/drug release 
kinetics, adjuvanticity, and opportunities for both local and systemic delivery.[12, 
13] Polyanhydride nanoparticles have displayed these characteristics in both in 
vitro and/or in vivo settings.[6, 9, 14-20] In particular, the use of biodegradable 
nanoparticles for lung delivery is an attractive proposition because of the 
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following advantages: 1) uniform particle distribution in the lung; 2) local 
administration of vaccine antigens or therapeutic drugs; 3) sustained delivery of 
macromolecules; 4) improved patient compliance associated with non-invasive 
immunization and administration of fewer doses; and 5) avoidance of first pass 
metabolism, among others.[2, 12, 21-23] 
In previous in vitro studies, it was demonstrated that di-mannose 
functionalization of polyanhydride nanoparticles, which would induce signaling 
via C-type lectin receptors (CLRs) on APCs, enhanced the activation of 
macrophages and dendritic cells (DCs).[6, 17, 18, 24] Because of the role of CLR 
signaling in stimulating innate immunity, identifying safe and effective means to 
selectively target APC receptors such as the macrophage mannose receptor 
(MMR) and the macrophage galactose binding lectin (MGL) will provide novel 
approaches to enhance and shape adaptive immunity.[3, 25, 26] Both the charge 
and surface properties of these polyanhydride nanoparticles are altered upon 
functionalization and could engage additional signaling cascade(s), which may 
affect the magnitude of immune response to the presence of these functionalized 
adjuvants/delivery vehicles. In this regard, even though these functionalized 
particles have displayed desirable properties (i.e., activation of APCs) in vitro, the 
focus of this study was to perform a systematic evaluation of their safety and 
biocompatibility profile in vivo to assess any toxicological effects that might be 
associated with functionalization.  
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6.3. Materials and Methods 
6.3.1. Materials 
Chemicals needed for monomer synthesis, polymerization, and 
nanoparticle synthesis included anhydrous (99+%) 1-methyl-2-pyrrolidinone 
(Aldrich, Milwaukee, WI); 1,6-dibromohexane, 4-p-hydroxybenzoic acid, N,N-
dimethylacetamide and triethylene glycol (Sigma Aldrich, St. Louis, MO); 4-p-
fluorobenzonitrile (Apollo Scientific, Cheshire, UK); acetic acid, acetic anhydride, 
acetone, acetonitrile, dimethyl formamide (DMF), hexanes, methylene chloride, 
pentane, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene 
(Fisher Scientific, Fairlawn, NJ). For NMR characterization, deuterated dimethyl 
sulfoxide was purchased from Cambridge Isotope Laboratories (Andover, MA). 
For nanoparticle tracking AlexaFluor® 647 hydrazide was purchased from Life 
Technologies (Grand Island, NY). For nanoparticle functionalization, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride, N-hydroxysuccinimide, and 
ethylenediamine were purchased from Thermo Scientific (Waltham, MA). Glycolic 
acid was purchased from Acros Organics (Pittsburgh, PA). Materials required for 
the lung tissue processing included: Dulbecco’s Modified Eagle Medium and 
Hank’s balanced salt solution (Life Technologies, Grand Island, NY); HEPES 
buffer, penicillin-streptomycin, and L-glutamine, (Mediatech, Herndon, VA); and 
heat inactivated fetal bovine serum (Atlanta Biologicals, Atlanta, GA); and 
ammonium chloride, potassium bicarbonate, 0.5 M EDTA and sodium azide 
(Fisher Scientific). β-mercaptoethanol and rat immunoglobulin (rat IgG) were 
purchased from Sigma Aldrich (St. Louis, MO). Materials used for flow cytometry 
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included: stabilizing cellular fixative solution (BD Bioscience, San Jose, CA); 
unlabeled anti-CD16/32 (i.e., anti-FcγR) (Southern Biotech, Birmingham, AL); 
FITC conjugated anti-mouse CD11c (clone N418), PE conjugated anti-mouse 
CD11b (clone M1/70), Alexa Fluor® 700 conjugated anti-mouse F4/80 (clone 
BM8), PerCP/Cy5.5 conjugated anti-mouse Ly-6G/Ly-6C (Gr-1) (clone RB6-
8C5), PE/Cy7 anti-mouse CD326 (clone G8.8) and their corresponding isotype 
controls: FITC conjugated Armenian Hamster IgG (clone HTK888), PE-
conjugated rat IgG2bκ (clone RTK4530), Alexa Fluor® 700 conjugated rat IgG2aκ 
(clone RTK2758), and PerCP/Cy5.5 conjugated rat IgG2bκ (clone RTK4530) and 
PE/Cy7 conjugated rat IgG2aκ (clone RTK2758) (BioLegend, San Diego, CA). 
Endotoxin-free saline was obtained from the Iowa State University College of 
Veterinary Medicine Pharmacy. 
6.3.2. Monomer and polymer synthesis 
Monomers of 1,6-bis(p-carboxyphenoxy) hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were synthesized as described 
previously.[15, 27] The 50:50 CPTEG:CPH copolymer was synthesized by melt 
polycondensation as previously described.[15] The chemical structure was 
characterized with 1H NMR using a Varian VXR 300 MHz spectrometer (Varian 
Inc., Palo Alto, CA). The synthesized 50:50 CPTEG:CPH copolymer had a Mw of 
10,500 Da, and the polydispersity index (PDI) of this copolymer was 1.5, which is 
consistent with previous work.[15, 20]  
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6.3.3. Nanoparticle synthesis 
Polyanhydride nanoparticles were synthesized using anti-solvent 
nanoencapsulation as described previously.[28] Briefly, for flow cytometry, 
AlexaFluor® 647 hydrazide (1% w/w) and 20 mg/mL 50:50 CPTEG:CPH polymer 
were dissolved in methylene chloride (at 4°C). For histological and cytokine 
analyses, blank nanoparticles were synthesized. The polymer solution was 
sonicated at 40 Hz for 30 s using a probe sonicator (Ultra Sonic Processor VC 
130PB, Sonics Vibra Cell, Newtown, CT) and rapidly poured into a pentane bath 
(at -40°C) at a solvent to non-solvent ratio of 1:2 50. Particles were collected by 
filtration and dried under vacuum for 30 min.  
 
6.3.4. Sugar synthesis 
6.3.4.1. Synthesis of carboxymethyl α-1,2-linked dimannoside 
Synthesis of carboxymethyl α-1,2-linked dimannose was carried out using 
fluorous-solid phase extraction (FSPE) as per literature procedure.[29-31] Each 
glycosylation was performed with 2.0 equivalents of the donor in anhydrous 
dichloromethane at 0 ºC for 15 min. Facile purification of crude product by FSPE 
enabled easy preparation of the protected linear α-1,2-linked dimannose in high 
yield. FSPE was very helpful in the context of this particular synthesis as isolation 
of the target compound using regular silica gel chromatography turned out to be 
difficult owing to the formation of unwanted side products (hydrolyzed and 
rearranged donor). The reducing terminal of the disaccharide was further 
functionalized by ozonolysis followed by Jone’s oxidation to yield a carboxylic 
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acid. Global deprotection was carried out using Birch reduction condition to 
produce the desired deprotected dimannoside.[6] 
 
6.3.4.2. Synthesis of carboxymethyl-β-galactoside 
Allylated β-galactose acetate was subjected to Ruthenium catalyzed 
Sharpless oxidation, which resulted in carboxylic acid terminated β-galactose 
acetate in high yield. Base catalyzed deacetylation yielded the desired 
galactoside in high yield. 
6.3.5. Surface functionalization 
carboxymethyl-α-D-mannopyranosyl-(1,2)-D-mannopyranoside and 
carboxymethyl-β-galactoside were conjugated onto the surface of polyanhydride 
nanoparticles using an amine-carboxylic acid coupling reaction.[6, 17, 18, 24] 
Particles with glycolic acid groups on the surface (linker) and non-functionalized 
(NF) particles were used as controls. The conjugation reaction was performed in 
two reaction steps, as described previously.[6, 18] Briefly, a nanoparticle 
suspension (10 mg/mL) was made using nanopure water, and 10 equivalents of 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and 12 
equivalents of N-hydroxysuccinimide (NHS), and 10 equivalents of 
ethylenediamine were added. This reaction was carried out at 4°C temperature 
for 1 h at a constant agitation of 17 rcf. Following the reaction, the particles were 
centrifuged at 10,000 rcf for 10 min and the supernatant was removed. The 
particles were washed with the same volume of nanopure water, centrifuged at 
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10,000 rcf for 10 min and the supernatant was removed. A second reaction was 
performed with 10 eq. of EDC, 12 eq. of NHS and 10 eq. of the corresponding 
functionalizing agent (i.e., di-mannose or galactose) in nanopure water, using 
constant agitation at 17 rcf for 1 h at 4°C. Partic les were sonicated before and 
after each reaction to break aggregates. After the reactions were completed, 
nanoparticles were collected by centrifugation (10,000 rcf, 10 min) and dried 
under vacuum for 1 h.  
6.3.6. Nanoparticle characterization 
Morphological and size characterization of both the functionalized and the 
NF nanoparticles was performed using scanning electron microscopy (SEM, FEI 
Quanta 250, Kyoto, Japan) and quasi-elastic light scattering (QELS, Zetasizer 
Nano, Malvern Instruments Ltd., Worchester, UK). The QELS experiments were 
used to measure the ζ-potential of the nanoparticles. To quantify the amounts of 
the carbohydrates conjugated to the nanoparticles, a high throughput version of a 
phenol-sulfuric acid assay was used.[6, 32] A microplate reader (SpectraMax M3, 
Molecular Devices, Sunnyvale, CA) was used to obtain the absorbance of 
standards and samples using a wavelength of 490 nm. The total amount of sugar 
per unit weight of nanoparticles (µg/mg) was calculated. 
 
6.3.7. Mice 
Female Swiss Webster outbred mice were purchased from Harlan 
Laboratories (Indianapolis, IN). Mice were housed in specific pathogen-free 
conditions where all bedding, caging, and feed were sterilized prior to use. All 
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animal procedures were conducted with the approval of the Iowa State University 
Institutional Animal Care and Use Committee.  
 
6.3.8. Mouse treatments 
6.3.8.1. Liver and kidney histological and biomarker examination 
Separate groups of five Swiss Webster outbred mice were subcutaneously 
injected with 5 mg of polyanhydride nanoparticles (non- or surface-functionalized) 
in 1.5 mL of phosphate buffer saline (PBS) at the nape of the neck.[33] Control 
animals received treatment that included Alum (100 µL) or saline (1.5 mL). Urine 
samples were collected at 7 and 30 days post-administration, prior to necropsy. 
Whole blood was collected via cardiac puncture in heparinated tubes, and liver 
and kidney tissues were harvested during necropsy and placed in phosphate-
buffered formalin. Formalin-fixed tissues after 7 and 30 days post-administration 
were embedded, sectioned, and stained with hematoxylin and eosin (H&E), and 
blindly evaluated by a board-certified veterinary pathologist. Histopathological 
damage caused by inflammation, the distribution of inflammatory cells, and tissue 
necrosis were evaluated using a 0-5 scoring system for each independent 
parameter.  
 
6.3.8.2. Serum biomarker analysis 
Serum biomarkers of kidney and liver function were analyzed using an 
Ortho Vitros 5.1 Chemistry Analyzer by the Iowa State University Clinical 
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Pathology Laboratory. Toxicological biomarkers analyzed included blood urea 
nitrogen (BUN), albumin, alkaline phosphatase (Alk Phos), alanine 
aminotransferase (ALT), serum creatinine, glucose, total bilirubin, cholesterol and 
total triglycerides. Normal range values for these biomarkers were obtained from 
the Laboratory and compared with literature.[34, 35] 
 
6.3.8.3. Urine creatinine and total protein quantification analysis 
Creatinine levels were measured in urine samples collected at 7 and 30 
days post-administraton using a creatinine assay kit (Sigma Aldrich). The ELISA-
based colorimetric assay was performed following the manufacturer’s 
specifications. Quantification of creatinine was performed using standards 
provided by the manufacturer. Total protein amount in urine was quantified using 
a micro-bicinchoninic acid (BCA) assay at an absorbance of 562 nm using a 
plate reader (SpectraMax M3).  
 
6.3.8.4. Intranasal administration of particle formulations 
Five separate groups of Swiss Webster mice were intranasally 
administered nanoparticle formulations. To sedate the mice prior to intranasal 
adminsitration of the nanoparticles, the mice were intraperitoneally injected with 
90 µL of anesthetic solution (20 mg/mL ketamine + 1 mg/mL xylazine). Particle 
treatment groups included mice that were administered: 1) 500 µg of non-
functionalized, 2) linker-functionalized, 3) galactose-functionalized or 4) di-
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mannose functionalized 50:50 CPTEG:CPH nanoparticles. Mice intranasally 
administered saline were used as a control. Nanoparticles were suspended in 
PBS and sonicated before administration. For all formulations, a volume of 50 µL 
was intranasally administered. After mice were deeply anesthetized, they were 
held upright by the nape of the neck and nanoparticle suspension was slowly 
applied through the nostrils of each mouse with a micropipette. They were held in 
this position until the breathing rate of the animals was back to normal. Mice 
were monitored after anaesthesia and mobile function was restored.  
 
6.3.8.5. Lung histological evaluation  
Lungs from Swiss Webster mice were excised at 6 h, 24 h and 48 h post-
immunization and formalin-fixed. Tissues were embedded, sectioned, and 
stained with H&E, and blindly evaluated by a board-certified veterinary 
pathologist. Adverse reactions in the lung tissue caused by inflammatory 
infiltration, necrosis, edema, bronchial associated lymphoid tissue (BALT) 
hyperplasia, and hemorrhage were evaluated using a 0-5 scoring system for 
each independent parameter.  
 
6.3.8.6. Flow cytometric analysis of lung tissue 
Mice were euthanized at 2 h, 24 h, and 48 h time points post-
immunization. Lungs were processed as previously described.[9] Briefly, lungs 
were excised and perfused with PBS. Lungs were incubated in Hank’s Balanced 
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Salt Solution with 1 mg/mL collagenase D and 60 U/mL DNAse II for 20 min at 
37°C. Lung tissue was homogenized using a gentleMAC S® tissue dissociator 
(Miltenyi Biotec, Cambridge, MA). To remove debris, samples were centrifuged 
for 250 rcf for 20 s, and filtered with a 40 µm cell filter. Red blood cells were lysed 
using ACK lysis buffer (150 mM ammonium chloride, 10 mM potassium 
bicarbonate, and 0.1 mM EDTA). Cell samples (1 x 106 cells/mL) were blocked to 
prevent non-specific binding with 1% Rat IgG, 0.1% anti-mouse CD16/32 and 
0.1% unconjugated Armenian Hamster IgG. Cells were surface stained with 
CD11c, CD11b, Ly6G/C Gr-1, and F4/80 markers. Samples were fixed with 
stabilizing fixative solution (BD Biosciences) and analyzed on a FACSCantoTM 
flow cytometer (Becton-Dickinson, San Jose, CA) and the data was processed 
using FlowJo vX software (TreeStar Inc., Ashland, OR). 
 
6.3.8.7. Bronchoalveolar lavage (BAL) fluid collection 
BAL fluid was collected after 6 h, 24 h, and 48 h post immunization.[36, 
37] Briefly, after mice were euthanized, a sterile catheter was inserted into the 
exteriorized trachea of each mouse. Using a 1 mL syringe attached to the 
catheter, 1 mL of PBS was infused into the lungs, and aspirated back to the 
syringe. The process was repeated 2-3 times, per mouse, while massaging the 
chest externally. Samples were placed on ice, and centrifuged at 300 rcf for 30 s 
at RT to remove cellular debris, and stored at -20°C until further analysis. 
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6.3.9. Cytokine and chemokine analysis  
BAL fluid samples obtained at 6 h, 24 h and 48 h post-immunization were 
analyzed using a 13-plex cytokine and chemokine quantification kit (MILLIPLEX® 
MAP mouse cytokine/chemokine magnetic bead panel, EMD Millipore, Billerica, 
MA). Analytes quantified included: IL-6, KC, MCP-1, MIP-1α, MIP-2, IP-10, TNF-
α, IFN-γ, IL-1β, IL-10, IL-12p40, MIG, and RANTES. The assay was performed 
following manufacturer’s instructions, and data was acquired and analyzed using 
a Bio-Plex 200 TM system (Bio-Rad, Hercules, CA) as described in previous 
protocols.[8, 17] 
 
6.3.10. Statistical Analysis 
Statistical analysis was used to analyze the cell surface marker 
expression and cytokine secretion data. Two-way ANOVA and Dunnett’s test 
were used to determine statistical significance among treatments and p-values < 
0.05 were considered significant. 
 
6.4. Results 
6.4.1. Functionalization and characterization of carbohydrate-modified 
nanoparticles 
Our previous work has shown that amphiphilic nanoparticle chemistries 
were suitable for protein stabilization[16, 24, 28, 38, 39], demonstrated potent 
adjuvant responses[20], and were effectively internalized by and activated 
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APCs.[6, 17, 24, 40] Therefore, the 50:50 CPTEG:CPH nanoparticle formulation 
was chosen to perform the carbohydrate functionalization and to evaluate safety 
upon in vivo administration.  
Particle morphology was characterized using scanning electron 
microscopy, as shown by the photomicrographs in Figure 6.1. The size of these 
particles was measured using ImageJ software (version 1.47v, NIH, Bethesda, 
MD). The diameter of the non-functionalized 50:50 CPTEG:CPH nanoparticles 
was 182 ± 59 nm. After functionalization, the diameter increased to 223 ± 61 nm, 
228 ± 43 nm, and 236 ± 55 nm, for linker-, galactose-, and di-mannose-modified 
particles, respectively. In addition, the ζ-potentials and the surface concentration 
of the sugars for each formulation were measured and are shown in Figure 6.1. 
The NF particles are negatively charged, consistent with the presence of 
carboxylic acid moieties with a ζ-potential of -21 ± 3.2 mV, while the addition of 
the amine linker to which the neutral sugar moieties (i.e., galactose and di-
mannose) were attached resulted in a positively charged surface with ζ-potentials 
of 18 ± 2.5 mV, 16 ± 2.1 mV and 19 ± 1.9 mV, respectively. After the 
carbohydrate modification was completed, quantification of the amount of sugar 
linked to the particle surface was measured using a phenol sulfuric acid assay 
and indicated that 15 ± 5.5 µg of galactose or 19 ± 2.4 µg of di-mannose were 
present per milligram of particles.  
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Figure 6.1. Polyanhydride nanoparticle characterization. Chemical structures of 
the surface moieties on non-functionalized, linker-, galactose-, and di-mannose-
functionalized nanoparticles are presented. Particle size data represent the mean 
± standard deviation (SD) of data collected from scanning electron microscopy 
photomicrographs using ImageJ software from four independent experiments. 
Zeta potential data were measuring using QELS and represent the mean ± SD of 
four independent experiments. Sugar density data were measured using a 
phenol sulphuric acid assay and are presented as the mean ± SD of four 
independent experiments. 
 
6.4.2. Kidney histological evaluation and renal function 
Following subcutaneous administration of 5 mg of particles to mice, 
serum, urine, and kidney samples were collected at 7 and 30 days. Histological 
evaluation of the tissue sections was performed and renal function biomarker 
levels were analyzed. Blood urea nitrogen (BUN) was measured in serum 
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samples, while creatinine and total protein were quantified in urine samples. As 
shown in the representative histological images in Figure 6.2A, the inflammatory 
changes in the kidney during the period of the study were unremarkable as no 
significant differences were observed between the histological scores of mice 
treated with saline and the animals treated with the various nanoparticle 
formulations. Using a five point scale, the inflammatory infiltration scores ranged 
from 0-2, in all groups, with an average of 0.67, and these levels did not worsen 
between 7 to 30 days post-administration indicating that no acute or chronic 
inflammation was induced (Figure 6.2B). The distribution of the cellular infiltration 
had an average score of ~1.67, with only one mouse that was administered the 
galactose nanoparticles receiving a score of 3 at 7 days post-administration. In 
summary, these studies show that there was no histological evidence of tissue 
damage in the kidneys. Figure 6.2C shows renal function biomarker levels, BUN, 
and creatinine, both indicative of normal glomerular filtration rate. For the two 
biomarkers assessed and the total protein/creatinine ratio in the urine, there were 
no significant differences in urine samples collected at 7 or 30 days post-
administration from mice that were treated with saline and samples from mice 
that received any of the nanoparticle treatments. Both BUN and creatinine levels 
were within previously reported normal range levels [41, 42]. Even though BUN 
levels were slightly lower than the reference values, there were no significant 
differences between the saline and particle groups. Variations in normal BUN 
levels have been previously reported to be mouse strain-dependent [34, 35, 43].  
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Figure 6.2. Administration of a 5 mg dose of surface-functionalized 50:50 
CPTEG:CPH nanoparticles did not affect renal function. Panel A shows 
representative histological sections of kidney samples from Swiss Webster mice 
(n= 6) seven days post-administration of the nanoparticle formulations. Panel B 
shows the inflammatory scores of kidney samples after histopathological 
evaluation. Panel C displays the levels of blood urea nitrogen (BUN) in serum 
and creatinine and total protein/creatinine ratio in urine samples from Swiss 
Webster mice seven and 30 days post-administration. Reference levels provided 
by the Iowa State University Clinical Pathology Laboratory are indicated as 
dashed lines. No significant differences were observed when compared to mice 
administered saline (n = 5 at each time point).  
 
6.4.3. Liver histological evaluation and hepatic function  
Seven and 30 days after subcutaneous administration of 5 mg of 
nanoparticle formulations, histological evaluation of the tissue sections was 
performed. Cholestasis and hepatocellular damage were evaluated in serum 
samples by measuring the levels of alkaline phosphatase (Alk Phos) and alanine 
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aminotransferase (ALT), respectively. As shown in Figure 6.3A, the inflammatory 
changes in the liver were mild, and these were interpreted as non-specific 
background changes common to this mouse strain. Representative histological 
images of liver tissue are shown. The inflammatory infiltration scores ranged from 
0-2 (on a scale of 0-5) in all the animals studied, with an average of ~1, 
regardless of the treatment as shown in Figure 6.3B. These scores did not 
significantly change between the two time points analyzed. The frequency of 
infiltration within the liver (distribution score) was also low; the distribution score 
ranged from 0-3, with an average of ~1.8. In Figure 6.3C, the levels of Alk Phos, 
ALT, and albumin are shown. There were no significant differences in the serum 
levels of any of the biomarkers analyzed between saline and nanoparticle 
treatment groups in the levels of these serum biomarkers at either time point. 
The ALT levels in mice administered the particle formulations were slightly higher 
than the upper limit of the reference values at day 30 post-administration; 
however, these were no different than the levels observed in mice treated with 
saline at the same time point.  
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Figure 6.3. Administration of a 5 mg dose of surface-functionalized 50:50 
CPTEG:CPH nanoparticles did not affect induce hepatic inflammation or alter 
hepatic function. Panel A shows representative histological sections of liver 
samples from Swiss Webster mice (n= 6) seven days post-administration of the 
nanoparticle formulations. Panel B shows the inflammatory scores of liver 
samples after histopathological evaluation. Panel C displays the levels of alkaline 
phosphatase, alanine aminotransferase, and albumin in serum samples from 
Swiss Webster mice seven and 30 days post-administration. Reference levels 
provided by the Iowa State University Clinical Pathology Laboratory are indicated 
as dashed lines. No significant differences were observed when compared to 
mice administered saline (n = 5 at each time point). 
 
6.4.4. Lung histological evaluation 
Based upon the results obtained so far, which suggested that the 
subcutaneous administration of carbohydrate-functionalized polyanhydride 
nanoparticles did not have a detrimental effect upon liver or kidney function of the 
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treated animals, we next evaluated the safety profile upon intranasal 
administration of surface-modified polyanhydride nanoparticles. Previous work 
from our laboratories has shown that nanovaccines delivered intranasally 
resulted in protective long-term immunity.[20] After intranasal administration of 
0.5 mg of nanoparticle formulations, tissue samples were collected at 6, 24, and 
48 h post-administration to evaluate acute histological changes. Figure 6.4A 
shows representative histological images from the lung for each treatment group 
at the 24 h time point (when the highest histological scores were registered). The 
parameter that contributed mostly to the final histological score was inflammation 
as shown in Figure 6.4B. Inflammatory infiltrates tended to be focused on 
bronchioles and adjacent alveolar spaces with neutrophils predominating. In 
general, the inflammatory scores peaked at 24 h, with scores up to 4 in some 
animals. The animals that received the linker and galactose-functionalized 
nanoparticles displayed a higher level of inflammation. In addition, the average 
necrosis values increased with time, with the highest value at 48 h, regardless of 
treatment groups (data not shown). There were only two mice with minor 
hemorrhage, with a score of 1, 24 h after administration of the NF particles. 
Hemorrhage was likely a tissue collection artifact. There were no mice with signs 
of edema or BALT hyperplasia at any time point analyzed (data not shown). Total 
histological scores are shown in Figure 6.4C. 
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Figure 6.4. Mild to moderate inflammation was observed in lung samples upon 
histological evaluation post-administration of surface-functionalized 
polyanhydride nanoparticles. Lung tissue samples from Swiss Webster mice 
were collected at 6, 24 and 48 hours post-administration. A) Representative 
images of each treatment group at 24 h post-administration. B) Inflammatory 
infiltration scores on a scale of 0-5 after histopathological evaluation. C) 
Composite histopathological scores representing the sum of five individual 
parameters (inflammatory infiltration, necrosis, edema, bronchial associated 
lymphoid tissue hyperplasia, and hemorrhage), with a total possible score of 25. 
No significant differences were observed when compared to mice administered 
saline (n = 6 at each time point). 
 
6.4.5. Distribution of lung cellular populations 
Given the inflammatory cell infiltration scores described above, the cell 
types recruited into the lungs following particle administration were assessed by 
flow cytometry. Cellular populations were analyzed in whole lung homogenate at 
2 h, 24 h, and 48 h post-intranasal administration. Flow cytometric analysis was 
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performed and populations were identified with the following surface marker 
combinations: dendritic cells (CD11c+ CD11b-), interstitial macrophages (CD11c- 
CD11b+ F4/80+), neutrophils (CD11b+ Ly6G/C Gr-1+), and activated monocytes 
(CD11b+ Ly6G/C Gr-1-).[44-47] Figure 6.5 shows the cellular population 
distribution in the lungs. The percentage of DCs (Figure 6.5A) increased with 
time for all the treatment groups including the saline control and ranged from 1-
4% of total lung cells. The percentage of interstitial macrophages (Figure 6.5B) 
peaked at 24 h, with all the treatment groups following similar dynamics. The 
neutrophil percentage (Figure 6.5C) at 2 h was the highest (2.5-5%) and with 
time, these populations decreased to 1.5-2.5% of all the cells; this behavior was 
observed in the tissue from the animals that received all the treatment groups 
except the NF nanoparticles, in which the neutrophil population peaked at 24 h. 
As another measure of cellular recruitment into the lungs, the presence of 
activated monocytes was assessed (Figure 6.5D) and the presence of this cell 
type followed similar dynamics as neutrophils, starting at 4-6%, and decaying to 
1.5-3% of total lung cells by 48 h. These data support the histological evaluation, 
as no major changes were observed in the inflammatory cell populations in the 
lungs of mice treated with saline or mice administered any of the nanoparticle 
formulations. 
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Figure 6.5. Cellular distribution of lung homogenates of Swiss Webster following 
administration of surface-functionalized polyanhydride nanoparticles. Cellular 
populations were analyzed by flow cytometry at 6, 24 and 48 hours post-
administration and various cell populations were analyzed. A) dendritic cells; B) 
interstitial macrophages; C) neutrophils; and D) activated monocytes. No 
significant differences were observed in these distributions when compared to 
mice administered saline (n = 6 at each time point). 
 
6.4.6. Cytokine/chemokine secretion 
To assess the inflammatory environment in the lungs following intranasal 
administration of 0.5 mg of nanoparticle formulations, the BAL fluid was collected 
and used to measure the amounts of the following chemokines and cytokines: IL-
6, KC, MCP-1, MIP-1α, MIP-2, IP-10, TNF-α, IFN-γ, IL-1β, IL-10, IL-12p40, MIG, 
and RANTES. Negligible amounts (i.e., below the levels of detection) of IFN-γ, 
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IL-1β, IL-10, IL-12p40, MIG, and RANTES were observed (data not shown). 
Figure 6.6 shows the kinetics of the secretion of IL-6, KC, MIP-2, TNF-α, IP-10, 
MCP-1, and MIP-1α. Two distinct trends were observed. The secretion of IL-6, 
KC, MIP-2, and TNF-α peaked at 6 h post-administration, while the highest 
amounts of IP-10, MCP-1, and MIP-1α secreted were observed 48 h post-
administration. The BAL fluid from animals that received the linker and galactose-
modified nanoparticle groups showed consistently higher amounts of these 
cytokines compared with saline. The absence of a major cytokine/chemokine 
response after intranasal administration of the nanoparticle formulations is 
consistent with the histological data and provides further evidence of the safety 
and biocompatibility of these materials following pulmonary delivery. 
Figure 6.6. Low amounts of cytokine/chemokine secretion were observed in 
bronchoalveolar lavage fluid 6, 24 and 48 hours after intranasal administration of 
surface-functionalized polyanhydride nanoparticles. The amounts of IL-6, KC, 
MIP-2, TNF-α, IP-10, MCP-1 and MIP-1α in the bronchoalveolar lavage fluid 
were quantified using a Multiplex magnetic bead assay. * represents groups that 
are statistically significant (p ≤ 0.05) compared to the saline control (n = 5 at each 
time point).  
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6.5. Discussion 
In this work we report on the safety profile of surface-functionalized 
polyanhydride nanoparticles following parenteral or intranasal administration to 
mice. The safety and biocompatibility of non-functionalized polyanhydride 
nanoparticles has been demonstrated previously[33]; however, the ability of di-
mannose functionalized nanoparticles to initiate signaling via CLRs warrants a 
systematic evaluation of the potential toxicity associated with the induction of 
innate and/or inflammatory responses by these novel biomaterials.  
As shown in Figure 6.1, the particle morphology and size of the 
functionalized particles were similar to previously reported data.[6, 19, 28, 48, 49] 
The characterization of polyanhydride nanoparticles before and after surface 
modification was consistent with previous studies.[6, 17, 18] The change in zeta 
potential from negative to positive charge after linker attachment can be 
beneficial for enhanced cellular uptake, as reported previously.[50, 51] In 
addition, carbohydrate functionalization is known to enhance both APC activation 
in vitro[6, 17, 18] as well as the therapeutic efficacy of drug delivery.[4] 
Based on the histological analysis scores reported in this work, 
subcutaneous administration of 5 mg of carbohydrate-functionalized 
nanoparticles did not result in tissue damage of the liver or kidney when 
assessed at 7 or 30 days post-administration and is consistent with previously 
reported safety profiles of parenterally administered polyanhydride 
nanoparticles.[33] The histological changes noted in hepatic tissue samples after 
nanoparticle administration were mild, which is comparable to other 
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biodegradable polymer formulations, but much less than that exhibited by 
extremely cytotoxic metal particles of similar size.[11] No other histological 
changes such as distortion and swelling of hepatocytes, cellular binucleation, or 
hydropic degeneration of the tissue were detected in the liver samples, as 
reported with other nanoparticle formulations.[52] The histological scores of the 
kidney samples of mice administered saline alone were not significantly different 
when compared to the scores from the kidneys of mice administered the various 
particle formulations. No interstitial edema, inflammatory cell infiltration, tubular 
epithelial flattening, urinary casts, or signs of renal histopathological lesions were 
detected, which have been reported previously for other nanoparticles.[53, 54] 
Based on the data presented here, the systemic effects of functionalized 
nanoparticle administration, in terms of hepatic and renal health, are consistent 
with effects of other biodegradable nanoparticle systems.[33, 55, 56]  
In addition to histological evaluation, serum and urine biomarkers, which 
are indicators of renal and hepatic injury and inflammation, were used to evaluate 
the safety of the functionalized nanoparticles. The levels of BUN, urine 
creatinine, and total protein/creatinine ratio in mice receiving the particle 
treatments were not significantly different from the levels in animals receiving the 
saline. Even though BUN content level was lower than the reference values 
provided, the values were consistent with previously reported data in Swiss 
Webster mice.[43] Creatinine and total protein to creatinine ratio levels in mice 
administered the particles were no different than in animals receiving the saline 
control, and consistent with amounts reported in urine from mice of this 
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lineage.[35, 41] Creatinine, a byproduct of muscle metabolism, is an important 
indicator of kidney function. When glomerular filtration rate is impaired, creatinine 
levels rise in the blood and in the urine.[57] Creatinine measurement is 
commonly used because urinary excretion of any biomarker that is filtered 
through the glomerulus is affected by the glomerular filtration rate and therefore 
used to normalize other markers, such as total protein or albumin.[58] Together 
with urine specific gravity, these markers are part of the standard clinical 
diagnosis for renal function during impairments such as chronic kidney 
disease[59], acute kidney injury[60], or renal injury.[41] Together, the inability to 
detect elevated levels of key biomarkers in serum and urine combined with the 
histopathology assessment of liver and kidney samples, demonstrates that there 
were no detrimental effects on renal or hepatic systems in mice treated with 5 mg 
of di-mannose functionalized nanoparticles.  
The use of the pulmonary route offers several advantages for drug and 
vaccine delivery since the lungs allow targeted [2], non-invasive administration 
[22], and the capability to ensure systemic or local delivery of agents.[12, 21] 
However, the respiratory system is also a more delicate environment, and 
parameters such as particle size [61-63], charge [2, 50, 51], chemistry [9, 33], 
and material [12, 64] affect deposition, distribution, and biocompatibility. In 
previous work, a single intranasal administration of non-functionalized 
polyanhydride nanovaccines demonstrated the ability to induce protective 
immunity upon lethal challenge.[9, 20, 65] The current work builds upon these 
studies by evaluating the safety profile of carbohydrate-functionalized 
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nanoparticles in the lung. The acute histopathology results from lung tissues after 
administration of particle formulations (Figure 6.4) displayed a bell-shaped curve 
with a peak at the 24 h time point. The lesions in the lung samples were mild to 
moderate, likely attributable to the administration procedure itself, because the 
lungs of the mice administered the saline control group received similar scores. 
As shown in Figure 6.4B, the major contributor to the histological scores was 
inflammatory cell infiltration.  
The inflammatory infiltrates found in the lung samples after intranasal 
administration were consistent with the recruitment kinetics described for other 
pulmonary innate immune responses[36, 50, 61, 66], in which initial cellular 
recruitment was primarily composed of mononuclear cells and neutrophils. Next, 
neutrophils and macrophage infiltrates appeared in the lung tissue by 24 h, and 
were still present 48 h post-administration. Since the differences in the 
inflammatory cell infiltrates in the lung samples may be attributed to pulmonary 
recruitment of cells from circulation[50], we analyzed the kinetics of various cell 
populations in the lungs of treated animals. As shown in Figure 6.5, there were 
no significant changes in lung cellular populations between the various particle 
treatment groups, but all of them followed similar kinetics. Consistent with the 
histological data and previous studies[66, 67], neutrophils were the first cells to 
be recruited to the administration site, followed by macrophages and/or DCs. 
Overall, the lung cellular populations observed were not statistically 
distinguishable from the populations in the lungs of mice receiving saline. This 
observation suggests that the administration of the nanoparticles likely caused a 
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mild inflammatory response similar to that induced by the administration of 
saline, and supports the conclusion that the particle formulations themselves 
were not detrimental to the health of the treated animals.  
Another component of lung response to foreign material is the secretion of 
cytokines and chemokines to recruit a cellular response and mediate clearance. 
The presence of these molecules can mediate leukocyte trafficking, 
inflammation, and link the innate and adaptive immune responses.[68] However, 
overproduction of chemokines and cytokines can cause severe tissue 
damage.[68, 69] As shown in Figure 6.6, different kinetics were observed for the 
analyzed cytokines and chemokines. The amounts of IL-6, KC, MIP-2 and TNF-α 
levels were elevated at early time points but decreased by 48 h, while the 
amounts of IP-10, MCP-1 and MIP-1α secreted were the highest at 48 h. The 
observed differential production of these cytokines/chemokines is likely related to 
the dynamic nature of the innate immune response and the different cell types 
that produce, utilize, and respond to these molecules. Nevertheless, our data 
indicate that intranasal administration of any of the nanoparticle formulations did 
not cause a major increase in cytokine or chemokine production that would result 
in severe tissue damage. All together, the histological evaluation of lung tissue, 
the unremarkable changes in the recruitment of inflammatory cells to the lung, 
and the absence of a major cytokine/chemokine response after intranasal 
administration of carbohydrate-functionalized polyanhydride nanoparticles 
provide confirmatory evidence of the safety and biocompatibility of these novel 
materials for pulmonary delivery.  
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6.6. Conclusions 
The studies reported herein demonstrate the safety and biocompatibility of 
carbohydrate-functionalized polyanhydride nanoparticles upon parenteral and 
intranasal administration. The results showed that a 5 mg dose of either linker- or 
di-mannose-functionalized nanoparticles did not induce hepatic or renal tissue 
damage or cause elevation of damage-related or functional biomarkers in serum 
or urine following subcutaneous administration. In addition, a 0.5 mg dose of 
either linker- or di-mannose-functionalized nanoparticles administered 
intranasally did not result in demonstrable tissue changes in the lungs of treated 
animals. The favorable histological profile, distribution and kinetics of cellular 
populations, and the lack of a remarkable pro-inflammatory cytokine and 
chemokine profile in the lungs of mice administered functionalized nanoparticles 
supported the biocompatibility of the linker- and di-mannose-functionalized 
nanoparticles. Together, these studies demonstrate the safety of administering 
carbohydrate-functionalized nanoparticles in vivo and provide foundational 
information to evaluate the capabilities of these surface-modified nanoparticles 
for drug and vaccine delivery.  
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7.1. Abstract 
Biodegradable polymeric nanoparticles have shown promising 
characteristics as adjuvants and/or delivery vehicles by enhancing antigen 
presentation and inducing protective immune responses compared with soluble 
protein. Specifically, polyanhydride nanoparticle-based vaccines (i.e., 
nanovaccines) have been shown to successfully encapsulate and release 
antigens, activate B and T cells, and induce both antibody- and cell-mediated 
immunity towards a variety of immunogens. One of the characteristics of strong 
antibody responses is the formation of germinal center B cells, which is part of 
the T helper cell driven cellular response. In order to further understand the role 
of these nanovaccines in the induction of antigen-specific immune responses, 
their ability to induce germinal center B cell formation and isotype switching and 
the effects thereof on serum antibody responses were investigated in these 
studies. Polyanhydride nanovaccines based on 1,6-bis-(p-
carboxyphenoxy)hexane and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane were 
used to subcutaneously administer a HIV-related antigen (gp41-54Q-GHC). The 
germinal center B cell formation and serum antibody responses induced by the 
nanovaccines were compared with that induced by vaccine formulations with 
non-degradable control adjuvants such as gold nanoparticles and alum. It was 
demonstrated that a single dose of polyanhydride nanovaccines resulted in the 
formation of robust B cell germinal centers and serum antibody in comparison to 
that induced by the control adjuvants. This was attributed to the sustained 
release of antigen provided by the nanovaccines. When administered in a 
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multiple dose regimen, the immune response induced by the nanovaccines was 
further amplified. These studies provide foundational information on the 
mechanism of action of polyanhydride nanovaccines. 
7.2. Introduction 
The design of novel adjuvant formulations to improve vaccine efficacy by 
inducing strong and balanced immune responses towards a variety of pathogens 
is one of the main goals in the development of new generation vaccines. In this 
regard, nanoparticle-based systems have shown desirable characteristics 
because they provide dual functions as adjuvants and delivery vehicles.[1-3] 
Among these systems, biodegradable polymers have been shown to stimulate 
the immune system and induce protective immunity.[3] In particular, 
polyanhydride nanoparticles have demonstrated the ability to stimulate and 
activate antigen presenting cells (APCs), induce both cellular and robust antibody 
responses with a variety of antigens, and provide protective immunity with a 
single dose.[4, 5] Antigen transport and presentation by APCs to B cells and T 
cells in the draining lymph node is one of the first steps in the induction of potent 
immune responses.  
Previous studies have shown the ability of biodegradable and non-
degradable nanoparticles to induce antibody responses with multiple antigens.[6, 
7] In particular, the use of polymeric nanoparticle systems for drug and vaccine 
delivery offers several advantages, including controlled delivery of encapsulated 
payload(s), and depending on their chemistry, improved biocompatibility, 
receptor targeting capabilities, sustained antigen/drug release kinetics, 
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adjuvanticity, and opportunities for both local and systemic delivery.[8, 9] Among 
these systems, polyanhydride nanoparticles have displayed many of these 
characteristics in both in vitro and/or in vivo settings. [4, 10-17] 
 
Even though polyanhydride nanoparticle-based vaccines (i.e., 
nanovaccines) have been demonstrated to induce protective antibody-driven 
immune responses, their ability to induce germinal center B cells, and hence 
activate the T helper cell driven cellular response, has not been investigated. 
Therefore, the main focus of these studies was the analysis of germinal center B 
cells and T follicular helper cells in the draining lymph nodes of animals 
immunized subcutaneously with vaccines based on three different adjuvants: 
gold nanoparticles, alum, and polyanhydride nanoparticles.  In these studies, an 
HIV-1 protein (gp41-54Q-GHC) was used as a model antigen. The results 
obtained showed that polyanhydride nanovaccines provided sustained antibody 
responses, induced germinal center B cell formation and T follicular helper cells, 
which led to robust serum antibody responses. In addition, it was shown that 
multiple immunizations improved the performance of the polyanhydride 
nanovaccines with respect to generating more robust immune responses. 
 
7.3. Materials and Methods 
7.3.1. Materials 
Chemicals needed for monomer synthesis, polymerization, and 
nanoparticle synthesis included anhydrous (99+%) 1-methyl-2-pyrrolidinone 
203 
 
 
(Aldrich, Milwaukee, WI); 1,6-dibromohexane, 4-p-hydroxybenzoic acid, N,N-
dimethylacetamide, triethylene glycol and Span® 80 (Sigma Aldrich, St. Louis, 
MO); 4-p-fluorobenzonitrile (Apollo Scientific, Cheshire, UK); acetic acid, acetic 
anhydride, acetone, acetonitrile, dimethyl formamide (DMF), hexanes, methylene 
chloride, pentane, potassium carbonate, sodium hydroxide, sulfuric acid, and 
toluene (Fisher Scientific, Fairlawn, NJ). For NMR characterization, deuterated 
dimethyl sulfoxide was purchased from Cambridge Isotope Laboratories 
(Andover, MA).  
 
7.3.2. Construction of pET-gp41-54Q-GHC 
The plasmid encoding gp41-54Q-GHC was constructed based on pET-
gp41-54Q, which encodes 54 amino acids of the C-terminal ectodomain of HIV-1 
gp41 (based on M group consensus sequence, MCON6). The terminal lysine 
residue was mutated to glutamine.[18]  A short linker (GSGSG), followed by a 
6xHis tag and a cysteine residue (C), was attached right after the glutamine[18] 
by PCR using a forward primer 5’-CGCGGATCCGAGTGGGAGCGCGAGATC-3’ 
and a reverse primer 5’-
ccatGAATTCttaGCAatggtgatgatggtgatgTCCCGATCCCGATCCC 
TgGATGTACCACAGCCAGTT-3’. The PCR product was digested by BamHI and 
EcoRI and then ligated into corresponding sites in pET-21a to yield pET-gp41-
54Q-GHC. The construct was confirmed by sequencing. 
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7.3.3. Expression and purification of gp41-54Q-GHC 
Protein expression and purification were performed according to the 
method of Penn-Nicholson et al. with a few modifications.[19] For gp41-54Q-
GHC expression, E. coli T7 Express IysY/Iq (New England Biolabs, Ipswich, MA) 
was transformed with pET-gp41-54Q-GHC and cultured overnight at 37 °C in 
superbroth containing ampicillin (50 µg/mL). Cells were diluted 1:100 in fresh 
superbroth and cultured to 1.0 OD600 at   37 °C. Protein expression was induced 
with 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) and continued to grow 
until OD600 reached 5.0. Cells were harvested by centrifugation at 4,600 rcf 
(relative centrifugal force) for 30 min in a Sorvall Legend XFR centrifuge (Thermo 
Scientific, Waltham, MA). The cell pellet was washed in phosphate-buffered 
saline (PBS, pH 7.4) and lysed by sonication using a Branson Digital Sonifier. 
The sample was sonicated until the suspension became translucent, followed by 
centrifugation at 15,000 rcf for 20 min in Avanti® J-26 XPI centrifuge (Beckman 
Coulter, Brea, CA). After an additional three repetitions of PBS resuspension, 
sonication, and centrifugation, the pellet containing inclusion bodies was 
solubilized in PBS containing 8 M urea and sonicated.  Insoluble debris was 
removed by centrifugation at 15,000 rcf for 20 min, and soluble proteins were 
bound to Ni-NTA resin (QIAGEN) by mixing on an end to end shaker overnight at 
4 °C. The mixture was loaded onto a column, and the  protein was renatured 
through serial incubations with 20 bed volumes of PBS containing a decreasing 
step gradient of urea at 8 M, 6 M, 4 M, 3 M, 2 M, 1 M, and 0 M. The column was 
washed with PBS containing 20 mM imidazole, and the protein was eluted with 
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PBS containing 250 mM of imidazole.  Purified protein was finally dialyzed in 
PBS (pH 8). 
 
7.3.4. Loading of gp41-54Q-GHC onto gold nanoparticles (GNPs)  
50 nm GNPs were purchased from NANOCSTM (New York, NY). 
Conjugation of gp41-54Q-GHC to the GNPs was performed according to the 
method of Chen et al. (2010).[20] As discussed, an extra cysteine residue (Cys) 
was added to the C-terminus of gp41-54Q-GHC to enhance binding of gp41-
54Q-GHC to the GNP surface. Antigen-GNP conjugation was achieved by 
titrating the antigens into a GNP suspension. After reaching the saturation point, 
the antigen-GNP complex was pelleted by centrifugation at 6000 rcf for 60 min at 
4 °C, and the supernatant was removed and saved for  protein analysis. The 
antigen-GNP pellet was then resuspended in 100 µL of PBS at pH 7.4 and used 
for immunization. To minimize aggregation, vaccine formulations were mixed well 
prior to each immunization. The amount of gp41-54Q-GHC loaded onto GNPs 
was calculated as the protein amount initially added minus the protein amount in 
the supernatant following centrifugation. 
 
7.3.5. Monomer and polymer synthesis 
Monomers of 1,6-bis(p-carboxyphenoxy) hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were synthesized as described 
previously.[11, 21] A 20:80 CPTEG:CPH copolymer was synthesized by melt 
polycondensation as previously described.[11] The chemical structure was 
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characterized with 1H NMR using a Varian VXR 300 MHz spectrometer (Varian 
Inc., Palo Alto, CA). The synthesized 20:80 CPTEG:CPH copolymer had a Mw of 
8,000 Da, and the polydispersity index (PDI) of this copolymer was 1.5, which is 
consistent with previous work.[4, 11]  
 
7.3.6. Nanoparticle synthesis 
Polyanhydride nanoparticles based on the 20:80 CPTEG:CPH chemistry 
were synthesized using anti-solvent nanoencapsulation as described 
previously.[22] Briefly, lyophilized gp41-54Q-GHC (2% w/w) and Span® 80 (1% 
v/v) and 20 mg/mL of 20:80 CPTEG:CPH polymer were dissolved in methylene 
chloride (at 4°C). The polymer solution was sonicat ed at 40 Hz for 30 s using a 
probe sonicator (Ultra Sonic Processor VC 130PB, Sonics Vibra Cell, Newtown, 
CT) and rapidly poured into a pentane bath (at -40°C) at a solvent to non-solvent 
ratio of 1:250. Particles were collected by filtration and dried under vacuum for 30 
min. 
 
7.3.7. Nanoparticle characterization 
Morphological and size characterization of the nanoparticles was 
performed using scanning electron microscopy (SEM, FEI Quanta 250, Kyoto, 
Japan) and quasi-elastic light scattering (QELS, Zetasizer Nano, Malvern 
Instruments Ltd., Worchester, UK). 
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7.3.8. Antigen release kinetics  
In vitro antigen release kinetics studies were performed using a micro 
bicinchoninic acid (BCA) assay. Samples of protein-loaded nanoparticles were 
suspended in 750 µL of phosphate buffered saline (0.1 M, pH 7.4) with 0.01% 
w/v sodium azide and incubated at 37°C and 106 rcf.  For each time point, 
samples were centrifuged at 10,000 rcf for 10 min, the supernatant was removed 
and aliquoted at 4°C, and fresh buffer was added to  each sample to maintain 
perfect sink conditions. Aliquots were analyzed using the micro BCA assay at an 
absorbance of 562 nm. The experiment was carried out for 30 days, and the 
amount of released protein was normalized with total amount of protein 
encapsulated, as described previously.[10, 23] After 30 days, the remaining 
protein was extracted by adding 750 µL of 17 mM NaOH solution. Protein 
encapsulation efficiency was estimated using the micro-BCA assay. 
 
7.3.9. Mice 
Specific pathogen free female BALB/c mice were purchased from the 
National Cancer Institute (Frederick, MD) and housed in barrier rooms at the 
University of Iowa Animal Care Facility. All mice used in the experiments were at 
least eight weeks of age. Animal procedures were approved by the University of 
Iowa Institutional Animal Care and Use Committee in accordance with 
Association for Assessment and Accreditation of Laboratory Animal Care, 
International (AAALAC International), and PHS Animal Welfare mandates.  
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7.3.10. Mouse treatments 
7.3.10.1. Preparation of antigens and immunizations 
Separate groups of mice were subcutaneously injected with 20:80 
CPTEG:CPH gp41-loaded polyanhydride nanoparticles, aluminium salts (Alum) 
and gold nanoparticles. Nanoparticles were resuspended in phosphate buffer 
saline by probe sonication (Sonicator Model CL-18, Fisher Scientific, Pittsburgh, 
PA). Mice were immunized subcutaneously in both rear footpads with 2 wt.% 
gp41-54Q-GHC-loaded 250 µg of antigen-loaded nanoparticles in a 50 µL 
volume (500 µg total per mouse containing a total of 10 µg of antigen). Single 
immunization experiments involved one administration of particle/antigen 
formulation and serum samples and popliteal draining lymph nodes (dLNs) were 
collected at days 8, 12 and 18 post-immunization. Multiple immunization 
regimens included the administration of particle/antigen formulations at days 0, 7 
and 14. Serum samples and popliteal dLNs were collected at day 21 post-
immunization. 
 
7.3.11. Flow cytometry 
Draining popliteal lymph nodes were harvested from immunized mice at 
the designated time points. To obtain single cell suspensions, dLNs were minced 
with frosted slides and washed with balanced salt solution. The cell suspensions 
were subjected to Fico/Lite-LM (Atlanta Biologicals, Norcross, GA) density 
centrifugation to obtain viable mononuclear cells, and resuspended in staining 
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buffer (balanced salt solution, 5% bovine calf serum, and 0.1% sodium azide). 5 
x 105 to 1 x 106 cells were stained with combinations of fluorochrome-conjugated 
antibodies to identify various cell subsets. Non-specific binding of conjugated 
antibodies was inhibited by blocking cells with 10 µL of rat serum (Pel Freez, 
Rogers, AR) and 10 µg of 2.4G2, an anti-FcγR monoclonal antibody. Rat anti-
mouse monoclonal antibodies used were anti-IgM (b7-6), anti-B220 (6B2), anti-
CD44 (9F3), anti-CD4 (PerCP/Cy5.5 conjugate, BioLegend, San Diego, CA), 
anti-CD150 (PE conjugate, BioLegend, San Diego, CA) and anti-CXCR5 (biotin 
conjugate, BD Pharmingen, San Diego, CA). Goat anti-mouse antibodies used 
were biotin-labeled anti-IgG1, -IgG2a, -IgG2b, and -IgG3 (all from Southern 
Biotechnology Associates, Birmingham, AL). FITC-conjugated peanut agglutinin 
(PNA) was purchased from Vector Laboratories (Burlingame, CA). 2.4G2, b7-6, 
6B2, 9F3 were semi-purified from HB101 serum-free supernatants using 50% 
ammonium sulfate precipitation. b7-6 was conjugated to biotin (Sigma-Aldrich, 
St. Louis, MO) and 6B2 and 9F3 were conjugated to Cy5 (Amersham Pharmacia, 
Piscataway, NJ) using standard procedures. Purified rat IgG (Jackson 
Immunoresearch Laboratories, West Grove, PA) was conjugated and used for 
isotype controls. Primary monoclonal antibodies or PNA were added to cells and 
incubated for 20 minutes on ice. For anti-CXCR5 staining, the primary incubation 
was 30 minutes at room temperature. After washing cells twice in staining buffer, 
PE-conjugated streptavidin (Southern Biotechnology Associates) was used to 
detect most biotinylated Abs. PE-Cy7-conjugated streptavidin (eBioscience, San 
Diego, CA) was used to detect biotin-conjugated anti-CXCR5 monoclonal 
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antibody. Cells were incubated on ice for 20 minutes and resuspended in fixative 
(1% formaldehyde in 1.25X PBS) after washing twice with staining buffer. 
Stained cells were run on a FACSCanto II (Becton Dickinson, San Jose, CA). All 
data were analyzed using FlowJo software (Tree Star, Ashland, OR). 
 
7.3.12. gp41-54Q-specific Enzyme-Linked Immunosorbent Assay 
(ELISA) 
Purified gp41 protein or overlapping peptides (0.5 or 20 pmoles per well, 
respectively) were coated onto 96-well Nunc-Immuno Plates (Nunc; Cat # 
439454) using antigen coating buffer (150 mM Na2CO3, 350 mM NaHCO3, 30 
mM NaN3, pH 9.6) at 4°C overnight. Plates were coated with  gp41 antigens at 33 
ng/well. Wells were blocked with PBS (pH 7.5) containing 2.5% skim milk and 
25% FBS at 37°C for 1 h, then washed four times wit h 0.1% Tween 20 in PBS. 
NP-40 was added to plasma samples (0.1% final) before dilution in blocking 
buffer. Antibodies and plasma samples were diluted as indicated, added to wells 
and incubated for 2 h at 37°C in 200 µL blocking buffer. Wells were washed 4 
times, and secondary antibody goat anti-human IgG conjugated to horseradish 
peroxidase (Pierce; Cat # 31410) was incubated at 1:3,000 dilution at 37°C for 
one hour. Wells were washed four times, and developed by adding 100 µL of 
TMB HRP-substrate (Bio-Rad) for 5–10 min. Reactions were stopped with 50 µL 
of 2 N H2SO4. Plates were read on a microplate reader (Versamax by Molecular 
Devices) at 450 nm. Experiments were performed in duplicate. 
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7.4. Results 
7.4.1. Synthesis and characterization of gp41-loaded polyanhydride 
nanoparticles 
Previous work has shown that amphiphilic nanoparticle chemistries 
exhibited desirable characteristics in terms of protein stabilization, robust 
antibody responses, activation of APCs, and induction of CD8+ T cell 
responses.[4, 10, 12, 16, 24, 25] Specifically, it was demonstrated that a 20:80 
CPTEG:CPH nanoparticle formulation provided sustained release of stable gp41-
54Q-GHC, as evidenced by the ability to be recognized by several HIV-1 
monoclonal antibodies.[26] Based on these studies, the 20:80 CPTEG:CPH 
nanoparticle formulation was selected to carry out the studies described herein. 
Particle morphology was characterized using scanning electron microscopy, and 
the size of these particles was measured using ImageJ software (version 1.47v, 
NIH, Bethesda, MD). The diameter of the 20:80 CPTEG:CPH nanoparticles was 
192 ± 79 nm, which is consistent with previous studies.[13, 16, 22, 27, 28] The 
encapsulation efficiency of the antigen was ~70%, and as shown in Figure 7.1, 
the 20:80 CPTEG:CPH gp41-54Q-GHC-loaded nanoparticles displayed 
sustained release kinetics over 30 days releasing ~95% of the encapsulated 
antigen, with an initial burst of ~20% of encapsulated gp41-54Q-GHC.  
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Figure 7.1. gp41-54Q-GHC antigen release kinetics from polyanhydride 
nanoparticles. Cumulative fraction of gp41-54Q-GHC released from (●) 20:80 
CPTEG:CPH nanoparticles. Error bars represent standard error of the mean; 
results are representative of two independent experiments with duplicate 
samples used in each experiment. Inset shows scanning electron 
photomicrograph of the antigen-loaded particles. Scale bar: 0.2 µm. 
 
7.4.2. Single immunization of gold nanoparticles, alum and 
polyanhydride nanoparticles elicited measurable anti-gp41 antibody  
Following a single subcutaneous administration in the footpad of 10 µg of 
gp41-antigen to mice using the three aforementioned vaccine formulations, 
serum and dLNs were collected at 8, 12 and 18 days. As shown in Figure 7.2, 
serum antibody levels in animals treated with the GNP formulation peaked at day 
12 post-immunization, reaching a maximum titer of 0.25 x 104. Initial antibody 
titers reached 1 x 103 however, they decreased by 18 days, waning down to 
background levels. These results indicate that even though the GNP formulation 
was able to induce an immune response towards the gp41 antigen, the response 
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induced was not robust or sustained. Therefore, we analyzed the quality of the 
immunity that was induced by this methodology by measuring the amounts of 
germinal center B cells and T follicular helper cells in the popliteal lymph nodes.  
Figure 7.2. Serum antibody response induced by single immunization with 
GNPs. BALB/c mice were injected s.c. with GNPs. Serum samples were 
collected at days 8, 12 and 18 post-challenge and antibody titers were measured 
via ELISA. Plates were scanned at 490 nm. 
 
The results shown in Figure 7.3 demonstrate that the amounts of germinal 
center B cells followed a bell shaped curve, with 5 x 104 cells present initially in 
the dLN, followed by a peak at day 12 (consistent with the antibody secretion 
data) with 8 x 104 cells and returning to 5 x 104 cells by day 18. Similar trends 
were found in the numbers of T follicular helper cells, but these numbers ranged 
from 0.5 x 104 to 1.5 x 104 cells over the course of the study.  
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Figure 7.3. B cell and T cell responses induced by single immunization with 
GNPs.  BALB/c mice were injected s.c. with 500 µg total of antigen loaded 
nanoparticles. dLNs were harvested at days 8, 12 and 18 post-challenge and cell 
suspensions stained with either PNA and anti-B220 mAb, or with anti-CD4, anti-
CD44, anti-CXCR5 and anti-CD150 mAbs. Stained cells were analyzed by flow 
cytometry. GC B cell bar graphs represent the total number of B220+PNAhi GC B 
cells per LN from mice at each time point. TFH bar graphs represent the total 
number of CD4+CD44hiCXCR5+CD150lo TFH cells per LN at each time point. Each 
bar represents mean ± SEM. n = 4-6 mice at each time point. 
 
Next, analysis of the immune responses elicited by a single administration 
of the gp41-antigen precipitated in alum were performed. As shown in Figure 7.4, 
similar serum antibody levels were obtained with this vaccine formulation as with 
the GNP formulation. However, the highest titer (1 x 103) was detected at day 8 
post-immunization, which was maintained through day 12, but not sustained 
beyond as evidenced by a decrease in the titer 18 days post-administration.  
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Figure 7.4. Serum antibody response induced by single immunization with Alum 
formulation. BALB/c mice were injected s.c. with gp41-protein precipitated in 
alum. Serum samples were collected at days 8, 12 and 18 post-challenge and 
antibody titers were measured via ELISA. Plates were scanned at 490 nm. 
 
Consistent with these results, the numbers of germinal center B cells and 
TFH cells in the dLNs of animals vaccinated with the alum formulation were similar 
to that elicited by the GNP formulation (Figure 7.5). Both the germinal center B 
cells and the TFH cells peaked at day 12, with 8 x 104 cells and 1.5 x 104 cells, 
respectively, and waned by day 18. 
  
Figure 7.5. B cell and T cell responses induced by single immunization with 
Alum.  BALB/c mice were injected s.c. with 10 µg of gp41-54Q-GHC precipitated 
in Alum. dLNs were harvested at days 8, 12 and 18 post-challenge and cell 
suspensions stained with either PNA and anti-B220 mAb, or with anti-CD4, anti-
CD44, anti-CXCR5 and anti-CD150 mAbs. Stained cells were analyzed by flow 
cytometry. GC B cell bar graphs represent the total number of B220+PNAhi GC B 
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cells per LN from mice at each time point. TFH bar graphs represent the total 
number of CD4+CD44hiCXCR5+CD150lo TFH cells per LN at each time point. Each 
bar represents mean ± SEM. n = 4-6 mice at each time point. 
 
Finally, similar experiments were carried out using the gp41-54Q-GHC-
loaded 20:80 CPTEG:CPH polyanhydride nanovaccine formulation . As shown 
in Figure 7.6, the serum antibody levels obtained with this vaccine formulation 
were more robust, reaching 2 x 104 within eight days post-vaccination, which 
was maintained through 18 days post-immunization (which was the duration of 
the study).  
Figure 7.6. Serum antibody response induced by single immunization with 20:80 
CPTEG:CPH nanovaccine. BALB/c mice were injected s.c. with polyanhydride 
nanovaccines. Serum samples were collected at days 8, 12 and 18 post-
challenge and antibody titers were measured via ELISA. Plates were scanned at 
490 nm. 
 
To be able to directly compare the responses induced by the three 
different vaccine formulations used, a quantification of the numbers of germinal 
center B cells and TFH cells in the dLNs was performed. The numbers of these 
cells were similar to the numbers observed in the dLNs of animals treated with 
GNPs or alum, as shown in Figure 7.7. However, the sustained release provided 
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by the polyanhydride nanoparticle formulations enabled the maintenance of the 
antibody titers and activated the T helper cellular responses more effectively. 
 
Figure 7.7. B cell and T cell responses induced by single immunizations with 
gp41-loaded polyanhydride nanovaccine  BALB/c mice were injected s.c. with 
500 µg total of 2%-antigen loaded nanoparticles. dLNs were harvested at days 8, 
12 and 18 post-challenge and cell suspensions stained with either PNA and anti-
B220 mAb, or with anti-CD4, anti-CD44, anti-CXCR5 and anti-CD150 mAbs. 
Stained cells were analyzed by flow cytometry. GC B cell bar graphs represent 
the total number of B220+PNAhi GC B cells per LN from mice at each time point. 
TFH bar graphs represent the total number of CD4+CD44hiCXCR5+CD150lo TFH 
cells per LN at each time point. Each bar represents mean ± SEM. n = 4-6 mice 
at each time point. 
 
7.4.3. Multiple immunization regimen using polyanhydride 
nanoparticles elicited robust anti-gp41 antibody responses 
In order to investigate if multiple immunizations with the polyanhydride 
nanovaccines induced even more robust immune responses, animals were 
immunized three times with gp41 antigen-loaded 20:80 CPTEG:CPH 
nanoparticles at 0, 7 and 14 days. As expected, the multiple immunizations 
resulted in the induction of a robust antibody response, with the titers reaching 2 
x 105 by 21 days post the first dose as shown in Figure 7.8. In addition, 6 x 104 
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germinal center B cells were detected in the dLN 21 days post-immunization, 
which is higher than the number of cells detected at day 18 with a single 
immunization. However, similar numbers (0.2 x 104) of follicular T helper cells 
were detected in the dLN at day 21 when compared to the number of TFH cells at 
day 18 in the single immunization experiments.  
 
Figure 7.8. Antibody and B cell and T cell responses induced by multiple 
immunizations with gp41-loaded polyanhydride nanovaccine.  BALB/c mice were 
injected s.c. with 500 µg total of 2%-antigen loaded nanoparticles. dLNs were 
harvested at day 21 post-immunization and cell suspensions stained with either 
PNA and anti-B220 mAb, or with anti-CD4, anti-CD44, anti-CXCR5 and anti-
CD150 mAbs. Stained cells were analyzed by flow cytometry. GC B cell bar 
graphs represent the total number of B220+PNAhi GC B cells per LN from mice at 
each time point. TFH bar graphs represent the total number of 
CD4+CD44hiCXCR5+CD150lo TFH cells per LN at each time point. Each bar 
represents mean ± SEM. n = 4-6 mice at each time point. 
 
Finally, isotype switching analysis was carried out in these serum 
samples. Figure 7.9 shows that the polyanhydride nanovaccines induced 
balanced immune responses after a multiple immunization regimen. The 
immunoglobulin [18] phenotypes switched from an IgG1-dominated response to 
a more balanced response that included IgG2a/b and IgG3. A balanced immune 
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response suggests the induction of both humoral and cell-mediated immunity, 
which is important to counter viral pathogens.  
 
Figure 7.9.  Isotype distribution of GC B cells after multiple immunizations with 
polyanhydride nanovaccine.  BALB/c mice were injected s.c. with 500 µg of 
antigen loaded polyanhydride nanoparticles on days 0, 7 and 14. dLNs were 
harvested 7 days after the last challenge (day 21). Cell suspensions were stained 
with PNA, anti-B220 mAb and either goat anti-IgG1, IgG2a+IgG2b (BALB/c), 
IgG2b+IgG2c (C57BL/6), or IgG3 specific Abs. Stained cells were analyzed by 
flow cytometry. A) Representative plots showing the gating strategy used to 
define IgM+, IgG1+, IgG2a+/IgG2b+, and IgG3+ B cells within the B220hiPNAhi GC 
B cell compartment. IgM+, IgG1+, IgG2+ and IgG3+ B cells as a percent of total 
GC B cells. Each bar represents mean ± SEM. n = 4 mice at each time point. 
 
7.5. Discussion 
In this work we report on the ability of polyanhydride nanovaccines to 
induce germinal center B cells and T follicular helper cells, using a viral antigen 
following subcutaneous administration to mice.[29] A variety of adjuvants have 
shown to elicit potent immune responses towards a variety of antigens.[30] In 
order to rationally design formulations that can elicit robust and balanced immune 
responses, it is necessary to understand the mechanisms by which these 
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materials induce immune responses. In this regard, the ability to induce germinal 
center B cells and serum antibody responses provides foundational information 
about the adjuvanticity provided by the nanovaccines and this work describes a 
systematic study of the adjuvant properties of three different vaccine delivery 
platforms using a viral antigen.  
It is known that B cell responses that include germinal center formation 
and generation of long-lived plasma cells and memory T cell responses are 
dependent on the involvement of CD4+ T cells.[31, 32] In order to help B cell 
development, a specialized group of T cells, known as T follicular helper cells, 
participate directly in the presentation of antigen to B cells.[29] The generation of 
long-lived plasma cells is a highly desirable outcome upon vaccination.[32] The 
induction of long-lived plasma cells has the ability to induce central memory, 
which is important upon re-introduction of the pathogen to the immune system. 
The work presented herein showed that single immunization with GNPs and 
alum was only able to elicit poor and short-lived antibody responses towards the 
gp41 antigen as shown in Figure 7.2 and Figure 7.4, respectively. These 
observations suggest that the generated plasma cells were short lived. In 
contrast, immunizing with the polyanhydride nanovaccines induced moderate 
antibody responses, which were sustained for up to 18 days post-immunization 
as shown in Figure 7.6. In addition, all three vaccine formulations induced the 
formation of germinal center B cells and TFH cells, with the responses peaking at 
12 days post-immunization, consistent with their antibody responses.  
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The relationship between GC formation and robust immune responses is 
strongly influenced by constant exposure to antigen.[29] It has been shown 
previously that TFH and germinal B cells require sustained presence of antigen in 
order to elicit memory T cell and B cell responses. Each of the vaccine 
formulations used in these experiments have different modes of making the 
antigen available to the immune system. Alum is physically mixed with the gp41 
antigen, the antigen is chemically attached to the surface of the GNPs, and the 
polyanhydride nanovaccines contain encapsulated antigen, which is slowly 
released upon degradation of the nanoparticles (as shown in Figure 7.1).[12, 20, 
33, 34] The data obtained in our experiments indicates that the sustained antigen 
release enabled by the polyanhydride nanoparticles may be critical for the 
induction of robust immune responses. This observation is consistent with other 
studies from our laboratories that also demonstrate the important of sustained 
antigen release kinetics in the maintenance of long-lived antibody with high 
avidity.[4, 24, 35] 
The induction of TFH cells in the lymph nodes is hypothesized to be a 
consequence of the participation of APCs, specifically dendritic cells (DCs), in 
carrying antigen to T cell zones and B-T cell zone borders in the lymph 
nodes.[31, 36] In previous studies, polyanhydride nanoparticles have 
demonstrated the ability to activate APCs [13, 25] and induce phenotypes that 
migrate to the lymph nodes. Based on the induction of TFH cells by all the vaccine 
formulations studied herein (as shown in Figures 7.3, 7.5 and 7.7), it can be 
hypothesized that all of these formulations are activating DCs. Future 
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improvements in the activation of DCs by nanoparticles could be achieved by the 
use of targeting mechanisms as suggested in several studies.[13, 37, 38]  
Follicular helper T cells that are CXCR5+ are known to play an important 
role in the induction of isotype switching and somatic hypermutation of B cells in 
germinal centers.[31, 39] TFH cells promote GC responses by providing 
developmental and survival signals, as well as soluble factors important for B 
cells, which eventually become memory B cells and long-lived antibody secreting 
plasma cells.[31] An important consideration in the development of vaccines is 
the quality of the antibody response elicited by the formulation, which is 
characterized by the isotype profile and the avidity of the antibody.[40] Therefore, 
the presence of isotype-switching evidence on the antigen-specific B cells 
(Figure 7.9) induced by immunization with polyanhydride nanovaccines is a 
desirable characteristic in the design of novel nanovaccines. These types of 
balanced immune responses, especially when induced with mild inflammatory 
responses[33], are important to neutralize viral pathogens that attack tissues 
such as the lungs where it is important to not induce inflammation. 
In previous work, a single intranasal administration of polyanhydride 
nanovaccines demonstrated the ability to induce high titer antibody and confer 
protective immunity upon lethal challenge with bacterial pathogens.[4, 17, 41] 
The current work builds upon these studies by evaluating the mechanisms by 
which these novel biodegradable nanovaccine formulations induce strong 
antibody responses. Overall, the successful induction of long-lived antibody 
against viral pathogens, the expansion of T follicular helper cells and the 
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formation of germinal center B cells are important components of mounting 
robust and balanced immune responses towards antigens. The polyanhydride 
nanovaccine platform has been demonstrated to exhibit all of these components, 
making it a promising vehicle for vaccine development. 
7.6. Conclusions 
The studies reported herein demonstrate the ability of polyanhydride 
nanovaccines to induce long-lived antibody against viral pathogens, expand T 
follicular helper cells and form B cells in germinal centers, especially in 
comparison to GNP- and alum-based vaccines. Low antibody titers were 
obtained from subcutaneous immunization of mice from GNP- and alum-based 
vaccine formulations. Finally, balanced immune responses were induced by the 
polyanhydride nanovaccines by initiation of isotype switching. Together, these 
studies demonstrate the ability of the polyanhydride nanovaccine platform to elicit 
robust antibody-mediated immune responses in vivo and provide foundational 
information to evaluate the capabilities of this novel platform for vaccine delivery.  
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CHAPTER 8 
 
Ongoing and Future Work 
 
 
8.1. Conclusions 
The research described in this thesis describes the promising properties of 
polyanhydride nanoparticles as targeted nanovaccines. The ability to modify the 
properties of polymeric nanomaterials by functionalizing their surface with a 
variety of immune-activating moieties offers a variety of options that can help 
direct and enhance the immune response induced by these materials. In these 
studies, nanoparticle interactions with immune cells using in vitro and in vivo 
models were analyzed in order to understand the different roles of antigen 
presenting cells (i.e. dendritic cells, macrophages), serum proteins, T cells and B 
cells in the induction of antigen-specific immune responses induced by 
polyanhydride nanovaccines.  
The work described in Chapters 4 and 6 showed that carbohydrate-
functionalized polyanhydride nanoparticles possess favorable properties with 
respect to their use as vaccine delivery vehicles. The work in Chapter 4 was in 
vitro and that in Chapter 6 analyzed the safety and biocompatibility of 
carbohydrate-functionalized nanocarriers, respectively. Therefore, the next step 
is to perform efficacy experiments to obtain better insights regarding their 
potential use as adjuvant platforms for vaccines. The work presented in Chapter 
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5 provided valuable insights on one of the important internalization pathways in 
the uptake of polyanhydride nanoparticle platforms. In order to fully understand 
the mechanisms by which these nanoparticles are internalized by antigen 
presenting cells, it is necessary to explore and analyze other signaling pathways 
that are engaged and involved in the uptake of these nanoparticles and that 
trigger immune responses. In Chapter 7, the capabilities of these polyanhydride 
nanoparticles in the induction of antigen-specific immune responses and on the 
formation of germinal B cell cells and T follicular helper cells were investigated. 
Overall, the studies described in this thesis have laid the foundation for future in-
depth analysis of the efficacy of these targeted nanomaterials for drug and 
vaccine delivery. Future research directions based on this work are briefly 
described next. 
 
8.2. Evaluation of nanoparticles functionalized with higher order mannoses 
It is known that the DC-SIGN receptor plays a vital role in the entrance of 
the HIV virion into the cell, and previous studies with HIV immunogens have 
shown that this receptor influences the induction of immune responses against 
HIV immunogens.[1, 2] It is also known that the DC-SIGN receptor, which is a 
CLR, specifically recognizes higher order mannose structures.[3-5] Therefore, in 
order to obtain further insights into the active targeting of DC-SIGN by 
functionalized nanoparticles, our ongoing collaboration with Dr. Nicola Pohl at 
Indiana University can be expanded to include the synthesis of high mannose 
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structures by the Pohl laboratory. These structures can be used to functionalize 
50:50 CPTEG:CPH nanoparticles using the methods described in Chapter 4.  
Our proposed studies will help characterize the role of this receptor in two 
different types of APCs: DCs and macrophages. For each cell type, it is known 
that DC-SIGN receptor activation generates different types of immune 
responses.[3, 6] For DCs, DC-SIGN is fundamental in the triggering of T cell 
responses via CD4+ T cells.[4, 7, 8] In this regard, the use of a DC-SIGN 
knockout mouse model will help delineate the specific role of this integrin in 
particle internalization and APC activation. On the other hand, for macrophages, 
highly structured carbohydrates have been reported to be very important for 
phagocytosis using DC-SIGN.[6, 9] Therefore, in addition to activation and 
internalization studies with these cells, analysis of the effect of DC-SIGN on the 
phagocytic activity of the cells will help characterize the mechanistic role of 
carbohydrate-functionalized polyanhydride nanoparticles in terms of activating 
APCs and influencing the downstream immune response. 
 
8.3. Optimization of targeted polyanhydride nanovaccines 
In order to optimize the immune response that can be induced by 
polyanhydride nanovaccines, this thesis explored targeting mechanisms (Chapter 
4) and surface functionalization of these nanomaterials with carbohydrate 
moieties. In addition, optimization of dose and route of immunization are 
necessary to elicit strong and balanced immune responses. While subcutaneous 
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administration (via the footpad) successfully demonstrated the induction and 
quantification of B cells and T follicular helper cells in germinal centers as 
described in Chapter 7, an in-depth investigation of the responses induced using 
different delivery routes, such as intranasal and subcutaneous (nape of the neck) 
immunizations, needs to be carried out. The intranasal route offers advantages 
since it can engage the mucosal system and simultaneously provide systemic 
immunity.[10] In addition, for viral diseases such as HIV or influenza, the 
capability to provide protection at the infection site offers an attractive alternative 
to traditional adjuvants. [11, 12] Subcutaneous administration in the nape of the 
neck has shown to provide an adequate environment for systemic distribution of 
polyanhydride nanoparticles as shown previously.[13] The dissemination of these 
nanomaterials helps in the induction of systemic immune responses compared to 
other alternatives (i.e., microparticles, alum) where the adjuvant effects are 
dependent upon the creation of a depot.[13] Finally, it is necessary to rationally 
identify the optimal combination of dose, route, and functionalization of 
polyanhydride nanovaccines in order to induce robust antigen-specific immune 
responses.  
 
8.4. Analysis of uptake mechanisms of polyanhydride nanoparticles 
To understand the mechanisms by which polyanhydride nanovaccines are 
internalized and identify the pathways involved in the activation of APCs to 
trigger the signaling cascade that elicits immune responses, exploration of 
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signaling pathways that involve Syk and MyD88, which are critical in particle 
internalization and B cell and T cell activation need to be carried out.[14-16] 
The presence of multiple families of receptors on the surface or in the 
cytoplasm of APCs, combined with innate immunity components (such as 
complement) offers a myriad of signaling pathways that may be involved in 
particle uptake and activation of the immune system.[14, 17] Thus, a combination 
of the work presented in Chapter 4 regarding the capability of carbohydrates in 
engaging CLRs and the data presented in Chapter 5 where the involvement of 
the complement receptor in the activation of immune cells was explored may 
offer new insights upon the complexity of the cellular activation systems. 
Concomitantly, the role of CLRs, Toll-like receptors, Fc receptors, and 
complement receptors and their synergistic effects must be explored in more 
detail in order to determine the specific mechanisms by which these 
nanovaccines effectively engage the immune system.  
In this regard, experiments on the role of the Fc γ chain receptor in particle 
uptake and macrophage activation are ongoing. In these studies, bone marrow 
cells from wild type and Fc γ -/- mice on the C57BL/6 background were harvested 
and cultured towards a macrophage phenotype (F4/80+). In addition to analysis 
of the role of this receptor, the effects on particle internalization and activation by 
the adsorption of serum proteins (such as immunoglobulins, complement 
component 3) onto the surface of these nanocarriers is also being investigated. 
By comparing the responses induced by serum-coated and non-serum coated 
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nanoparticles, the role of Fc receptors in particle internalization and APC 
activation can be determined.   
Furthermore, future studies with MyD88-/- and Syk-/- mice need to be 
performed since these two major enzymes are involved in the signaling pathways 
from CLRs and TLRs to determine the relevance of these receptors. These 
studies need to be performed with both non-functionalized and carbohydrate-
functionalized polyanhydrides to fully understand the mechanisms by which 
these particles induce antigen-specific immune responses. Such studies will 
provide mechanistic information that will lead to rational design of vaccine 
adjuvants based on these biomaterials. 
 
8.5. Functionalization of nanoparticles with small molecules or peptides 
In order to take full advantage of the properties and capabilities of the 
polyanhydride nanocarriers, exploration of other surface modifications to 
enhance drug delivery to APCs are being performed. In the work presented in 
this thesis, the main focus of the surface modification of polyanhydride 
nanoparticles was to target CLRs with carbohydrate moieties. For other 
applications (e.g., drug delivery to specific cells, organs, or organelles) it may be 
more relevant to target these particles using other molecules (such as peptides) 
to maximize their efficacy.  
Experiments on surface functionalization of polyanhydride nanoparticles 
with folic acid molecules to target the folate receptor in macrophages are ongoing 
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in order to deliver antioxidants across the blood brain barrier (BBB). [18, 19] 
These studies are focused on the design of a polyanhydride nanoparticle-based 
delivery system for treatment of traumatic brain injury.  
In this work, a similar approach to the one described in Chapter 4 is being 
followed for the attachment of folic acid molecules onto the surface of the 
polyanhydride nanoparticles. Using an amine-carboxylic acid coupling reaction, 
an ethylenediamine linker was conjugated to the carboxylic acids present on the 
surface of the polyanhydride nanoparticles and then folic acid was used to cap 
the amine linker.[20] In vitro experiments using macrophages and neuronal cells 
have been performed in collaboration with the Gendelman and Kanmogne 
groups at the University of Nebraska Medical Center and with the Kanthasamy 
group at Iowa State University.  
These experiments showed enhanced uptake of polyanhydride 
nanoparticles when they were modified with folic acid compared to that of the 
non-functionalized nanoparticles. In addition, the amount of drug delivered (an 
oxidase assembly inhibitor called Mito-APO) using these nanomaterials was 
enhanced compared to soluble formulations.[21] Finally, the efficacy of these 
Mito-APO-loaded folate-modified nanoparticles was evaluated in neuronal cell 
models, showing promising results in terms of protection of these cells from 
insult. Related experiments on folate-modified nanoparticles are being carried out 
to enhance their uptake by macrophages, and using these cells as a carrier 
model for drug delivery across the blood brain barrier (BBB).[19] Future 
experiments can include the use of this methodology in in vivo models and 
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observe if the in vitro results on the delivery system based on functionalized 
polyanhydride nanoparticles can translate to delivery across the BBB under in 
vivo conditions.  
 
8.6. Polyanhydride functionalization with carbohydrate moieties 
The use of carbohydrates as targeting moieties has been shown to be a 
promising approach as described in the work in this thesis (Chapters 4 and 6). 
However, the approach used in these studies was to functionalize only the 
surface of the polyanhydride nanoparticles. This was accomplished by carrying 
out the functionalization reaction after particle formation. In order to increase the 
density of the sugar in each particle and to be able to modify the properties of the 
copolymers used, ongoing experiments are exploring the functionalization of the 
polymer prior to particle synthesis. This way, the carbohydrate moieties will be 
present not only on the surface, but also within the bulk of the nanoparticles.  
Due to the concentration-dependent solubility of sugars (such as lactose) 
and carboxylic acid molecules (i.e., glycolic acid) in tetrahydrofuran and its 
compatibility with pentane, ongoing experiments are exploring the ability of this 
solent/non-solvent system to successfully synthesize carbohydrate-functionalized 
polyanhydride nanoparticles.[22] NMR, scanning electron microscopy, and 
energy-dispersive X-ray spectroscopy have been used to confirm the successful 
attachment of the aforementioned molecules onto the polymers.  
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Initial results showed the dependence of the sugar concentration on the 
particle formation process. In order to proceed with encapsulation and release of 
relevant antigens or molecules and their analysis using in vitro models, it is 
necessary to determine the range of the amounts of these targeting molecules 
that can be attached to allow particle formation. Ongoing experiments are 
underway using various amounts of glycolic acid in the functionalization of the 
polyanhydride nanoparticles and the polymer concentration in the initial solvent 
step.  
Future experiments can include the encapsulation of model antigens and 
drug molecules and focus on analysis of any changes in the release kinetics 
mechanisms caused by the functionalization of the polyanhydrides. In addition, 
the ability of these nanoparticles to effectively stimulate APCs can be examined. 
Altogether, this approach may offer a new alternative in the use of these 
materials as drug and vaccine delivery vehicles. 
 
8.7. Analysis of polyanhydride nanoparticle trafficking mechanisms to the lymph 
nodes 
It is important to build upon the results described in Chapter 7, where B 
cell and T follicular helper cell formation in the germinal centers were 
demonstrated upon polyanhydride nanovaccine immunizations, and further 
understand the mechanisms by which these nanocarriers induce antigen-specific 
immune responses. In previous experiments these nanoparticles have shown the 
237 
 
 
ability to engage T cells and to generate high antibody titers, thus inducing both 
humoral and cellular immune responses.[23] One of the main steps in the 
induction of strong immunity is antigen trafficking to the lymph nodes, either 
solubly or via transport by APCs. [24, 25] As shown previously in Chapter 4 and 
in previous studies, polyanhydride nanoparticles have the ability to activate 
APCs, and process and present antigen on their surface either in a MHC I or 
MHC II context.[26] Based on these results, further understanding on the 
mechanisms by which these particles result in antigen trafficking to the lymph 
nodes is necessary.  
Ongoing studies include the synthesis of <100 nm polyanhydride 
nanoparticles by the incorporation of surfactants, varying solvent/non-solvent 
ratios, and modifying the synthesis methodology used in this thesis. Since it has 
been reported that particles of this size can directly traffic to the lymph nodes, 
use of small polyanhydride nanoparticles may elucidate the mechanisms by 
which nanoparticles can deliver antigen to the lymph nodes.[27, 28] 
Complementing this work, analysis of the APC-dependent particle transport to 
the lymphatic system can be performed to be able to understand the dynamics of 
these particles after in vivo administration.  
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